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ABSTRACT 
 
 
Tuberculosis (TB) killed 1.5 million people and rivaled AIDS, becoming the 
leading cause of death from infectious disease in 2014. The prevalence of multidrug 
resistant TB has intensified the current therapeutic procedure, making it urgent to find 
novel anti-tubercular agents and to come up with solutions to retard the emergence of the 
drug resistance. This dissertation focuses on the identification of drug targets, the 
exploration of drug resistance mechanisms, and the identification of novel inhibitors.  
In the first part, the mechanism of action of the classic anti-tubercular drug, para-
aminosalicylic acid (PAS), was explored through genetic, cell viability and molecular 
modeling studies. Dihydrofolate reductase (DHFR) was identified to be the putative 
intracellular target of PAS. In addition, the molecular mechanism of PAS resistance was 
intensively investigated for the clinically relevant Rv2671 up-regulation mutant. 
Biochemical assays showed that Rv2671 exhibited a low DHFR activity with a high Km 
for the substrate, 7,8-dihydrofolate. X-ray crystal structure of the Rv2671 in complex 
with NADP+ and tetrahydrofolate (THF) further confirmed the structural similarity 
between Rv2671 and DHFR. These studies together suggested that PAS resistance of 
this mutant is derived from the ability to complement the DHFR activity with the high 
level of Rv2671.  
The second part of this dissertation details the characteristics of Mycobacterium 
tuberculosis isocitrate dehydrogenase-2 (Mtb IDH2). The kinetic study of Mtb IDH2 
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suggested that it catalyzes an ordered sequential reaction by binding NADP+ first. X-ray 
crystal structure revealed the fairly conserved active site and dissimilar overall structure 
compared to human IDHs (HIDHs), suggesting a potential for drug selectivity. A 
screening of known inhibitors of mutant HIDHs and a high-throughput screening of Mtb 
whole cell active compounds were further implemented to identify inhibitors for Mtb 
IDH2. Two compounds from the screenings exhibited IC50s below 10 µM. The enzyme 
structure and the modest potency inhibitors of Mtb IDH2 can serve as viable starting 
points for the follow-up inhibitor development of Mtb IDH2.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
 
Tuberculosis Is a Public Health Issue  
 
Tuberculosis (TB) is an ancient disease and was one of the top 10 leading causes 
of death worldwide in 2012. The emergence of HIV and the prevalence of the drug 
resistant strains make TB a public health issue. In 2014, 1.5 million people died because 
of TB and of this group, 27% were human immunodeficiency virus (HIV) positive.1 In 
addition, 480,000 people developed multidrug-resistant TB (MDR-TB) and only 1 out of 
2 MDR-TB patients can be cured.1 Therefore, there is an urgent need to develop new 
effective anti-tubercular agents to treat the drug-resistant TB.  
The occurrence of drug resistant Mycobacterium tuberculosis (Mtb) is not a new 
phenomenon. Indeed, Mtb showed a high drug resistant mutant emergence rate when 
patients were treated with a single anti-tubercular drug. Drug resistant Mtb was observed 
quickly following the discovery of streptomycin, one of the oldest anti-tubercular drugs. 
In 1942, over 80% of TB patients showed resistance in the first TB clinical trial with 
streptomycin.2, 3 A combination of streptomycin and para-aminosalicylic acid effectively 
overcame the high resistant mutant frequency. Combination therapy then became a 
standard for TB treatment.  
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The high drug resistant characteristic of Mtb is associated with the high bacterial 
density in pulmonary cavities. The bacterial population (~108−109) in the cavities of 
infected lungs4 is higher than the typically observed resistant mutant frequency of a drug 
(~ 10−6−10−9).5 An increasing amount of literature discussed drug resistant TB after the 
outbreak of the MDR-TB at US hospitals in the early 1990s.6 MDR-TB is resistant to 
two powerful anti-tubercular drugs, isoniazid and rifampicin. In addition to MDR-TB, 
extensively drug-resistant TB (XDR-TB) was reported.7 Not only resistant to isoniazid 
and rifampicin, XDR-TB is also resistant to any of the fluoroquinolones and to at least 
one of the three injectable drugs, amikacin, capreomycin, or kanamycin. It is estimated 
that 9.7% of the MDR-TB cases are XDR-TB.1 Moreover, cases of totally drug-resistant 
TB (TDR-TB) have been reported all over the world.8 The first TDR-TB cases appeared 
in Italy in 2003.9 Recently, TDR-TB was reported in Iran, India, and South Africa.10-12 
The emergence of TDR-TB reinforces the urgent need for new anti-tubercular drugs. 
 
Persistence, Latency, and Dormancy 
 
Persistence 
Standardized TB treatment, which is suggested by WHO,13 takes 6 months. It 
includes a combination of isoniazid, rifampicin, pyrazinamide, and ethambutol for the 
first 2 months, followed by a combination of isoniazid and rifampicin for the final 4 
months. Most active Mtb are killed during the first two months, and the residual bacteria 
are in a persistent state (Figure 1). Persistence is a term associated with a state in which a 
  3 
bacterium shows high tolerance to a sufficient amount of antibiotic that is able to kill a 
major bacterial population. Persistent Mtb shows a phenotypic resistance to most of the 
anti-tubercular agents except rifampicin. Therefore, isoniazid and rifampicin are 
implemented in the last 4 months treatment to kill the trace amount of active Mtb and the 
persistent Mtb, respectively. Long, multidrug therapy is often complicated by incomplete 
treatments for patients, which subsequently causes their strain of Mtb to become drug 
resistant.   
The ability of Mtb to persist in the host is thought to be responsible for the need 
of long treatment duration; hence, identifying a drug for persistent Mtb is another 
important mission for TB control. In 1994, Bigger used the term persisters to describe a 
subgroup of Staphylococcus spp. that was phenotypically insensitive to a high dose of 
penicillin.14 He believed that the high tolerance was because these Staphylococcus spp. 
were in a dormant and non-replicating state.  
Persisters were reported in almost all organisms, and recently they were observed 
in cancer cells.15 The population of persisters is influenced by several factors such as 
types of antibiotics, age of bacterial culture, and environmental stresses. After a decade 
of study, persisters now are generally divided into two types: continuously generated 
persisters (Type I persisters) and stress induced persisters (Type II persisters). In general, 
bacteria evolve two ways to adapt the environmental change: generating different 
phenotypes by randomly fluctuating the gene expression or possessing a constitutively 
expressed sensor. If the change is a result of an unpredictable perturbation, the former is 
preferred to save the energy consumption. This stochastically phenotypic switch within 
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an exponentially growing culture leads to the formation of Type I persisters and can be 
considered as a “bet-hedge: strategy of bacteria.16 Type II persisters, however, are 
induced by environmental stresses, such as starvation, heat shock, and pH change, with 
the assistance of the sensors. For example, the levels of persisters are significantly higher 
when a culture is in a stationary phase.17 Bacteria usually face a challenge of low 
nutrient supply in this stage that was demonstrated to induce the transition from a normal 
growing state into a slow or non-growing state. Most antibiotics are not effective against 
these slow or non-growing bacteria since their molecular targets are no longer required 
for bacteria.  The actual mechanism which triggers the formation of Type II persisters is 
still unclear, and may vary in different organisms or the environmental stresses. 
Nevertheless, mechanisms, such as toxin-antitoxin (TA) modules and stringent response, 
are found to participate in the regulation of Type II persisters.  
 
Latency 
Latency or latent infection with Mtb (LTBI) is another important topic for TB 
especially with the current prevalence of HIV. LTBI is a clinical phenomenon of 
infection in which patients show positive reaction to the tuberculin skin test or the IFN-γ 
release assay but without any symptoms. WHO estimated that one-third of the world’s 
populations carried LTBI.19 It is unrealistic to treat patients with LTBI as they stay 
healthy, and LTBI is unable to transmit the disease to other people. 
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Figure 1. Killing curve during standard anti-tubercular chemotherapy.18 The x-axis 
represents the time of the therapy and the y-axis represents the total counts of bacteria in 
lungs. The amount of bacteria drops rapidly at the first two month while treated with 
rifampin (R), pyrazinamide (Z), isoniazid (H), and ethambutol (E). Reprinted with 
permission from Jain, S. K., Lamichhane, G., Nimmagadda, S., Pomper, M. G., and 
Bishai, W. R. (2008) Antibiotic treatment of tuberculosis: old problems, new solutions, 
Microbe 3, 285. Copyright 2008 by American Society for Microbiology. 
 
 
 However, LTBI carriers with a higher chance of progression to active disease 
such as HIV infected patients or those obtaining a treatment against tumor necrosis 
factor (TNF) are recommended to receive a treatment to decrease the reactivation risk. 
Five types of treatment for LTBI are suggested by WHO: (i) 6 months isoniazid daily, 
(ii) 9 months isoniazid daily, (iii) 3 months rifapentine and isoniazid combination 
also is called “short-course” anti-TB therapy.
When administered daily, a typical adult patient is
required to consume more than one-third of a
kilogram of anti-TB drugs in a series of 182 daily
doses—in contrast to 2–5 grams in 5–7 doses for
curing an uncomplicated, community-acquired
bacterial pneumonia or similar infection.
So why does it take so long to treat TB disease
in humans when cultures ofM. tuberculosismay
be killed in a matter of mere hours to days?
According to current models, several popula-
tions of bacilli have to be dealt with in infected
individuals: those that are growing rapidly,
those growing slowly, and those that sporadi-
cally replicate. Cells falling into
these separate populations are
killed biphasically, with the rapid
multipliers being cleared during
the earlier bactericidal phase, and
the slowly and sporadically multi-
plying organisms killed during the
later sterilizing phase (Fig. 1).
Isoniazid and streptomycin (S)
have good early bactericidal activ-
ity when tested in animals, reduc-
ing infection burdens initially by
four to five orders of magnitude.
However, these agents do not clear
the infections. Thus, despite the
early rapid kill, the slowly and
sporadically multiplying popula-
tions of M. tuberculosis remain as
“persisters,” and these may only
be cleared by antibiotics possess-
ing “sterilizing” activity.
Such persister cells are more
slowly cleared and may be tolerant
(phenotypically resistant) to anti-
TB therapy. Treatment with ri-
fampin, a sterilizing antibiotic,
gradually reduces bacillary counts
to zero during the latter phase of
therapy in humans.When pyrazin-
amide is administered during the
first two months of treatment, it
shortens the overall length of ther-
apy, albeit without showing much
bactericidal activity when used on
its own. Ethambutol, superfluous
in treating drug-susceptible M. tu-
berculosis, is a drug that is rou-
tinely included in the regimen
when particular populations are
believed to harbor drug-resistant TB.
Candidate Drugs For Treating TB
While prospects for new broad-spectrum anti-
bacterials are limited, several promising nar-
row-spectrum anti-TB drugs are under develop-
ent (Table 1). Among those new agents are
two nitroimidazoles, PA-824 (Pa) being devel-
oped by the TB Alliance and Chiron, OPC-
67683 (O) by Otsuka, a diarylquinoline TMC-
207 by Tibotec, an ethambutol derivative
SQ-109 by Sequella, and a pyrrole LL-3858 by
F I G U R E 1
Standard anti-TB therapy. Current model of short-course therapy for tuberculosis showing the
intensive (bactericidal) phase in the first 2 months during which rapid killing is observed and
the inclusion of pyrazinamide is necessary for long-term treatment shortening. Typically,
optimal r gimens in is phase require four drugs: i oniazid (H), rifampin (R), pyrazinamide (Z),
and ethambutol (E). The continuation (sterilizing) phase during the remaining 4 months is
shown where the rate of killing is lower due to persister bacteria which are slowly or
sporadically multiplying. If the isolate is susceptible, Z and E are dropped in the continuation
phase. In abbreviated form, standard therapy in humans is HRZE2-HR4. (Adapted from J.
Gr sset, Cli . Chest Med. 1:231–241, 1980).
286 YMicrobe / Volume 3, Number 6, 2008
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weekly, (iv) 3−4 months isoniazid plus rifampicin daily, or (v) 3- or 4-month 
rifampicin alone daily.20  
 
Dormancy 
Mtb in dormancy is thought to be responsible for the LTBI. Before moving into 
a review of dormancy, it is necessary to point out that there is a degree of uncertainty 
around the use of the terms dormancy and persistence in scientific literature. Often 
times, persistence is misused to describe dormancy. In this dissertation, dormancy will 
be used solely when referring to viable but non-culturable (VBNC) cells.21 However, 
there is no standard definition for non-culturable, such as what kinds of media or 
stimuli should be tried or how long incubation should occur before concluding a cell is 
non-culturable. Therefore, a term “non-growing but metabolically active (NGMA)” is 
introduced to avoid the confusion about culturability.22 The NGMA state is a VBNC-
like state in which a cell is slow or non-replicating, but with detectable metabolic 
activities. 
Dormancy is a mechanism for organisms to adapt to environmental stresses. 
Organisms stop growth and division during dormancy and are in a minimal metabolic 
state to reduce energy consumption. Dormancy is observed in various organisms such as 
hibernation in animals, or bud and seed dormancy in plants. Dormancy in bacteria was 
usually linked to a special morphology (e.g. spores or cysts). However, this concept 
changed when the dormancy of non-sporulating bacteria was discovered in 1982.23 
According to Kaprelyants et al. (1993)24, dormancy in non-sporulating bacteria such as 
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mycobacteria can be defined as a reversible state of low metabolic activity and non-
replication.  In addition, a dormant bacterium is unable to form a colony in a routine 
solid media but can resume division after a proper resuscitation from dormancy. Within 
this publication, dormant bacteria were defined as viable but non-culturable (VBNC) 
bacteria.  
The existence of VBNC state was first observed on E. coli and V. cholera by Xu 
et al.23 and was reported on over 85 different bacteria.25 Before the observation of 
VBNC state, the viability of a cell equaled the ability of cell proliferation in the classical 
microbiology. Culturing the cells on a defined solid plate was a widely accepted method 
to examine the capability of cell proliferation and subsequently to estimate the cell 
viability. Therefore, new detection methods are required to evaluate the cell viability of 
the VBNC cells. The BacLight Live/Dead assay and RT-PCR are commonly used to 
quantify the total viable cells. The BacLight Live/Dead assay uses red fluorescing 
propidium iodide (PI) and green fluorescing SYTO9 to distinguish the viable and dead 
cells. SYTO9 can enter all cells but PI only penetrates cells with damaged cytoplasmic 
membrane.26 A combination of the BacLight Live/Dead assay with flow cytometry 
provides an even better way to quantify the result.27 However, this method is not perfect 
since this assay is based on the assumption that cells with damaged membrane are dead 
cells. Alternatively, cell viability may be determined by the metabolic activity in an RT-
PCR assay. A short half-life mRNA (~ a few minutes28, 29) is measured and correlated 
with metabolic activity. Detectable mRNA indicates living or the recently dead cells at 
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the sampling time.30 The results can be misleading, as the measurement is an ensemble 
average that may not represent the condition of a single cell or a minor subpopulation. 
Another key aspect of dormancy is resuscitation. The success of resuscitation 
depends on organisms, dormancy inducing conditions, and the duration within the 
dormant state. To date, only half of the VBNC genera have been successfully 
resuscitated and returned to an active state. The failure of resuscitation suggested either 
this group of bacteria could not resume division or the currently tested methods were 
unable to resuscitate these bacteria. Different environmental stresses have been used to 
induce bacteria into a VBNC state such as starvation, unfavorable growth temperature or 
pH.31-33 Thus, removal of the environmental stresses was often the simplest resuscitation 
process.34, 35 However, the longer the bacterial cells are in the VBNC state, the lower 
population of the VBNC cells can be resuscitated.36, 37 Other than changing the cultural 
conditions, the cell proliferation can be reactivated by compounds including amino 
acids38, resuscitation-promoting factors (Rpfs39) and autoinducers.40  
A much debated issue is whether persistence equals dormancy. Some research 
groups believe they are the same, especially for Type II persisters, as they share several 
commonalities such as in an energy generating state and with a high tolerance to 
environmental stresses and antibiotics. The only confirmed difference is the duration for 
resuscitation from these two states. Persisters can resume replication in a short period of 
time after the antibiotics or the environmental stresses are removed, but the resuscitation 
time varied for different VBNC cells. Experimental results from early studies were 
insufficient to draw a conclusion whether they are the same. However, some persisters 
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were demonstrated to conduct translation to some degrees in a single cell flow cytometry 
experiment. In addition, persisters with normal replicating ability were observed in 
recent studies.  Inability to generate a toxic radical, or the induction of the expression of 
efflux pumps was found to be associated with these bacterial persisters. 
Taken together, Type II persisters can be predecessors of dormant cells. They are 
in a transition state, on the way to dormancy. Moreover, it may be necessary to introduce 
another category, Type III persisters, for the persisters with a regular metabolic activity 
and replicating state or to expand the definition of Type I persisters to refer not only to 
the low metabolic bacteria but all heterogenetic bacteria, which have phenotypic 
tolerance to antibiotics.  
 
Persistent and Dormant Mtb 
 
Persistence and dormancy make the TB treatment more difficult. In fact, it is 
hard to separate persistence and dormancy in the study of Mtb since the multiple 
environmental stresses in its life cycle within the host often prompt the formation of 
Type II persisters. Type II persisters, i.e., the stress induced persisters, are indeed highly 
correlated with dormancy. Therefore, understanding the environmental stresses Mtb 
encounters in vivo is required to study Mtb persistence or dormancy. A brief summary of 
the Mtb’s life cycle helps to rationalize the study of the models for the Type II persisters 
and dormant Mtb. 
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Mtb exists with different physiological states in response to different infection 
stages. The infection cycle starts from the inhalation of aerosolized Mtb. The aerosolized 
Mtb is taken up through phagocytosis and resides in the phagosomes of the lung 
macrophage. Around 5−10% of the infected individuals received will progressive to 
active TB, while others lapse into a dormant state resulting in a latent infection.  
In the primary infection, Mtb arrests the phagosomes containing bacteria in an 
immature stage that prevents the phagosomes from fusing with a lysosome. However, 
some phagosomes overcome the Mtb’s survival strategy by the stimulation of the host 
immune system. More specifically, the infected phagosome becomes a phagolysosome 
by the stimulation of IFN-γ.41 The phagolysosome then kills some bacteria. In mature 
macrophages, Mtb needs to tolerate the low pH and oxidative stress such as NO and CO.  
Some activated macrophages induce the formation of a granuloma, the hallmark 
of Mtb. For	a healthy individual, TB infection is usually controlled at this stage. The 
granuloma is an organized structure composed of T-cells, B-cells, dendritic cells, and a 
fibrous capsule. A caseous granuloma is the most common type in which cell debris 
accumulates and forms a necrotic area in the center. In addition to caseous granuloma, 
various other types of granulomas are observed in humans, including non-necrotic, 
suppurative, fibrotic, and mineralized. In active TB, all types of granulomas coexist. 
However, caseous, mineralized, or fibrotic granulomas are predominant in latent TB.42 
Cavity formation is a key event in severe TB. Some groups believe that the cavity is 
produced by the expansion of the caseous granuloma. The caseous center will be 
softened and becomes liquefied. Eventually, a cavity forms along with overloaded 
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extracellular bacterial growth. However, other groups believe that the caseous 
granuloma plays no role in the formation of cavities. They suggest that the cavity is 
produced through the localized caseous pneumonia in the progressive primary TB. 
Massive caseation occurs, which blocks the bronchus, and subsequently results in the 
formation of cavities.43 Nevertheless, Mtb grows on the surface of the cavities. When the 
cavities connect with the airways, Mtb grows exponentially. In the end of the infection, 
Mtb is released from airways and causes the infection to move to other hosts.  
The granuloma is thought to be a product of coevolution in which Mtb and the 
host immunologic system reach a balance. In the granuloma, some induced or pre-
existing NGMA Mtb survive and cause the LTBI. The center of the granuloma is thought 
to be low in oxygen and nutrient limited due to a dysfunctional vasculature.44 In 
summary, Mtb endures starvation and low pH within macrophages, and it suffers from 
low oxygen tension and nutrient limitation in the granuloma.  
Several in vitro and in vivo models have been designed to study Type II 
persisters and dormant Mtb. Notably, even though the original intention of these models 
is to study dormant Mtb, NGMA Mtb is a better term to describe the Mtb in these 
models, not only because the definition of culturable is vague, but also because of the 
difficulty of examining the real-time viability of a cell. The models can be mainly 
divided into four groups: hypoxia, starvation, macrophage, and murine infection. These 
models are useful to understand the NGMA Mtb, but none of them can fully represent 
the state of human infection.  
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The hypoxia model,45 a gradual O2 depletion model, mimics the low oxygen 
situation in a granuloma but is missing the stresses generated from immune response and 
macrophage phagocytocis. In addition to the same limitations as the hypoxia model, the 
oxygen constraint does not occur in the starvation model. The macrophage model 
captures the situation for initial infection but not for the late infection. Even though the 
infection and reactivation are established, the mouse model suffers from a high bacterial 
load at the chronic infection and lacks a well formed granuloma, especially lacking the 
caseous and necrotic granulomas.  
Nevertheless, studies carried out with these models reveal the physiology of 
NGMA Mtb. Transcriptomic and proteomic studies were performed to understand the 
molecular mechanism and metabolic realignment of NGMA Mtb in these models. The 
exact molecular mechanisms of dormancy and antibiotic persistence remained unclear, 
but several genes have encoded critical regulators for these NGMA bacteria. Three 
molecular mechanisms associated with these genes are proposed to explain the formation 
of the mycobacterial persistence and dormancy: the Toxin-Antitoxin (TA) model, the 
stringent response, and the Dos regulation. 
The TA model is the most studied molecular mechanism for bacterial 
persistence. It is a two-component system with a toxin and an antitoxin. Toxin arrests 
the cell growth by interfering with either transcription or translation. Its unstable 
antitoxin counterpart neutralizes the activity of the toxin. The TA model was first 
introduced when the observation of a mutant in gene hipA resulted in a significant 
increase of persistent E. coli.46 HipA was later proved to be a toxin with an antitoxin 
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counterpart, HipB. In fact, TA models can be a plasmid maintenance system or a 
chromosomally-encoded system, and they are highly redundant in cells. Knocking-out 
an individual pair does not change the subpopulation of persisters. However, 
overexpression of toxin usually slows down the bacterial growth. TA systems can be 
classified on the basis of the nature of antitoxin into five groups. In the type I TA 
family, the antitoxin is an antisense RNA, which regulates the toxin synthesis by 
binding to the toxin mRNA. In the type II TA family, the antitoxin is a toxin binding 
protein, inhibiting the toxin by forming a complex with it. In the type III TA family, the 
antitoxin is an RNA, which inhibits the toxin by forming a protein-RNA complex. In 
the type IV TA family, the antitoxin is protein, which inhibits the toxin by competing 
for the same target. In the type V TA family, the antitoxin is an endoribonuclease, 
which specifically cleaves the mRNA of the toxin.47-50 Based on a sequence similarity 
search, around 80−90 TA loci were found in Mtb. The results of a study conducted by 
Sala et al.51 with a brief introduction of each TA system are listed in Table 1.  
In their report, 79 loci were assigned as TA systems including 67 from the type II 
TA family, 1 tripartite type II TAC system, 3 putative type IV systems, and 8 
uncharacterized TA pairs. 30 showed an intracellular function in an ectopic expression 
assay within M. smegmatis. Evidence suggests that some TA pairs contributed to the 
antibiotic and environmental persistence in Mtb. The expression level of different 
subsets of TA loci is altered in the presence of environmental stresses such as starvation, 
hypoxia, and macrophage infection.52-54 In addition, 10 TA pairs are up-regulated in D-
cycloserine induced persisters.55
14 
Table 1. Function and mechanism of the identified TA systems in Mtb50 
TA family 
(locus) 
Number 
of loci 
Toxin Target of toxin Inhibitory mechanism of the toxin Antitoxin 
VapBC 50 VapC Translation Cleavage of RNA molecules52 or RNA binding56 VapB 
MazEF 10 MazF  Translation Cleavage of a sequence-specific mRNA,57-59 
cleavage 23S rRNA,58 or interacting with DNA 
topoisomerase I60 
MazE 
RelBE 2 RelE Translation 
elongation 
Binding with 16S rRNA, interacting with the 30S 
subunit and resulting in the cleavage of mRNA at 
ribosomal A site61 
RelB 
YefM/YoeB 1 YoeB Translation 
initiation 
Interaction with the 50S subunit and preventing the 
formation of the initiation complex on mRNAs62 
YefM 
HigBA 2 HigB Translation Binding with the ribosomal 50S subunit and 
cleavage of mRNA at AAA sites63 
HigA 
ParDE 2 ParE Cell division Targets DNA gyrase64 ParD 
TAC system* 1 HigB1 Translation Binding with the ribosomal 50S subunit and 
cleavage of mRNA at AAA sites63 
HigA1 
Others 11 
* In TAC system, the antitoxin is in collaboration with a SecB type chaperone
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The stringent response model is described as a series of global physiological 
changes induced by the accumulated alarmone, (p)ppGpp. It occurs when a bacterium 
signals a nutrition deprivation, especially the amino acid depletion. The intracellular 
concentration of (p)ppGpp is controlled by a ATP: GTP/GDP/ITP 3’-
pyrophosphoryltransferase and a (p)ppGpp 3’-pyrophosphohydrolase. In 
Mycobacterium, a bifunctional enzyme, RelA, carries out both reactions.65 The 
regulatory system of RelA in Mycobacterium has been characterized in M. smegmatis66 
(Figure 2). The transcription of relA is mediated by a positive feedback system 
composed of a sigma factor (σE), two stress response enzymes (MprAB) and a signaling 
molecule, polyphosphate. The stress-responsive sensor, histidine kinase (MprB), 
autophosphorylates using the polyphosphate as a phosphate donor and then transfers the 
phosphate group to the transcriptional response regulator (MprA). The phosphorylated 
MprA conducts tighter binding and causes up-regulations to its targets, promoters of 
MprA and σE in this case. The transcription of rel gene is induced by the up-regulated 
σE. The amount of polyphosphate is controlled by polyphosphate kinase (PPK)67 and 
exopolyphosphatase (PPX)68-70 that mediate the synthesis and hydrolysis of 
polyphosphate, respectively. Notably, the function of PPXs is inhibited by (p)ppGpp,68, 
71 therefore, generating another positive feedback loop. In summary, high levels of 
polyphosphate result in high levels of RelA. As mentioned above, RelA in 
Mycobacterium carries out two reactions. The preference of the reactions is determined 
by the ratio of charged and uncharged tRNA.72 The (p)ppGpp synthesis activity of 
RelA increases in the presence of uncharged tRNA.73 As a result, (p)ppGpp 
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accumulates and subsequently increases the intracellular concentrations of 
polyphosphate by inhibiting the PPXs in starvation.  
In respect to the (p)ppGpp accumulation, rRNA and ribosomal protein syntheses 
are down-regulated, and some amino acid biosynthetic enzymes are up-regulated.74, 75 
The decline of rRNA and ribosome causes cell growth arrest. In E. coli, the 
transcriptional realignment is triggered by a direct interaction between (p)ppGpp and 
RNA polymerase in cooperation with a transcriptional factor DskA. In B. subtillis, the 
changes result from the (p)ppGpp mediated intracellular GTP depletion through 
inhibiting GTP biosynthesis.76 Neither mechanism has been validated in Mtb. However, 
the interference of RNA polymerase activity by (p)ppGpp was observed in several 
studies.77  
Even though some molecular mechanisms remain unclear, the stringent response 
model may be critical for Mtb survival in vivo. Growth attenuation was observed when 
RelA knocked-out Mtb was cultured in the long-term nutrient or oxygen depletion.78 In 
addition, Mtb loses its ability to persist in mice and guinea pig when RelA is deleted.54, 79 
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Figure 2. Regulation system of the stringent response model in Mycobacterium.66 The 
core of the stringent response is the synthesis of (p)ppGpp by Rel. In Mycobacterium, 
the expression of Rel depends on the intracellular levels of polyphosphate. High levels 
of polyphosphate result in the increase concentrations of MprA and SigE and 
subsequently increase the levels of Rel and (p)pGpp. Reprinted with permission from 
Boutte, C., Crosson, S. (2013) Bacterial lifestyle shapes stringent response activation, 
Trend in Microbiology 21, 174-180. Copyright 2013 by Elsevier.  
 
 
 
The Dos regulation model is another persistence related mechanism for Mtb. A 
different expression level between the virulent H37Rv and the avirulent H37Ra strains 
permitted the Dos regulation system to be first observed.80, 81 Later, the Dos regulon was 
shown to facilitate the adaption for the hypoxia and the presence of oxidative species 
such as carbon monoxide and nitric oxide.82-84 Dos regulation is a two-component 
regulatory system, composed of a regulation protein (DosR) and two sensor kinases 
(DosS and DosT) (Figure 3).85 DosS and DosT activate DosR by conducting a 
phosphorylation reaction. DosS is a redox sensor and DosT is a hypoxia sensor. After 
receiving the signals, DosS and DosT first rapidly autophosphorylate at a histidine 
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residue and catalyze the phosphotransfer to an aspartate residue of DosR.86, 87 The 
activated DosR influences the expression of over 50 genes. As a result, genes for 
triacylglycerol biosynthesis and electron acceptors for the anaerobic respiration, such as 
the nitrate/fumarate and succinate systems, are up-regulated. Alternatively, genes for the 
basal metabolisms are down-regulated.  
DosR was found to be highly expressed in a hypoxia model and during human 
disease. DosR is dispensable for in vitro survival and replication in human monocytes, 
but mutations in DosR results in a virulence attenuation of Mtb in guinea pigs and 
rabbits.81 However, a recent transcriptional profiling study demonstrated that the DosR 
regulon is not responsible for the long term survival under anaerobic conditions.88 The 
DosR regulon was highly expressed at the outset of anaerobic conditions but returned to 
its basal level within 24 h. The expression level of another set of genes was altered in the 
enduring hypoxic situation. Notably, these enduring hypoxic response enzymes did not 
overlap with any enzymes belonging to the DosR regulon. These results underscore the 
role of DosR regulon in mediating the transition from aerobic to anaerobic conditions. 
 
  19 
 
Figure 3. Dos regulation in Mtb.85 Dos regulon is induced by DosT and DosS when Mtb 
is in hypoxia. After sensing the hypoxia, DosT is autophosphorylated in the early stage 
to mediate the metabolic switch from aerobic to hypoxia, and DosS gets 
autophosphorylated in the later stage to maintain the metabolic state in hypoxia. DosT 
and DosS transfer the phosphate group to DosR. The phosphorylated DosR binds DNA 
and causes an up-regulation of a series of enzymes called DosR regulon.  
 
 
Although the exact mechanism of how NGMA cells are produced remains 
unclear, NGMA bacteria exhibit a unique phenotype and a differential metabolism. 
NGMA Mtb possesses a lipid body accumulation and is negative for acid-fast staining. 
To establish a low metabolic state, bacteria reduce nearly all basal metabolism such as 
amino acid, cofactor, ATP, and lipid syntheses, DNA replication and repair, translation, 
etc. Besides this reduction, some metabolism undergoes reprogramming including those 
of central carbon metabolism (CCM), respiratory chain, and redox state homeostasis 
(NAD+/NADH ratio). For CCM, enzymes involved in glycolysis and the tricarboxylic 
acid cycle are down-regulated. Instead, a few enzymes involved in the fatty acid 
catabolism such as β-oxidation, glyoxylate shunt, and gluconeogenesis are up-regulated. 
Biosensors 2013, 3 271 
 
 
phosphorylation of DosR by DosS and renders it functionally inactive in vivo, although it doesn’t seem 
to perturb the protein-protein interaction between DosR and DosS [46]. 
Figure 4. (A) The deoxy ferrous form of DosS/DosT is autophosphorylated under hypoxia 
or upon binding CO or NO, while no phosphorylation is observed when the proteins bind 
oxygen. The phosphorylated protein transfers the phosphate group to DosR, which then 
binds DNA resulting in downstream signaling leading to the upregulation of the 47 other 
genes necessary for dormancy. (B) DosT is sensitive to low oxygen concentrations  
inside the cell and responds during the early transition from aerobic to hypoxia by 
autophosphorylation and induction of the dosR regulon. DosS detects hypoxia at later 
stages and is responsible for maintaining the dormancy regulon induction. 
 
9. Roles of DosS and DosT 
The relative roles of DosS and DosT in inducing the Mtb dosR regulon were examined by 
comparative microarray analysis of 'dosS, 'dosT, and t  double mu nt i  the W yne anaerobic 
model [16]. The results indicated that DosT, which is not part of the DosR regulon, initiates the 
response to hypoxia or NO and induces the dosR regulon. DosS is part of that regulon, so it is itself 
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These gene expression changes highlight the fact that fatty acids are used as the major 
carbon source in the NGMA state.  
To adapt to different oxygen tensions in its life cycle, Mtb has evolved three 
respiratory chains. A complete respiratory chain usually consists of three parts, an 
electron donor, an electron transport chain, and an elector acceptor. Mtb has redundant 
enzymes for each part (Table 2). Metabolic realignment is mainly observed within the 
electron transport chain. The cytochrome complexes and fumarate dehydrogenase (FRD) 
facilitate the oxidization of reduced menaquinol in mycobacteria individually. The 
cytochrome systems mediate the electron transfer in the presence of O2. In addition, 
FRD catalyzes the electron transfer to alternative electron acceptor, fumarate, under 
hypoxia. Two cytochrome complexes, cytochrome bcc-aa3 and cytochrome bd oxidase, 
are present in Mtb. Transcriptional profiling analysis in the mouse infection model 
suggested that cytochrome bcc-aa3 is used in the active mycobacteria, and nitrate 
reductase (NR) is predominately used in the NGMA mycobacteria. Cytochrome bd 
oxidase, however, is a transient enzyme to reshape electron flow and the redox balance 
during the environmental change,89 and therefore is important for chronic infection.  
Other than participating in energy production, some enzymes facilitate redox 
balance. Succinate dehydrogenase (SDH) and FRD were demonstrated to maintain the 
membrane potential and the redox balance in the hypoxia condition,90, 91 and NR is used 
to maintain the intracellular redox balance when Mtb is in active macrophages.92  
Notably, even though possessing an alternative ETC, and down-regulation of the 
F1F0 ATP synthase, the remaining ATP synthesis activity of F1F0 ATP synthase is 
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critical for cell survival in NGMA state. F1F0 ATP synthase was found to be the 
molecular target of the recently approval anti-tubercular drug, TMC-207. TMC-207 
shows potent inhibition against both multidrug resistant and NGMA Mtb.93, 94 In fact, it 
is more effective to the NGMA Mtb. This result opens a door to target the NGMA Mtb. 
Enzymes involved in the energy metabolism and the alternative carbon metabolism 
therefore become an attractive drug targets of NGMA Mtb. 
 
Table 2. Enzymes involved in the respiratory chains of Mtb. 
Primary dehydeogenases and 
decarboxylases 
Terminal oxidases and 
reductases 
Redox carriers ATP 
synthase 
NADH dehydrogenase I 
NADH dehydrogenase II (2) 
Succinate dehydrogenase (2) 
Formate dehydrogenase? 
Carbon monoxide dehydrogenase 
Cytochrome bcc-aa3 
complex 
Cytochrom bd oxidase 
Fumarate reductase 
Nitrate reductase (2) 
Menaquinone H+-F1F0 
 
 
 
Strategies to Identify Novel Chemotherapeutic Agents for Multidrug Resistant Mtb 
and Persistent Mtb 
 
To efficiently combat TB, we need to first find drugs for the MDR- or XDR-TB 
to solve the current emergency. In the long term, finding drugs for persistent and 
dormant Mtb will decrease treatment duration and the occurrence of the drug resistance. 
A novel drug usually comes from (i) a structural modification of a currently used drug, 
(ii) a compound with a novel chemical scaffold but targeting the same molecular 
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mechanism as an existing pharmaceutical drug, or (iii) a compound with a novel 
chemical scaffold and a novel molecular mechanism. 
The first antibiotic was discovered in the 1940s, and numerous antibiotics were 
discovered by screening soil-derived actinomycetes between 1940−1960, which was the 
so-called golden era of antibiotic discovery. In the golden era, the discovery of 
antibiotics was through natural product phenotypic screening in which molecules with 
therapeutic effects were identified and isolated. However, it became harder and harder to 
find a novel series of antibiotics using this approach in the 1990s. The increased 
knowledge of biochemistry and advances in technologies of molecular biology such as 
cloning and recombineering in the 1980s, moved antibiotic discovery into a rational 
design era, which is also known as the target-based drug discovery approach. This 
method was anticipated to fill the gap of finding novel antibiotics through the natural 
product screening approach. The target-based drug discovery approach starts from target 
selection. In the field of antibiotic discovery, a target is chosen based on two criteria, 
essentiality and selectivity. Essentiality means the target is critical for the pathogens’ 
survival or virulence. Selectivity means the target is absent in humans or shows a large 
difference to its human counterpart. The breakthroughs of the genomic technology 
further laid the foundation of the target-based approach. After the mid 1990s, the 
improvement of sequencing skills allowed us to examine the sequence of the entire 
genome of an organism. In 1995, the first entire genome of Haemophilus influenzae was 
deciphered.95 In addition, the first whole genomic sequence of a human was released in 
2003.96 The genomic study of pathogens illustrated the essential genes and their 
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corresponding gene products. The comparison with the human genome helps pre-
eliminate those targets, whose inhibitors may lead to toxicity or side effect issues. Since 
then, the target-based approach has dominated the pharmaceutical industry including 
those working in antibiotic discovery.   
However, the quantities of novel FDA approved drugs declined steadily after the 
1990s.97 A number of researchers believe that the decline is due to the overestimation of 
success in the target–based drug discovery approach.97 Between 1999 and 2008, 50 out 
of 75 first-in-class (compounds with novel chemical scaffolds) FDA approved drugs 
were small-molecule drugs. Twenty-eight were derived from the phenotypic based drug 
discovery, and 17 derived from the target based drug discovery.98 In addition, the 
approval of novel antibiotics dropped by 60%, from 33 between 1985 to 1999 to 13 
between 2000 and 2014.99 More seriously, of these only four are first-in-class.100  
The decline of the approval of novel antibiotics results from an overall decrease in 
research efforts for the antibiotic discovery due to the difficulty in licensing and poor 
return on investment. The productivity of the target-based approach is also questioned in 
the antibiotic discovery field. Multiple reviews have discussed the reasons for the failure 
of the target-based drug discovery.101 The conclusions agree with the observations in a 
key report provided by the GSK for using the target-based approach to look for novel 
antibiotics.102 Researchers in GSK summarized their findings after studying 300 genes 
and performing 70 high-throughput screens of individual targets from 1995−2001. They 
pointed out some explanations for why most hit molecules showed high potency against 
the chosen targets but without in vivo efficacy for the diseases. From the target 
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perspective, the target chosen based on the essentiality from the in vitro study often 
cannot pass the in vivo test, meaning inhibition of these selected targets would not affect 
the growth of bacteria in vivo. From the hit perspective, several hits suffer from bad 
pharmaceutical characteristics, such as low solubility or inability to penetrate bacterial 
cell walls, and also results in poor in vivo efficacy. In the end, the authors of this 
report102 suggested that currently used pharmaceutical targets or targets that are obtained 
from the phenotypic screening are more valuable for a follow-up target-based drug 
discovery than those derived from genetic studies. 
In response to the first suggestion, an examination of the molecular mechanism 
of PAS, a second-line anti-tubercular drug, is presented in Chapter II. PAS is one of the 
first discovered anti-tubercular drugs. It is currently used to treat the MDR- or XDR-TB, 
however, with an unclear molecular mechanism. Understanding the molecular 
mechanism is key to producing a new generation of PAS derivatives with improved 
efficacy and lower side effects. In addition, the definition of the molecular target also 
may provide a pharmacologically validated target for renewed target-based drug 
discovery.  
 
Enzymes Involved in Central Carbon Metabolism (CCM) Are Promising Targets to 
Combat Persistent or Dormant Mtb 
 
Lack of effective drugs against NGMA Mtb underlines the requirement to 
explore novel targets through phenotypic screening. However, it is challenging to 
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conduct a phenotypic screening for dormant Mtb since almost all models cannot reflect 
the true physiology.  Hence, enzymes are considered to be potential targets when they 
are associated with the transition to the NGMA state and are essential for bacterial 
growth or virulence in the persistent models. However, a detailed biochemical and 
biophysical examination is required prior to further exploitation.  
Enzymes involved in CCM are putative targets for NGMA Mtb since CCM is an 
important player for Mtb to transition between active and NGMA states. To adapt to the 
extracellular stresses in macrophages and granulomas, Mtb has evolved a flexible 
metabolic system to produce energy. A differential expression profile of CCM was 
observed when Mtb resided in macrophages. Several lipid catabolism enzymes are up-
regulated; on the contrary, enzymes involved in glycolysis, the tricarboxylic acid (TCA) 
cycle, and aerobic respiration are down-regulated. These results suggest that Mtb relies 
on fatty acids as the predominant carbon source in macrophages. Noteworthy is that the 
replication capability of Mtb in immature macrophages implies that it evolves an optimal 
CCM to generate energy and required metabolites through fatty acids. In addition, the 
same alternations in the transcriptional levels of the CCM were observed while Mtb was 
cultured in the two well-known in vitro models for NGMA Mtb, the Loebel carbon 
starvation model and the Wayne hypoxia model.103 These results reinforce the 
importance of CCM and therefore motivate researchers to develop inhibitors using these 
models.  
The CCM plays important roles in all living organisms. It breaks down nutrients 
uptaken from the environment and converts them into energy and biomass for cell 
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survival. CCM is composed of multiple pathways including glycolysis, gluconeogenesis, 
the pentose phosphate shunt, the TCA cycle, and the methylcitrate cycle. Although it has 
been extensively studied in E. coli and also showed a high conservation with that in 
mammals, a relatively complicated and flexible CCM was observed in Mtb to adapt to 
the nutrient limiting environment during its life cycle. In fact, the rearrangement of CCM 
components in Mtb determines its fate in the host.  
The advances in genomic sequencing, metabolomics and transcriptional profile 
analyses allow us to decipher the CCM in Mtb. Earlier studies were primarily conducted 
through the gene expression profile analysis via microarrays.83, 104-106 In general, 
isocitrate lyase 1 (ICL-1) encoded by icl and aceA, phosphoenolpyruvate carboxykinase 
(PEPCK) encoded by pcaA, and enzymes involved in the β-oxidation are up-regulated in 
the intraphagosomal Mtb and become further up-regulated under the nutrient starvation 
or the hypoxia conditions. The genome of Mtb was deciphered in 1998,107 and it 
provides an a glance of the overall picture of CCM in Mtb. Through homology-based 
sequence analysis, around 90 genes were annotated to be related to CCM and have been 
extensively detailed reviewed.108, 109 Several proteins with functional redundancy are 
present in the CCM of Mtb that supports ideas about metabolism rerouting in response to 
different environments.  
Another distinction of the CCM in Mtb is the ability to cocatabolize different 
carbon sources. Most bacteria use carbon sources under a carbon catabolite repression 
mechanism.110 Bacteria utilize preferred carbon sources first, usually glucose, by 
repressing the enzymes involving the catabolism of other carbon sources when cultured 
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in a mixed carbon source. However, metabolites from different routes were observed 
simultaneously in 13C metabolomics experiments when Mtb was cultured in vitro with a 
mixed carbon source.111 In addition, a recent 13C flux study demonstrated that Mtb used 
all available carbon sources such as C2 metabolites, CO2, or amino acids at the same 
time in macrophages.112  
The 13C flux study under hypoxia implied a general activity depletion of the TCA 
cycle enzymes and an activity increase of methylcitrate cycle enzymes that agrees with 
the transcriptional profiling. It also found a drastic increase of the intracellular levels of 
succinate.90 The increased succinate served as an agent to maintain membrane potential, 
ATP synthesis, and anaplerosis. To summarize, Mtb uses fatty acid as the major carbon 
source during infection113 and faces two challenges when using fatty acid as the carbon 
source: the generation of glucose through fatty acid and the detoxification of propionyl-
CoA, a metabolites produced in the β-oxidation of odd-chain-length fatty acids and 
branched chain amino acids. To solve these challenges, ICL and PEPCK are in high 
demand. PEPCK is the first enzyme in gluconeogenesis, which mediates the generation 
of glucose from non-glucose carbon sources. In additional, Mtb ICL is a dual function 
enzyme, which functions as an isocitrate lyase in the glyoxylate shunt and a 
methylisocitrate lyase in the methylcitrate cycle.114 The glyoxylate shunt serves as a 
bypass of the TCA cycle. The CO2 releasing steps are omitted through the glyoxylate 
shunt so it is a carbon conserved pathway compared with the TCA cycle. The 
methylisocitrate reduction is the critical step to detoxify the propionyl-CoA intermediate. 
Therefore, either or both functional roles can explain why ICL is up-regulated. In 
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addition, knocked-out Mtb ICLs115 or PEPCK116 impaired the ability to infect mice and 
demonstrated that Mtb ICLs and PEPCK are promising anti-tubercular drug targets. 
Compared with PEPCK, ICLs serve as better targets since there is no counterpart in 
humans.  
Compelling research was performed on the Mtb ICLs, but little attention was 
placed on their substrate competing enzyme, IDHs. As mentioned before, the glyoxylate 
shunt is a bypass of the TCA cycle. ICL and IDH are in the niche of the branch point 
sharing the same substrate, isocitrate (ICT).  Activities of ICL and IDH determine the 
carbon flux and therefore determine the fate of Mtb in different environments. Mtb 
possesses two IDHs, Mtb IDH1 and Mtb IDH2. Mtb IDH1 is annotated as a homo-
dimeric enzyme encoded by the gene Rv3339c. To the contrary, Mtb IDH2 belongs to 
the monomeric IDH superfamily and is encoded by the gene Rv0066c.  
Transposon mutagenesis experiments suggested that individual IDHs are non-essential 
for Mtb survival in 2003.117 However, studies carried out in BCG underscored that IDH2 
can be a potential synergetic drug target.118 In this study, the individual IDH knock-out 
BCG strains were generated, which supported the idea that IDH1 and IDH2 are non-
essential individually. Intriguingly, no IDH activity was detected for the IDH2 knock-out 
strain, suggesting that IDH2 was the only functional IDH in vivo. Moreover, the potency 
of the ICL inhibitor, 3-nitropropionate, increased in the IDH2 knock-out strain.  
The co-catabolic characteristic of Mtb suggests that the co-inhibition of ICLs and IDHs 
is necessary to achieve bacterial death. The greater effect of ICL inhibitor in the IDH2 
knock-out BCG strain further supports this hypothesis. A detailed introduction to IDH 
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followed by a thorough study of Mtb IDH2, including a complete biochemical and 
biophysical characterization and preliminary inhibitor screening, are presented in 
Chapter IV. 
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CHAPTER II 
MECHANISM ACTION STUDY OF A SECOND-LINE ANTI-TUBERCULAR 
DRUG PARA-AMINOSALICYLIC ACID (PAS) 
 
 
Introduction 
 
Para-aminosalicylic acid (PAS) (Figure 4A) was the first anti-tubercular drug119 
discovered, and it is still used as a second line drug for TB treatment, especially for 
MDR-TB. The anti-tubercular activity of PAS was first reported by Lehmann in 1946 
when looking for bacteriostatic agents against TB within a collection of more than 50 
derivatives of benzoic acid.120 PAS was thereafter used as a first-line drug in 
combination with isoniazid and streptomycin until it was replaced by ethambutol in the 
1960s as the combination with PAS showed higher frequency of vestibular and gastric 
side effects in patients.121 PAS was reintroduced to treat MDR-TB and XDR-TB in 
1992.122  
PAS exhibited an EC90 value of 1.25 µg/mL for Mtb H37Rv in an in vitro 
microplate alamar blue assay with a 7H9 buffer supplemented with glycerol, OADC 
(oleic acid, albumin, dextrose, and catalase), and tween80.123 The recommended dosage 
of PAS granules is 4 g in a single dose and one dose twice per day. This dosage 
maintains PAS in an intracellular concentration higher than the reported MIC (> 1 
µg/mL), for effectively controlling the MDR-TB.124 
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Figure 4. Chemical structures of PAS (left) and its structural related metabolites, para-
aminobenzoic acid (pABA) (middle) and salicylic acid (right) 
 
 
Intriguingly, PAS is an organism specific antibiotic. Diczfaluzi et al. found that it 
is not active against E. coli, S. aureus, or S. haemolyticus.125 Moreover, it shows less 
potency against mycobacteria such as M. avium (EC90 =80 µg/mL),123 M smegmatis 
(EC90=512 µg/mL),126 M. fortuitum (EC90> 128 µg/mL),127 and M. chelonae (EC90> 128 
µg/mL).127 Even though the anti-tubercular effect of PAS has been demonstrated over 70 
years, its mode of action and molecular target were unclear. A lack of published data on 
these studies could be due to the discontinued use in the clinic during the 1960s to 1992. 
One putative mechanism of action of PAS is to interfere with the folate 
biosynthetic pathway. Folates, tetrahydrofolate (THF) and its analogs, consist of three 
moieties, a pteridine, p-aminobenzoic acid (pABA) and L-glutamate. They function as 
carbon carriers in the one-carbon metabolism.128 One-carbon groups from serine, 
glycine, histidine, and formate, are added to N5, N10, or both on the pyridine ring of 
folates. The common observed derivatives include 5-methyl-, 5,10-methylene-, 5,10-
methenyl-, 5-formimino-, 5-formyl- and 10-formyl-THF. These derivatives are used as 
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OH
NH2
COOH
OH
COOH
NH2
PAS pABA Salicylic acid
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carbon donors in several biosynthetic reactions, particularly the synthesis of purine, 
thymidylate, and methionine.128 
Plants and most bacteria, including mycobacteria, generate THF by a de novo 
biosynthesis (Figure 5).129 This pathway can be divided into two branches, the pteridine 
branch and the pABA branch. GTP is the precursor of the pteridine branch.130 Following 
the consecutive action of FolE (EC 3.5.4.16), an unidentified Phosphatase, FolB (EC 
4.1.2.25), and FolK (EC 2.7.6.3), GTP is converted into 7,8-dihydroneopterin 3’-
triphosphate, 7,8- dihydroneopterin, 6-hydroxymethyl-7,8-dihydropterin, and then 6-
hydroxymethyl-7,8-dihydropteridine pyrophosphate (HP).131 Additionally, the pABA 
branch starts from chorismate, the product of the shikimate pathway.132 First, chorismate 
is converted into 4-amino-4-deoxychorismate via a 4-amino-4-deoxychorismate synthase 
(EC 2.6.1.85) and further is turned into pABA by 4-amino-4-deoxychorimatelyase (EC 
4.1.3.38).132  
The two branches merge together when HP and pABA are condensed by 
dihydropteroate synthase (DHPS) (EC 2.5.1.15) forming 7,8-dihydropteroate (DHP). 
Dihydrofolate synthase (DHFS) (EC 6.3.2.12) then adds an L-glutamate to DHP to 
produce dihydrofolate (DHF). The produced DHF then reduces to the final product, 
THF, by dihydrofolate reductase (DHFR) (EC 1.5.1.3.). A polyglutamate tail (2−7 
glutamyl residues133) is addition to the γ-carboxy of the THF glutamate via 
folylpolyglutamate synthetase (FPGS) (EC 6.3.2.17). In Mtb, a bifunctional enzyme, 
FolC, catalyzes the reactions of DHFS and FPGS. In addition to the de novo synthesis, 
THF can be generated through recycling the reducing DHF in the thymidylate synthesis. 
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Figure 5. De novo folate metabolism and the sites at which antimetabolites act. 
Metabolites are shown in black, enzymes are labeled in blue, and inhibitors are colored 
in red. 
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PAS was first thought to be a competitive inhibitor of DHPS due to being a 
structural analogue of pABA (Figure 4B). However, PAS showed a different inhibition 
profile with sulfonamides and sulfones, the well studied inhibitors of DHPS (Table 3).134 
PAS exhibited a high inhibitory constant for Mtb DHPS but a better whole cell efficacy 
for Mtb when compared with that for the sulfonamides and sulfones. The unexpectedly 
low whole cell activities of sulfonamides and sulfones indicate the difficulty they face in 
accessing the intracellular target in Mtb. The different inhibition profiles therefore 
suggest that Mtb DHPS may not be the molecular target of PAS, unless there is a unique 
uptake system for PAS. 
 
Table 3. Inhibition profile of PAS, sulfones and sulfonamides against the activity of Mtb 
DHPS and the growth of Mtb134  
Compound Ki (µg/mL) for 
Mtb DHPS 
EC90 
(µg/mL) 
PAS 0.18 0.3−1.0 
Dapsone (sulfone) 0.002 >32 
Sulfamethoxazole (sulfonamide) 0.004 8 
  
 
Despite the fact that DHPS is not the target of PAS, the folate pathway is still 
associated with the mechanism of action of PAS due to the observed correlation between 
the PAS resistance and the mutation in thymidylate synthase (ThyA).135 ThyA catalyzes 
the reductive methylation of 2’-deoxyuridine-5’-monophosphate (dUMP) to 2’-
deoxythymidine-5’-monophosphate (dTMP).135, 136 In this reaction, 5,10-methylene-
tetrahydrofolate (5,10-methylene-THF) functions as a one-carbon donor and is converted 
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to a byproduct, dihydrofolate (DHF). 5,10-methylene-THF is a derivative of THF, the 
final product of the folate pathway. Mutations in gene thyA are one of the most common 
PAS resistant mechanisms in the clinical isolates. Around 37% of PAS resistant strains 
contain mutations in thyA in a study that took place in 2009.136 A recombinant 
Mycobacterium bovis (M. bovis) BCG strain expressing Mtb ThyA showed a 
hypersensitivity to PAS, which indicates that ThyA can be an activator instead of a 
molecular target of PAS.135 No previous study has investigated the biochemical 
relationship between ThyA and PAS. Therefore, the interconnection between PAS and 
the folate pathway remains unclear. 
Alternatively, PAS is related to the iron acquisition mechanism. Microorganisms 
acquire irons from the environment via siderophores. Siderophores chelate Fe3+ and 
transfer it into cells. Two types of siderophores, carboxymycobactin and mycobactin, are 
found in Mtb.137 Mycobactin (Figure 6) contains a long alkyl chain (n= 19 in Mtb) that 
makes it lipophilic; in contrast, the alkyl chain of carboxymycobactin (Figure 6) is 
shorter (n= 2−9) and with a carboxylate group at the end resulting in a hydrophilic 
characteristic.138 Carboxymycobactin is secreted out from Mtb and collects the iron from 
the host.139 The ferri-carboxymycobactin would either deliver the iron to the membrane 
associated mycobactin139 or pass the cell membrane by an ABC transport system, 
IrtAB140 (Figure 7). Salicylic acid plays a key role in the iron acquisition mechanism. It 
is not only a precursor of the siderophores but also a sensor to signal the intracellular 
iron status. As for pABA, PAS is a structural analogue of salicylic acid, and it shows 
potent inhibition against the mycobactin synthesis.141  
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Figure 6. Chemical structures of siderophores produced by Mtb. Mycobactin (left) is 
membrane associated, and carboxymycobactin (right) is water soluble. The acyl chain on 
the hydroxylated lysine of the carboxymycobactin is 2−9 carbon long. Salicylic acid 
moiety is highlighted in red. 
 
 
 
 
Figure 7. Iron acquisition system of Mtb. To obtain the iron, the water soluble 
carboxymycobacins are secreted by Mtb in an iron deficiency condition. The 
carboxymycobatins chelate Fe3+ from the host to form Fe3+-carboxymycobactin 
complexes. The complexes are transported back through the mycobacterial outer 
membrane by the Msp family porins first. The complexes then either transfer the Fe3+ to 
the membrane associated mycobactins or are transported into the cell by the iron 
regulated ABC-transporter, IrtAB. Blue pentagon, orange rod, and green cube represent 
carboxymycobactin, IrtAB, and mycobactin, respectively.     
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Therefore, the mechanism of action of PAS is a controversial subject since no 
molecular based evidence supports the hypothesis that the folate pathway is the target, 
and no clinical evidence gets behind the idea that PAS targets the iron acquisition 
pathway. After the reintroduction of PAS, understanding the insight into the mechanism 
of action of PAS becomes important. The knowledge of the mechanism can provide a 
platform for designing PAS analogues with reduced toxicity and illustrate a molecular 
target with a validated clinical therapeutic ability for a target-based drug screening. In 
this chapter, a genetic study was implemented to characterize the putative molecular 
target of PAS. In addition, a structural investigation was carried out to justify the 
mechanism from a molecular basis.  
 
Results and Discussion 
 
Mutations in the Folate Biosynthesis Genes Make Mtb mc27000 Resistant to PAS 
Advances in DNA sequencing technology allow a quick and affordable 
investigation of the entire genome of the drug resistant individual instead of examining 
the sequence of the pre-suggested target gene alone. Spontaneous laboratory PAS 
resistant mutants were isolated from the two Mtb mc27000 strains, wild-type (WT) and 
overexpressing exogenous ThyA strains. The additional copies of ThyA would 
compensate for resistance caused by the mutation of ThyA and presumably enhanced the 
chance to obtain the mutant strains with mutations other than ThyA.  
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Whole genome sequencing was conducted on five PAS resistant Mtb mc27000 
strains that were isolated from the WT Mtb mc27000 experimental trial. Mutations in the 
thyA gene were detected in four of them, and a deletion across dfrA and thyA genes was 
observed in Strain 5 (Table 4). Strain 1 contained a deletion of 3 base pairs in thyA, 
which encoded Ala 40 in the WT ThyA. Strain 2 harbored a W60* nonsense mutation in 
thyA, resulting in a premature ThyA protein. Strain 3 had a potential recombination 
event between thyA and its downstream gene, PPE44, which caused an inversion 
mutation. Similar to Strain 2, Stain 4 had a nonsense mutation of W83* in thyA.  A 
deletion of 824 base pairs, base pair numbers from 3073139 to 3073962, was observed 
on Strain 5 spanning genes dfrA (Rv2763) and thyA (Rv2764c).  
As mentioned earlier, PAS resistance can emerge due to the point mutations in 
thyA, and a broad spectrum of mutation positions were reported. In the study conducted 
by Mathys et al., 24 different mutation positions in thyA were observed within 118 
clinical and laboratory PAS resistant isolates.136 Many diverse mutation positions in thyA 
suggested that there is no mutation hot spot for this gene. Among the four thyA 
mutations in our study, only the W83* mutation had been reported previously in five 
clinical isolates from the Beijing family142 and one spontaneous mutant isolated from a 
7H11 plate supplemented with 16 µg/mL PAS.136 The low re-emergence of the reported 
mutants in our study could be due to the application of the mutagen, ethyl 
methanesulfonate (EMS), during the mutant isolation process for Strains 2−5. EMS 
mainly promotes the GC to AT substitution mutation and occasionally increases the 
frequency of the frameshift mutation event, which decreases the mutation diversity of 
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the selection pool. Moreover, the increased number of SNPs also corresponds to the 
EMS treatment. 
To obtain PAS resistant mutants with mutations in genes other than thyA, PAS 
resistant strains were isolated in the presence of excessive ThyA by an overexpression 
plasmid. Two stains, Strain 6 and Strain 7, were obtained and sequenced (Table 4). 
Notably, mutations in another folate biosynthetic gene folC were observed in both 
strains, although the exact mutation positions were different. Gene folC encodes a 
bifunctional enzyme with DHFS and FPGS activities. DHFS catalyzes the conversion 
from DHP to DHF by adding an L-glutamate, and FPGS catalyzes the addition of poly-
glutamate residues to DHF via the same reaction. Strain 6 and Strain 7 contained 
missense mutations of I43T and D135V, respectively. The mutations observed in folC 
are critical for the substrate binding of the encoded protein according to the crystal 
structure (2VOS143). I43 is located on the binding loop, and D135 is located in α4, which 
forms a salt bridge with the binding loop. These results indicate that FolC may be the 
molecular target of PAS or at least is involved in the targeting mechanism of PAS.  
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Table 4. The sequencing results of the PAS resistant strains 
Strain Strain 
manipulation 
Conc. of 
PAS used 
for selection 
(µg/mL) 
Gene modifications in folate 
biosynthetic genes 
Total 
SNPs 
MICs 
(µg/mL) 
folC thyA dfrA 
1 None 4 None A40del  None 2 >8 
2 Exposed with 0.1% 
EMS 
4 None W61* None 15 >8 
3 Exposed with 0.1% 
EMS 
4 None Potential 
recombinat
ion event 
None 15 >8 
4 Exposed with 0.1% 
EMS 
4 None W83* None 9 >8 
5 Exposed with 0.1% 
EMS 
4 None Deletion Deletion None >8 
6 Overexpression of 
ThyA 
4 I43T None None 2 >8 
7 Overexpression of 
ThyA 
4 D135V None None 2 >8 
 
 
DHFR Is Essential Only When ThyA Is Active 
Before proceeding to examine the role of the mutation containing enzymes, it 
will be necessary to discuss why a strain with a deletion mutation in dfrA can survive. 
The existence of the dfrA deletion strain is surprising since it is thought to be essential 
for Mtb survival according to a transposon mutagenesis study.144 It has been reported136 
that a PAS resistant strain contains point mutations in dfrA and thyA simultaneously; 
however, in our study, we observed a strain with a thyA and dfrA double deletion for the 
first time. Indeed, a double deletion of these two genes was recently observed in some 
clinical PAS-resistant isolates,145, 146 demonstrating its clinical relevance.  
A possible explanation would be the presence of ThyX, an alternative pathway to 
thymidine biosynthesis. A ThyA/DHFR coupled pathway was thought to be the only 
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pathway to synthesize dTMP. ThyA used 5,10-methylene-THF as the one-carbon unit 
donor and a reductant to catalyze the methylation of dUMP (Figure 8). 5,10-methylene-
THF is therefore oxidized to DHF.147 This resulting DHF is rapidly reduced to THF by 
DHFR. In 2002, the enzyme, ThyX, was first identified.148 ThyX catalyzes the synthesis 
of dTMP in the presence of 5,10-methylene-THF, FAD and NADPH (Figure 8). 5,10-
methylene-THF is only used as a carbon donor, and the FAD/NADPH couple provides 
the electrons for the methylation process of ThyX. Notably, instead of DHF, 5,10-
methylene-THF is converted into THF in the reaction driven by ThyX. Therefore, ThyX 
is an alternative to the ThyA/DHFR coupled pathway not only in place of the ThyA.  
dTMP biosynthesis is required for cell survival, and most bacteria have either a 
ThyA/DHFR or a ThyX pathway. However, corynebacteria, including Mtb, are found to 
possess both thyA and thyX genes.148 Notably, it was demonstrated149 that Mtb ThyA is 
non-essential for Mtb survival by a knock-out study. This result suggested that Mtb 
ThyX would compensate for the loss of Mtb ThyA. However, because Mtb ThyA shows 
a better catalytic activity and a higher expression level compared to Mtb ThyX,149, 150 the 
ThyA/DHFR coupled pathway may dominate the thymidine biosynthesis in Mtb. Mtb 
DHFR is therefore required to recycle 5,10-methylene-THF and is essential for cell 
survival under normal conditions. For Strain 5, Mtb DHFR is dispensable since ThyA is 
dysfunctional, and ThyX is sufficient to replace the role of ThyA.   
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Figure 8. Thymidylate synthase reaction. There are two classes of thymidylate 
synthases, ThyA and ThyX. ThyA catalyzes the reductive methylation of dUMP using 
5,10-methylene-THF as a one-carbon donor and a reductive power. Alternatively, ThyX 
catalyzes the reductive methylation of dUMP with 5,10-methylene-THF and an 
FAD/NADPH couple serving as the one-carbon donor and the reductant, respectively. 
 
 
MIC of mc27000 against PAS Increased When DHFR Was Overexpressed 
Mechanisms of drug resistance resulting from mutations include (i) directly 
disrupting the binding between the drug and its molecular target; (ii) inducing the 
expression of the targeted enzyme or its functional counterpart; (iii) reducing the activity 
of the intracellular activator; and (iv) altering the drug transport system. Since mutations 
in thyA, dfrA, and folC are associated with the PAS resistance, their corresponding 
enzymes, ThyA, DHFR and FolC, are potential molecular targets or activators of PAS.  
Gene knock-out and overexpression analyses are commonly used to investigate 
the influence of a specific enzyme on an inhibitor. In this study, PAS susceptibility tests 
were conducted on strains with the overexpression of ThyA, DHFR or FolC to evaluate 
if there is a true target or activator within these putative candidates. ThyA and FolC were 
overexpressed in Mtb mc27000 (ThyAox and FolCox strains) through a tetracycline 
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inducible expression vector151 (pDT) with an N-terminal 6x His-tag. The overexpression 
of the proteins was confirmed by immunoblotting the 6x His-tag using an anti-His tag 
antibody. DHFR overexpression in mc27000 (DHFRox strain) was first constructed by the 
same method; however, neither the N-terminal nor the C-terminal 6x His tagged DHFR 
overexpression was observed. The effect of overexpressing DHFR on PAS resistance 
was therefore tested by cloning DHFR into a pMV261 plasmid, which expresses genes 
constitutively under the control of the hsp60 gene promoter. MICs for PAS did not show 
significant differences when the FolCox or ThyAox strains were induced by 100 ng/mL of 
anhydrotetracycline when compared with that of both un-induced cells and the parental 
untransformed mc27000 cells (MICs were 4 µg/mL for all experiments). To the contrary, 
MIC of PAS increased (>16 µg/mL) in the pMV261::dhrA transformed mc27000 cells 
(Figure 9). This observation suggests that Mtb DHFR is the molecular target of PAS. 
This hypothesis explains the role of defective or dysfunctional ThyA in the PAS 
resistance. As discuss earlier, Mtb DHFR is a conditionally essential gene. It is essential 
when Mtb ThyA facilitates the dTMP synthesis. Therefore, a defective or dysfunctional 
ThyA makes Mtb DHFR dispensable and then causes resistance to a DHFR inhibitor, 
PAS.     
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Figure 9. Whole cell assay of PAS to Mtb mc27000 strain with a DHFR overexpression 
vector. Each well (A-F) has different concentrations of PAS, wells A-C: 0, 1, 2 µg/mL, 
wells D-F: 4, 8, 16 µg/mL. For each well, the top left spot contains 10 µL of OD=1 cells 
with empty pMV261 vector; the top right spot contains 10 µL OD=0.2 cells with empty 
pMV261 vector; the bottom right spot contains 10 µL of OD=1 cells with pMV261:: 
dfrA vector; and the bottom left spot contains 10 µL of OD=0.2 cells with pMV261:: 
dfrA vector. 
PAS Is Incorporated into the Folate Pathway and DHPS or PAS Uptake Is the Rate-
Limiting Step of the PAS Activation Process 
 After our study was conducted, one important observation was reported by 
Chakraborty et al. 152 that PAS is incorporated into the folate pathway. An Mtb cell 
lysate after PAS treatment was analyzed by LC-MS. A series of hydroxylated folate 
metabolites were isolated and identified including the hydroxylated products of DHPS 
and FolC. Combining this result with our data, we concluded that PAS is a prodrug and 
targets DHFR. This hypothesis was soon confirmed by a follow-up paper published by 
Zheng et al. in 2014.153 They further proposed that hydroxy-DHF is the toxic component 
inhibiting Mtb DHFR.153 
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An in vitro experiment was designed to investigate the effects of each 
hydroxylated metabolite against Mtb DHFR. Indeed, all hydroxylated metabolites are the 
putative active forms of PAS since the observation of the downstream metabolites does 
not rule out the possibility that one of the intermediate metabolites accumulates and 
results in toxicity. The hydroxylated metabolites are not commercially available. Thus, 
an enzymatically synthetic approach was used to obtain the putative compounds. The 
enzymes involved in the Mtb folate biosynthetic pathway were cloned and purified 
including FolK, FolP1, DHPS, and FolC. PAS was used as the substrate in the reaction 
of FolP1 to generate the hydroxy-substrate for the next step and so on. As a control, 
pABA was used as the substrate to evaluate the enzyme assay. After reaction, enzymes 
were removed via a 10kDa spin column, and the product of each reaction was monitored 
by LC-MS. The individual incorporated product was observed in the flow through by the 
LC-MS. The instability of the dihydropteridine group, however, makes it difficult to 
conduct a purification step. Nevertheless, the unpurified reaction flow through from each 
step was used as an inhibitor stock in the Mtb DHFR enzyme assay. The inhibitory 
activity of individual hydroxylated metabolites turned out to be inconclusive due to the 
low product yield after the multiple steps reaction and the unknown concentration in the 
unpurified metabolites solution. Therefore, the intracellular active chemical form awaits 
further investigation.  
Alternatively, the whole cell efficacy of the FolCox strain provides another 
insight into the activation procedure of PAS. Assuming that the hydroxy-DHF is the 
ultimate active chemical species, overexpression of FolC should induce the PAS 
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sensitivity of Mtb by increasing the production of the toxin. However, no MIC decrease 
was found when FolC was overexpressed. The non-correlation between the whole cell 
efficacy and the activity of FolC suggests that the determinant of the PAS activity occurs 
before this step, which are the uptake step or the conversion by DHPS.   
 
Molecular Modeling Revealing a Water-Mediated Hydrogen Bond Network Providing 
Selectivity between DHF and Hydroxy-DHF 
A structural study was performed to understand the binding mode of the 
hydroxy-DHF and the role of the hydroxyl group in terms of selectivity even though its 
biochemical inhibition awaits further investigation. An in silico docking experiment was 
conducted due to hydroxy-DHF being unavailable. Hydroxy-DHF was modeled by a 
Glide program in its flexible docking mode into a methotrexate (MTX) bound Mtb 
DHFR structure (Protein Databank (PDB) code: 1DF7154). In fact, a DHF bound Mtb 
DHFR would be the best model for this experiment since DHF is the closest structural 
analogue of the hydroxy-DHF. Whereas, the structure of the DHF bound Mtb DHFR has 
not been solved at this time, so the MTX bound Mtb DHFR structure was used instead. 
MTX is a tight binding DHF competitive inhibitor of DHFR. It exhibits an IC50 value of 
6.8 nM to Mtb DHFR.155 A structural comparison was conducted to investigate whether 
the MTX bound Mtb DHFR structure is a good substitute. It has been demonstrated in E. 
coli DHFR that MTX and DHF are located at the same binding cavities. The difference 
is that the pteridine ring of MTX has a 180° rotation about the axis which is collinear 
with the line between C2 and N5 of DHF (Figure 10), and the remaining pABA and 
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glutamate moieties have the same binding mode comparing with DHF at the active 
site.156 This binding correlation is conserved for the DHFRs with both MTX-bound and 
DHF-bound structures available.157-159 These results suggests not only that MTX bound 
DHFR structure can be a good replacement but also that the docking results can be 
evaluated by the conserved binding mode alternation. 
 
 
 
 
Figure 10. Chemical structure of (A) DHF and (B) MTX with numbering 
 
 
 
Other than NADPH and MTX, a glycerol molecule is found nearby the N8 of 
MTX (Figure 10) in this MTX bound Mtb DHFR structure. To explore the most binding 
poses, NADPH and glycerol were removed from the structure before docking. The 
molecular modeling results revealed the interaction of the hydroxy-DHF with the MTX 
binding site in Mtb DHFR. Eight ligand poses were reported from the Glide docking, 
and the ligand strain energy of each ligand was calculated using ICM-browser pro (Table 
5).  
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Table 5. Ligand conformations of the modelled hydroxy-DHF derived from the Glide 
docking and their corresponding strain energy calculated by ICM-browser pro 
Ligand 
conformation 
Ligand Strain 
Energy 
Hydrogen bonding 
with H2O (644) 
1 31 Yes 
2 83  
3 96  
4 35 Yes 
5 92 Yes 
6 78 Yes 
7 75 Yes 
8 32  
 
 
In general, all conformations, except pose 8, are located at the MTX binding site. 
Specifically, the dihydropteridine moiety of the hydroxy-DHF appeared at the same 
position where the corresponding pteridine moiety of MTX is located, but the 
aforementioned 180° rotation was observed only in poses 1, 6 and 7. As shown in Figure 
11, the additional hydroxyl groups pointed to the N-terminus of the helix B in pose 1 and 
poses 3−7. Alternatively, it pointed against the N-terminus in pose 2.  
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Figure 11. Two possible orientations of the hydroxyl groups of the hydroxy-DHFs as 
docking in the MTX binding site of Mtb DHFR. Helix B of Mtb DHFR is colored in 
yellow. The hydroxyl groups face the N-terminus of the helix B of Mtb DHFR in the 
majority docking poses expect pose 2, which faces the C-terminus of the helix B. Pose 6 
shown in green represents the major orientation, and the binding mode of pose 2 is 
shown in pink.  
 
 
 
The hydroxyl group did not form a direct hydrogen bond with the surrounding 
residues of Mtb DHFR in any pose. However, a conserved water mediated hydrogen 
bond network was observed in poses 1, 4, 5, 6, and 7 (Figure 11). The hydroxyl group 
formed a hydrogen bond with an ordered water molecule (H2O 644). This water 
molecule also formed a hydrogen bond with the side chain of Gln28. This water 
mediated hydrogen bond network may lead to the selectivity between DHF and hydroxy 
DHF. Poses 1 and 4 were considered to be the better binding modes within eight poses. 
Hydroxy-DHFs in pose 1 and 4 had relatively low strain energy. In addition, the binding 
mode of pose 1 was similar to that of folate when compared with a reported folate bound 
E. coli DHFR structure.160 The interaction of Mtb DHFR and the hydroxy-DHF in pose 1 
and pose 4 are shown in Figure 12. In summary, the current mechanism of action of PAS 
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would be that PAS is incorporated into the folate pathway of Mtb and converted into 
hydroxy-DHF. Hydroxy-DHF then serves as an inhibitor to Mtb DHFR by competing 
with DHF through an extra water mediated hydrogen bond network.  
 
 
A B 
 
 
Figure 12. Detailed interactions between the top ranked poses and Mtb DHFR. Ligplot 
diagrams represent the interactions between Mtb DHFR and the top ranked poses (A) 
Pose 1 and (B) Pose 4. The hydrogen bonds are shown in green dashes line and the 
hydrophobic interactions in red arcs. The carbon atoms, oxygen atoms, and nitrogen 
atoms are colored by black, red, and blue, respectively. The ligand bonds are in light 
blue and protein bonds in black. 
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PAS Targets More than One Pathway 
Selectivity within different species of Mycobacterium is another question about 
the mechanism of action of PAS. Based on the proposed model, one possibility is that 
DHPS or FolC have critical differences in varied species of Mycobacteria. As a result, 
PAS cannot be converted into the active chemical form. After conducting a sequence 
analysis, we found that both DHPS and FolC showed high sequence identity (70%−99% 
with coverage more than 93%) among different species of Mycobacterium. These results 
rule out the first possibility. The second possibility would be a lack of residue, which can 
form the hydrogen bond with the conserved water as Gln28 in Mtb. A sequence 
alignment was performed on a collection of mycobacterial DHFRs composed of species 
of Mycobacterium for which PAS whole cell activity have been reported. As shown in 
Figure 13, three types of residues (glutamine, leucine, and methionine) were found at 
corresponding position of Gln28 in Mtb DHFR. 
 
 
Figure 13. Multiple sequence alignment of a collection of DHFR from different species 
of Mycobacterium. Invariant residues (white on red background) and conservatively 
substituted residues (red) are indicated. Q28 and its corresponding residues are shaded in 
yellow. The figure is prepared using ESPript.161  
 
Mtb H37Rv 
M. bovis 
M. aurum 
M. avium 
M. chelonae 
M. fortuitum 
M. kansasii 
M. marinum 
M. smegmatis mc2155 
    1       10        20        30 
sp|P9WNX1|DYR_MYCTU                      IWAQ   G IG    IPW  PED  V L    TS V  R    RL   A....MTM G A GGD Q
gi|960313553|ref|WP_058222282.1|           IWAQ   G IG    IPW  PED  V L    TS V  R    RL   A....MTM G A GGD Q
gi|873941886|ref|WP_048634696.1|           IWAQ   G IG    IPW  PED  L M    SSS V  R    HV   V...MPSN G DNG M
gi|518566105|ref|WP_019736312.1|           IWAQ   G IG    IPW  PED  L L    S S V  R    RL   A....MSA A V AGG Q
tr|A0A0E3XQJ1|A0A0E3XQJ1_MYCCH            IWAQ   G IG    IPW  PED  I L    S  V     RL   A...MTGT G RD ADGA Q
gi|937420428|gb|ALI26427.1|              IWAQ   G IG    IPW  PED  L M    STS V  R    HL   AMTDDLRQ A DNG Q
tr|U5WVG5|U5WVG5_MYCKA                   IWAQ   G IG    IPW  PED  V L    STS V  R    RV   ....MTA G GGD LS
gi|522803072|ref|WP_020728368.1|           IWAQ   G IG    IPW  PED  V L    STS V  R    RL   A....MTS G DGG L
G9X-5536-MONOMER                         IWAQ   G IG    IPW  PED  M L    STS I  R    RL   A....... R DNS L
       40        50        60      
sp|P9WNX1|DYR_MYCTU              F   T G    MGR TW SLP   RPLPGR N VH R I M H IV     D   A V      R V E T R K
gi|960313553|ref|WP_058222282.1|  F   T G    MGR TW SLP   RPLPGR N VH R I M H IV     D   A V      R V E T R K
gi|873941886|ref|WP_048634696.1|  F   T G    MGR TW SLP   RPLPGR N VR K L M H VI     E         R V E T M EKF
gi|518566105|ref|WP_019736312.1|  F   T G    MGR TW SLP   RPLPGR N VR K L L H VV     E   A V       V E R L A T
tr|A0A0E3XQJ1|A0A0E3XQJ1_MYCCH   F   T G    MGR TW SLP   RPLPGR N VR K I M H VI     E   V       I R T K SS P
gi|937420428|gb|ALI26427.1|      F   T G    MGR TW SLP   RPLPGR N VR K L V VI     E   A V      R V Q QT L R
tr|U5WVG5|U5WVG5_MYCKA           F   T G    MGR TW SLP   RPLPGR N VH K I M H VV     D   A A      R V R T R S
gi|522803072|ref|WP_020728368.1|  F   T G    MGR TW SLP   RPLPGR N VH K L M H VV     D   A       R V R A R AN
G9X-5536-MONOMER                 F   T G    MGR TW SLP   RPLPGR N VR K M M H VV     E   A V      R I E P L S
  70        80        90           
sp|P9WNX1|DYR_MYCTU               R       GA                   WVIGLS F A   VV LE A     QAD M S E GS E LTSP...E.T
gi|960313553|ref|WP_058222282.1|   R       GA                   WVIGLS F A   VV LE A     QAD M S E GS E LTSP...E.T
gi|873941886|ref|WP_048634696.1|   R       GA                   WVIGVT Y A   VV IE A     QAD T E E TS D P.....LDDA
gi|518566105|ref|WP_019736312.1|   R       GA                   WVIGVT Y A   VV LD A     DPD R D G ST A LTD....AET
tr|A0A0E3XQJ1|A0A0E3XQJ1_MYCCH    R       GA                   WVIGLT F   AV AD A     DAL EPD L GC A LAAS..DEAP
gi|937420428|gb|ALI26427.1|       R       GA                   WVIGIT Y A   VL LD V     DPG I E E TG D .......FRG
tr|U5WVG5|U5WVG5_MYCKA            R       GA                   WVIGLS F A   VV LE A     QPG V E E GS D LTGP...EDT
gi|522803072|ref|WP_020728368.1|   R       GA                   WVIGVT A   VV LE A     QTGLV H Q GS Q LCPAEPDAET
G9X-5536-MONOMER                  R       GA                   WVIGVT Y A   VV L     DAD R E E TD PDE.......PDA
100       110       120       130  
sp|P9WNX1|DYR_MYCTU             G   Y      A RCEVT           DA AP  QV LALP       EVDI LP   L  VG A Y T G REAG
gi|960313553|ref|WP_058222282.1| G   Y      A RCEVT           DA AP  QV LALP       EVDI LP   L  VG A Y T G REAG
gi|873941886|ref|WP_048634696.1| G   Y      A RCEVT           DA AP  QI LAAP       EVDI V   L  LS G L T D RREDD
gi|518566105|ref|WP_019736312.1| G   Y      A RCEVT           DA AP  QI LALP       EVEI LP   V  VA A L T D RQDA
tr|A0A0E3XQJ1|A0A0E3XQJ1_MYCCH  G   Y      A RCEVT           DA AP  I L LP       VDA VP   L  GE R F L Q V D ...G E
gi|937420428|gb|ALI26427.1|     G   Y      A RCEVT           DA AP  QI ALP       EIDI LP   M  VA AQ F V D PAAG
tr|U5WVG5|U5WVG5_MYCKA          G   Y      A RCEVT           DA AP  QI LALP       EVDV LP   L  E T R I D RDDD P
gi|522803072|ref|WP_020728368.1| G   Y      A RCEVT           DA AP  QI LALP       EVDV LP   L  VA A L N D PEDE
G9X-5536-MONOMER                G   Y      A RCEVT           DA AP  QI MAL       EVDI L     VA A AR D A TPLDG R
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PAS may not inhibit the group of DHFR with the leucine, which has neither a 
hydrogen bond donor nor an acceptor at its side chain to form the hydrogen bond with 
the ordered water. Therefore, the growth of this group of mycobacterium should be 
insensitive to PAS. A comparison of the PAS efficacy and the residues at Gln28 for 
different species is listed in Table 6. There is no significant correlation between the cell 
growth inhibition and the type of the residue. Particularly, M. avium, M. chelonae, and 
M. fortuitum have a conserved Gln but show high MIC values to PAS. This result 
indicates that the Gln28 hydrogen bond network is not the determinant for the 
selectivity.  
The sequence analysis indicates that the current model is inadequate to explain 
the mechanism of action of PAS. Therefore, PAS may target another pathway such as 
the iron acquisition pathway, or the interaction between PAS and the folate pathway is 
more complicated than the current understandings. 
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Table 6. Whole cell activity of PAS against different species of Mycobacterium and the 
residue of their DHFR corresponding to Gln28 in Mtb DHFR 
 EC90 (µg/mL) Putative water 
interacting residue 
Mtb H37Rv 1.0123 Q (Gln28) 
M. bovis 1162 Q 
M. aurum 1162 M 
M. avium >256163 Q 
M. chelonae >128127 Q 
M. fortuitum >128127 Q 
M. kansasii >256163 L 
M. marium >256163 L 
M. smegmatis 512126 L 
 
 
 
Materials and Methods 
 
Bacterial Strains, Media and Growth Condition 
Mtb mc27000 strain was used in this study. Mtb mc27000 is an Mtb strain without 
the primary attenuating mutation of BCG (RD1) and two genes for the pantothenate 
biosynthesis (panC and panD). The Mtb mc27000 strain has been approved for use in 
Biosafety Level 2 laboratory since it fails to kill SCID mice following intravenous 
challenge and is ultimately cleared. Mtb mc27000 was grown in Middlebrook 7H9 media 
(Difco, Sparks, MD) supplemented with 10% oleic acid-albumine-dextrose-catalase 
(OADC), 0.2% dextrose, 0.05% (vol/vol) tyloxapol (Sigma) and 25 µg/mL pantothenic 
acid (Sigma). The antibiotic hygromycin (50 µg/mL) was added as required for 
maintenance for the pDT plasmid. The culture was also grown in Middlebrook 7H10 
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media (Difco) supplemented with 0.5% dextrose and 25 µg/mL pantothenic acid when 
selections were conducted. 
 
Generation and Selection of PAS Resistant Mutants 
Mtb mc27000 was first grown in supplemented 7H9 media to an optical density at 
600 nm (OD600) of ~1.0. Then 1 mL of cells containing broth was plated onto a 
supplemented 7H10 media plates containing 10 µg/mL PAS (Sigma). The plate was 
incubated at 37C and the colonies were picked after 1 month. Selected colonies were 
cultured in supplemented 7H9 media with 10 µg/mL PAS to confirm their PAS 
resistance.  
 
DNA Isolation  
To analyze the genomes of the PAS resistant strains, 10 mL of cultures were 
grown in the supplemented 7H9 media in the presence of 10 µg/mL PAS. Genomic 
DNAs of the PAS resistant strains were extracted by the cetyltrimethylammonium 
bromide (CTAB) method164 when the cultures reached OD600 of 1.0 and 1 mL of the 
cultures were flash frozen and stored for further use. 
 
Construction of an N-terminal 6x-His Tagged ThyA and FolC Overexpression Vector 
Genes of thyA and folC conjugated with 6x His-tag were first amplified from 
wild-type Mtb H37Rv genomic DNA using PCR with the following primers. Primer 5’-
GGGGACAAGTTTGTACAAAAAAGCAG-3’ was used for extending the additional 
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N-terminal segment. Primer pairs 5’-GGCTTCCACCATCATCACCACCATGT-3’ and 
5’-GGGGACCACTTTGTACAAGAAAGCTG-3’ were used for the thyA gene. Primer 
pairs 5’-GCAGGCTTCCACCATCATCACCACCA-3’ and 5’-
GGGGACCACTTTGTACAAGAAAGCTG-3’ were used for the folC gene. The genes 
were cloned into an anhydrotetracycline inducible pDTCF plasmid165, 166 via a gateway 
cloning procedure.  
 
Construction of DHFR Overexpression Vector  
A dfrA containing pMV261 vector was obtained from Dr. Jacobs. An empty 
pMV261 vector was constructed to serve as a control. Gene dfrA was first removed from 
the vector by the enzymes, BamH1 and HindIII. The empty vector was then religated 
with a joining linker. The linker primers’ sequences are as follows: forward primer: 5’-
GGATCCAGCTGCAGAATTCGAAGCTT-3’; reverse primer: 5’-AGCTTCGA 
ATTCTGCAGCTG-3’. 
 
MICs Determination of Mtb mc27000 Overexpression Strains 
Mtb mc27000 cells were first transformed with overexpression vectors 
containing, folC, thyA, and dfrA, by electroporation. A single bacterial colony was 
picked and grown at 37C to OD600 of 0.6−0.8 in supplemented 7H9 media with either 
kanamycin (20 µg/mL for pMV261) or hygromycin B (50 µg/mL for pDT system). 
FolCox and ThyAox strains were induced with 100 ng/mL anhydrotetracycline. MICs of 
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different overexpression strains were investigated on supplemented 7H10 plates 
containing different concentrations of PAS (0 µg/mL to 16 µg/mL). 
 
Hydroxy-DHF Modeling Study 
The crystal structure of Mtb DHFR in complex with NADPH and methotrexate 
(1DF7) was used as the original model for the docking study. The downloaded structure 
was processed using the protein preparation wizard in the Schrodinger software. The 
protein preparation wizard167 would add hydrogen atoms to the structure, optimize the 
hydrogen bond network, and minimize the restraint of the modified structure. Hydroxy-
DHF was docked on the active site of Mtb DHFR with Glide.168 A flexible ligand mode 
was selected, in which the ligand with different conformations were docking into a rigid 
protein structure. A systematic search was conducted by Glide for an optimal ligand 
conformation in response to the shape and properties of the binding cavity. The search 
relied on fitting the docking ligand with various conformations, orientations, and 
positions into the defined receptor. The information of the docked ligand, including its 
conformation, orientation and position, corresponding to the receptor is defined as 
“pose” by the Glide program. The searching can be divided into three steps. The initial 
step was a rough screening for all available space to the ligand. The pose of the ligand 
was then minimized within the receptor using the OPLS-AA force field function. 
Finally, 3 to 6 conformations with the lowest energy were further refined by a Monte 
Carlo procedure. 
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CHAPTER III 
 STRUCTURAL INSIGHTS INTO MYCOBACTERIUM TUBERCULOSIS RV2671 
PROTEIN AS A DIHYDROFOLATE REDUCTASE FUNCTIONAL ANALOGUE 
CONTRIBUTING TO PARA-AMINOSALICYLIC ACID RESISTANCE*  
 
 
Introduction 
 
One of the first drugs developed to treate tuberculosis (TB) was para-
aminosalicylic acid (PAS), and over 70 years later, it is still in use. While PAS has been 
replaced as a first line drug by isoniazid, pyrazinamide, and rifampin, it has found new 
usefulness as a second line drug to treat drug-resistant TB.122  
PAS is a structural analogue of p-aminobenzoic acid (pABA), the substrate of 
dihydropteroate synthase (DHPS), and for years DHPS was thought to be the target. 
However, PAS was recently shown to be a prodrug,152, 153 which is incorporated into the 
folate pathway through the conversion to hydroxy intermediates. Mycobacterium 
tuberculosis (Mtb) cytotoxicity is due to either a general poisoning of the folate-
dependent pathway by hydroxy intermediates152 or the inhibition of dihydrofolate 
reductase (DHFR) by 12-hydroxy-7,8- dihydrofolate (hydroxy dihydrofolate).153 In the 
                                                
* This work has been published in and is reprinted with permission from: Cheng, Y. S., and Sacchettini, J. 
C. (2016) Structural insights into Mycobacterium tuberculosis Rv2671 protein as a dihydrofolate reductase 
functional analogue contributing to para-aminosalicylic acid resistance, Biochemistry 55, 1107-1119. 
Copyright 2016 by American Chemical Society. 
	
  58 
previously referenced study, a laboratory-derived Mtb mutant strain resistant to a DHFR 
inhibitor (NITD344,153 a WR99210169-analogue ) was found to also be cross-resistant to 
PAS. Most notably, this same mutation has been reported in 10 out of 208 PAS resistant 
clinical isolates of Mtb, plainly demonstrating its association with PAS resistance in 
vivo.142 This resistant strain (R7) contained a mutation in a noncoding region upstream 
of the Mtb Rv2671153 and produced increased levels of Mtb RibD (Rv2671). Mtb Rv2671 
is currently annotated as RibD, an enzyme in the riboflavin biosynthetic pathway;107 
therefore, it was surprising to find that increased expression of an enzyme involved in 
riboflavin biosynthesis would confer resistance to PAS.  
In eubacteria RibD, also referred to as RibG in some organisms, is typically a 
bifunctional enzyme which catalyzes the second and third reactions of the riboflavin 
biosynthetic pathway, that is, the conversion of 2,5-diamino-6-ribosylamino-4(3H)-
pyrimidinone 5’-phosphate (DAROPP) to 5-amino-6-ribitylamino-2,4(1H,3H)-
pyrimidinedione 5’-phosphate (ARIPP). The RibD catalyzes the reaction that involves 
the deamination of the 2-amino group of the pyrimidine ring followed by a reduction of 
the ribose ring using either NADPH or NADH.170 In some eubacteria, the two activities 
are on separate enzymes. Mtb Rv3752c is annotated as the deaminase that would convert 
DAROPP to 5-amino-6-ribitylamino-2,4(1H,3H)-pyrimidinedione 5’-phosphate 
(AROPP), and Mtb Rv2671 is annotated as an AROPP reductase converting AROPP to 
ARIPP. In fungi and some archaea, the reduction precedes the deamination, and the 
reactions are catalyzed by two monofunctional enzymes: the reductase Rib7 and the 
deaminase Rib2, respectively171, 172 (Scheme 1). Other than Rv2671 and Rv3572c, Mtb 
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RibG (Rv1409) encodes for a bifunctional RibD containing a DAROPP deaminase 
domain and an AROPP reductase domain. This is particularly unusual as the reactions, 
substrates, and products of Rv1409 should be identical to that of Rv2671 and Rv3571c.  
 
Scheme 1 
 
 
 
 
 
 In order to gain insights into the molecular mechanisms of PAS resistance and 
define the catalytic activity of Rv2671, we have completed a biochemical and structural 
characterization of Mtb Rv2671. The biochemical assays indicated that Mtb Rv2671 
catalyzes the reduction of dihydrofolate (DHF) and the structural studies assisted in 
defining the molecular basis for the high Km for DHF. Our results also explained the 
mechanism for the resistance to PAS in the R7 and clinical strains. Furthermore, activity 
assays using purified recombinant Mtb Rv2671 revealed that it is neither an AROPP nor 
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a DAROPP reductase, suggesting that Rv2671 and other related orthologues are not 
involved in riboflavin biosynthesis.  
 
Results and Discussion 
 
Determination of Dihydrofolate Reductase Activity of Rv2671 
The genome sequence of Mtb has Rv2671 annotated as an AROPP reductase 
(RibD) which is part of the riboflavin biosynthetic pathway that catalyzes the reduction 
of AROPP to ARIPP.107 Its annotation was most likely due to the sequence similarity 
analysis showing that Rv2671 has a significantly better sequence similarity to the 
reductase domains of prokaryotic RibDs (AROPP reductases) (22% identity with E. coli 
RibD) and Rib7s (DAROPP reductases) (22% identity with Methanocaldococcus 
jannaschii Rib7), compared to that of any other enzyme family. The next closest was the 
dihydrofolate reductase family (14% identity with E. coli DHFR). Therefore, it was 
surprising that the overexpression of Rv2671 was able to replace Mtb DHFR function in 
vitro.153 Specifically, a mutant strain of Mtb with increased levels of Rv2671 was shown 
to be resistant to the DHFR inhibitor NITD344,153 an analogue of a well-known DHFR 
inhibitor WR99210.169 In addition, a multicopy plasmid that expressed Rv2671 was 
sufficient to allow for the production of a knockout of the dfrA gene,153 which codes for 
DHFR and is essential in Mtb based on transposon hybridization.144 Together, these 
studies suggested the possibility that Rv2671 was a bifunctional enzyme capable of 
catalyzing the reduction of DHF (Figure 14A) as well as AROPP. 
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Figure 14. Characterization of Rv2671 as a DHFR. (A) Scheme of the DHF reduction 
reaction. (B) HPLC analysis of the in vitro reaction and the relevant control. (C) Time 
course for the reaction shows that the amount of THF increases with time. (D) Steady 
state kinetic reaction measured in the presence of Rv2671 and saturated NADPH. 
Reaction velocity plotted versus DHF concentration (Km =136 ± 32 µM; kcat =0.15 ± 
0.016 s−1). Each DHF concentration was performed in triplicate, and the data represent 
mean values ± SD. 
 
 
 
We implemented a direct DHFR in vitro assay with pure recombinant Mtb 
Rv2671 to determine if Rv2671 could catalyze the reversible reduction of DHF to THF 
in the presence of NADPH. Tetrahydrofolate, the product of the reaction, was observed 
by HPLC spectrometry after the addition of DHF and NADPH to Rv2671 (Figure 14B 
and C). We detected an increase in a single species over time and the HPLC peak 
comigrated with a tetrahydrofolate standard (rt= 10.4 min). The identity was further 
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confirmed to be tetrahydrofolate by MS. The Km and kcat of Rv2671 for DHF were 
determined to be 136 ± 32 µM and 0.15 ± 0.016 s−1, respectively (Figure 14D). A 
comparison of the kinetic parameters with DHFRs from different organisms is listed in 
Table 7. Briefly, the kcat of the DHFRs ranged from 2 to 30 s−1, at least 1 order of 
magnitude faster than the kcat of Rv2671. Moreover, studied DHFRs have a lower Km for 
DHF, in the range of 0.7 to 4 µM, which is at least 25 times lower than that of Rv2671 
(136 ± 32 µM). The Km of DHF for Mtb DHFR is 4.2 ± 6 µM with a kcat of 2.3 s−1.173 
The Km of DHF is about 30 times lower than that of Rv2671, and the reaction rate is 15 
times faster. Therefore, Rv2671 can indeed catalyze the DHF reduction reaction but with 
less efficiency than the DHFRs of Mtb and other organisms. 
 
 
Table 7. Kinetic parameters of Rv2671 and DHFRs 
 
 
 
 
 
 
 
kcat (s−1) 
Km (µM) 
DHF NADPH 
Rv2671  0.15 ± 0.016 136 ± 32 -  
Organism    
Mycobacterium tuberculosis  2.3173  1.6173  < 1174  
Mycobacterium avium  20.5175  0.7175  1.55175  
Escherichia coli  12.6176  0.7177  4.8177  
Streptococcus pneumoniae  31.5178  4.4178  15.7178  
Mus musculus 7.2179  0.9179  -  
Homo sapiens  11180  0.12180  4.2180  
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Overall Structures of Rv2671 with Co-factor  
The X-ray crystal structure of recombinant E. coli-derived Rv2671 was 
determined to 1.9 Å resolution. The crystal belongs to the orthorhombic space group 
C2221 with one molecule in the asymmetric unit. In the final refined structure (Table 8), 
a total of 246 out of 258 residues were built into the electron density map. Residues 1−9 
and 91−95 were disordered in the structure. The structure of Rv2671 is a variant 
Rossmann fold, composed of eight parallel β-strands (β8, β7, β1, β6, β2, β3, β4, and β5) 
and one antiparallel β-strand, β9. This mixed β-sheet is surrounded by seven α-helices 
and one 310-helix (η1). Helices α1 to α5 are on one side of the central sheet and α6, α7, 
and η1 are on the opposite side (Figure A-1A). Weak electron density for NADP(H) was 
observed in the active site suggesting NADP(H) copurified with the protein. The 
electron density of the NADP(H) indicates an occupancy of less than 50% in the crystal.  
Rv2671 is a homodimer in solution as determined by size-exclusion chromatography 
(Figure A-1B). In the crystal, the homodimer is generated by 2-fold crystallographic 
symmetry (Figure 15A). The free energy of assembly dissociation (Gdiss) is 44.3 
kcal/mol; the positive value suggests that this dimer is thermodynamically stable. The 
buried surface area of the dimer interface accounts for 37% of the total surface area.181 
This large dimer interface contains residues from three loops (L1, L3, and L15) and four 
β-strands (β1, β7, β8, and β9). 
  64 
Table 8. Data collection and refinement statistics 
 copurified NADP(H)  
bound Rv2671 
NADP+ bound 
Rv2671 
THF bound Rv2671 
PDB ID 4XRB 4XT5 4XT6 
Data collection    
Space group C2221 C2221 C2221 
Cell Dimensions    
a, b, c (Å) 71.4, 96.6, 75.7 69.7, 95.3, 73.9 70.5, 95.9,76.1 
α ,  β ,  γ  (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å)a 27.4-1.9 (1.93-1.9) 44.75-2.13 (2.17-2.13) 36.61-1.85 (1.88-1.85) 
Rsym or Rmerge 0.045 (0.290) 0.069 (0.418) 0.053 (0.274) 
I/σ(I) 30.97 (8.33) 26.80 (7.02) 34.12(9.68) 
Completeness (%) 99.36 (100) 99.96 (99.71) 99.34 (97.58) 
Redundancy 7.1 (7.3) 9.0 (8.9) 8.7(9.0) 
    
Refinement    
No. reflections 149934 127251 194557 
Rwork/ Rfree 0.18/0.20 0.19/0.24 0.20/0.24 
No. atoms 1974 1975 1919 
Protein 1851 1863 1799 
Ligand/ion 55 48 44 
Water 68 64 73 
B-factors 36.4 37.9 30.9 
Protein 36.0 37.9 30.6 
Ligand/ion 48.3 35.6 35.8 
Water 38.9 38.9 33.7 
R.m.s deviations    
Bond lengths (Å) 0.018 0.013 0.015 
Bond angles (º) 1.96 1.36 1.24 
Ramachandran favered (%) 99 97 97 
Ramachandran allowed (%) 1 3 3 
Ramachandran outliers (%) 0 0 0 
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Table 8. Data collection and refinement statistics (cont.) 
 TMP bound Rv2671 TMQ bound Rv2671 DHP bound Rv2671 
PDB ID 4XT7 4XT8 4XT4 
Data collection    
Space group C2221 C2221 C2221 
Cell Dimensions    
a, b, c (Å) 69.0, 93.2, 74.6 69.4, 93.6, 74.3 70.3, 94.4, 75.8 
α ,  β ,  γ  (°) 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å)a 46.56-2.3 (2.34-2.3) 46.81-1.95 (1.98-1.95) 45.24-1.89 (1.92-1.89) 
Rsym or Rmerge 0.081 (0.331) 0.08 (0.288) 0.070 (0.585) 
I/σ(I) 21.31 (6.50) 34.82 (12.88) 21.72 (2.42) 
Completeness (%) 99.94 (99.36) 99.89 (99.72) 99.43 (94.66) 
Redundancy 7.3 (7.4) 8.6 (8.8) 9.3 (6.6) 
    
Refinement    
No. reflections 81136 155567 189305 
Rwork/ Rfree 0.17/0.22 0.18/0.22 0.19/0.22 
No. atoms 2006 2072 2002 
Protein 1858 1885 1864 
Ligand/ion 82 103 56 
Water 66 84 82 
B-factors 24.4 23.9 33.8 
Protein 24.3 23.6 33.5 
Ligand/ion 25.9 24.6 36.1 
Water 25.5 28.2 38.2 
R.m.s deviations    
Bond lengths (Å) 0.054 0.051 0.011 
Bond angles (º) 1.43 1.43 1.36 
Ramachandran favered 
(%) 
98 98 97 
Ramachandran allowed 
(%) 
2 2 3 
Ramachandran outliers 
(%) 
0 0 0 
a Resolution values for collection and refinement are the same. 
 
 
 
The intersubunit interactions are dominated by hydrogen bonds and electrostatic 
interactions, with roughly 56 hydrogen bonds and 8 electrostatic interactions across the 
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interface. Each subunit of the homodimer contains one active site. The oligomeric state 
of Rv2671 is consistent with that of other RibD/Gs and Rib7s, except Bacillus subtilis 
RibG (Bs RibG), which is reported to be a tetramer in solution.182-185 In contrast, most 
DHFRs are monomeric.186 
The crystals of Rv2671 preincubated with NADP+ were nearly isomorphous with 
the natively purified Rv2671 crystals and the structure was refined with diffraction data 
extending to 2.1 Å resolution (Table 8). The overall fold of the protein is highly 
conserved, with the partial NADP(H) bound structure having a root-mean-square 
deviation (rmsd) of 0.42 Å over 243 Cα pairs. The disordered segment (residues 91−95) 
of the partial NADP(H) bound structure was clear in the electron density map and 
formed a loop in the NADP+ bound structure. With the exception of the loop, NADP+ 
bound Rv2671 exhibits no significant structural differences to the partial NADP(H) 
bound structure. This loop is near the NADP+ binding site and interacts directly with the 
cofactor and is stabilized by both a hydrogen bond between the side chain oxygen of 
Glu91 and the 2’ hydroxyl group of the nicotinamide ribose group (2.6 Å), and multiple 
van der Waals interactions (Figure 15B). The NADP+ binds at the C-terminal edge of the 
central β-sheet (β2, β3, and β6) and the pyrophosphate group locates between the α3 and 
α6 adjacent to the putative substrate binding cleft formed by α2, α3, β2, and β3 (Figure 
15B). The conformation of NADP+ and its binding site is very similar to that of RibD/G 
structures, as well as DHFR structures.184  
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Figure 15. Crystal structure of Rv2671 and the THF binding mode. (A) Ribbon 
representation of the dimeric Rv2671. (B) Ribbon representation of the Rv2671 in 
complex with NADP+. The secondary structural elements are labeled sequentially. The 
loop (residue 91–95) disordered in the native purified structure is shown in purple, and 
NADP+ is shown in the green ball and stick model. The hydrogen bond interaction 
between the ribose group of NADP+ and Glu 91 in the loop (residue 91–95) is shown in 
the zoomed-in figure. (C) Superimposition of the THF bound Rv2671 structure (yellow) 
with the NADP+ bound Rv2671 structure (blue). NADP+ and the pteridine ring of THF 
are colored in green and yellow. The simulated annealing omit map contoured at 2.5σ 
around the pteridine ring is shown in blue. Distances between the C4 of nicotinamide 
and the C6 and C7 of the pteridine are labeled. (D) Superimposition of the NADP+ 
bound Rv2671 structure (green) with the folate-NADPH bound E. coli RibD (4pdj, 
blue). Folate is colored in yellow. The side chain of the Arg 97 in the Rv2671 complex 
structure points to the other direction against the folate. The distances between α-carbon 
of the glutamate group in folate and the main chain carbon of the arginines are 6.9 and 
10.7 Å, respectively. 
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Complex Structure of Rv2671 with THF 
In order to understand the molecular basis for the relatively low DHFR activity 
of Rv2671, the structure of Rv2671 ternary complex with the products, NADP+ and THF 
was solved. The crystals diffracted to about 2.1 Å resolution (Table 8). The backbone Cα 
rmsd between 236 atom pairs is 0.49 Å with the NADP+ bound structure. The electron 
density was not visible for residues 90−95, residues 56−57, or the nicotinamide ribose 
moiety of the NADP+ in the THF bound structure. Notably, the disordering of the 
nicotinamide ribose moiety of the NADP+ was also observed in a recent Mtb DHFR 
structural report187 which showed that the density for the nicotinamide ribose moiety of 
NADPH was missing in the open conformation of the Mtb DHFR-NADPH complex 
structure.187 We observed the same phenomenon in Rv2671. After soaking NADP+ 
bound Rv2671 crystals with THF, the density for the nicotinamide ribose moiety 
disappeared along with the density for the adjacent loop residues 90−95. These residues 
correspond to loop2 (L2), a part of the ligand access control segment in Mtb DHFR,187  
suggesting that residues 90−95 serve the same function in Rv2671.  
Unambiguous electron density for the tetrahydropteridine ring of THF was 
observed and built into the electron density (Figure 15C). However, electron density for 
the pABG group (pABA and the glutamate tail) of THF was not visible. NA2 and N3 of 
the pteridine ring interact with the side chain of Asp67 (2.7 and 2.7 Å), which is 
typically observed in DHF-complexed DHFR structures. Although the nicotinamide 
ribose moiety is disordered in the ternary structure, after we overlaid it with the NADP+ 
Rv2671 structure the distances between the nicotinamide C4 and the pteridine C6 and 
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C7, where the hydride transfer would occur, were measured to be 2.5 and 2.3 Å (Figure 
15C). Similar positions for these groups have been observed in the E. coli DHFR−DHF 
complex structure.188 Upon the basis of the theoretical calculation, 2.6 Å is the optimal 
distance between the donor and acceptor atoms, while the hydride transfer occurs via a 
bent geometry.189, 190 
The missing density for the pABG group in the ternary structure suggests that 
Rv2671 does not have the optimal amino acids to mediate its binding. In all 
DHF−DHFR complex structures, a conserved arginine forms an electrostatic interaction 
with the α-carboxyl group of the glutamate tail. In the E. coli folate−DHFR structure 
(4pdj),191 Arg57 corresponds to the conserved arginine in DHFRs. Superimposition of 
Rv2671 and E. coli folate-DHFR structures put E-coli folate−DHFR Arg57 at the cleft 
of loop 6 (L6) and loop 7 (L7) in Rv2671 (Figure 15D). The main chain of Arg97 at L6 
in Rv2671 is in close proximity to that of E. coli DHFR Arg57. However, Arg97 is 3 Å 
closer to the α-carboxyl group and points in the opposite direction against the DHF 
(Figure 15D). Therefore, it is unlikely that this Arg97 can fulfill the role of stabilizing 
the α-carboxyl group of DHF. The position of Arg97 may be responsible for the 30 times 
higher Km for Rv2671 compared to that of other DHFRs. The potential pABG binding 
cavity is also larger in Rv2671 (16 Å long, 12.5 Å wide) than it is in Mtb DHFR (17 Å 
long, 7.5 Å wide). This could reduce the affinity of pABG for Rv2671 but may also 
provide Rv2671 with the ability to bind another ligand.  
Dihydropteroic acid (DHP) was tested as a potential substrate for Rv2671 since 
DHP contains a dihydropteridine ring and a benzoic acid group like THF, but does not 
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have the glutamate tail. The Km of Rv2671 for DHP was 180.2 ± 25.5 µM with a kcat of 
0.32 ± 0.016 s−1, unexpectedly similar to the Km and kcat for DHF. Therefore, the crystal 
structure of DHP complexed to Rv2671 was solved and refined to 1.89 Å resolution 
(Table 8) to investigate the binding mode of DHP. The overall structure was nearly 
identical to the THF bound structure with an rmsd of 0.36 Å over 236 Cα pairs. The 
location of the dihydropteridine ring of DHP was also identical to the tetrahydropteridine 
ring of THF. The benzoic acid in the DHP and the nicotinamide ribose moiety of 
NADP+ are disordered, as in the THF bound structure. The structural similarity and the 
missing benzoic acid density explain the similar steady state kinetic parameters for DHF 
and DHP. This result also suggests that Rv2671 can bind and reduce a broad spectrum of 
dihydropteridine containing analogues. 
As previously stated, the drug PAS is converted in the cell to hydroxylated 
intermediates by enzymes in the folate biosynthetic pathway.152, 153 The ability of 
Rv2671 to catalyze the reduction of DHF suggests several potential mechanisms for the 
observed resistance to PAS (Scheme 2). One scenario is that Rv2671, like DHFR, binds 
and is inhibited by the 12-hydroxy-7,8-dihydrofolate (hydroxy dihydrofolate) (Scheme 
2, Case 1). In this case, the higher levels of Rv2671 would serve to sequester the 
inhibitor that would otherwise bind to DHFR within the cell. However, due to the high 
Km and inability to see in the structure, our studies indicate that this scenario is unlikely 
to be the reason for resistance since the lack of affinity of Rv2671 for DHF suggests that 
hydroxy dihydrofolate would likely prefer binding with Mtb DHFR instead of Rv2671. 
A second and more likely scenario is that the hydroxy dihydrofolate is a substrate of 
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Rv2671 based on the less specific dihydropteridine reductase activity of Rv2671 
(Scheme 2, Case 2). Thus, the higher levels of Rv2671 would effectively reduce the 
levels of DHFR inhibitor (hydroxy dihydrofolate) in the cell by converting it to the 
product hydroxy tetrahydrofolate. A third possibility is that Rv2671 does not bind to the 
hydroxy dihydrofolate (Scheme 2, Case 3). For this scenario, Rv2671 serves as the 
functional homologue of DHFR and overrides DHFR’s inhibition by hydroxy 
dihydrofolate. It has been shown that Mtb can survive in a strain where > 97% of the 
DHFR enzyme had been depleted.192 Therefore, the higher levels of Rv2671 would be 
able to sustain folate biosynthesis at a level sufficient to support Mtb even though 
Rv2671 has only about 10% of the wild-type DHFR activity.  
Another outstanding question is whether PAS’s cytotoxicity results from a 
general poisoning of folate-dependent pathways152 or if it acts specifically on DHFR 
through the conversion of PAS to hydroxy dihydrofolate.153 The nonspecific 
dihydropteridine reductase activity of Rv2671 indicates that the hydroxy dihydrofolate is 
likely a substrate of Rv2671 capable of converting a hydroxy dihydrofolate into a 
hydroxy tetrahydrofolate. This would mean that higher levels of Rv2671 in the cell 
would lead to the production of more hydroxy-folate intermediates which would in turn 
cause higher levels of sensitivity to PAS, if indeed PAS’s cytotoxicity results from the 
assumption of general poison. Since this was not the case, and the cells were resistant to 
PAS when Rv2671 was at higher levels, the data suggest that hydroxy dihydrofolate 
inhibition of DHFR is the event that leads to cell death. 
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Scheme 2 
 
 
 
Potential of Other Riboflavin Biosynthesis Reductases to Carry out DHFR’s Function 
Our discovery that Rv2671 has DHFR activity led us to test to see if DHFR 
activity is a general feature of the AROPP reductase domains of RibD/Gs. DHFR 
activity was not detected for the recombinant E. coli RibD (the AROPP reductase 
domain shows 22% sequence identity to Rv2671). This is not surprising since 
overexpression of Mtb RibG with both DAROPP deaminase domain and AROPP 
reductase domain was unable to replace the function of Mtb DHFR.153 In all known 
AROPP reductase sequences, there is a conserved lysine which interacts with the keto 
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group of the pyrimidine ring of the AROPP in the active site.182-185 In the Bs RibG 
complex structure, the side chain of Lys151 forms a hydrogen bond with the keto group 
of the AROPP (3.4 Å).193 Superimposing E. coli RibD (2OBC)184 with Rv2671 shows 
that Asn44 in Rv2671 is in place of the aforementioned lysine (Lys152 in E. coli RibD) 
(Figure A-2). The side chain carbonyl group of Asn44 forms a hydrogen bond with the 
pteridine NA2 of THF (3.1 Å) in the Rv2671 structure. A clash of the lysine side chain 
with the THF pteridine ring was observed when superimposing the structures. Our 
results indicate that bacterial AROPP reductases are unable to catalyze the reduction of 
DHF. This is consistent with the inability of bifunctional Mtb RibG (Rv1409) to 
compensate for a loss in DHFR activity.153  
 
DHFR Inhibitors, Trimethoprim (TMP) and Trimetrexate (TMQ), Bind and Inhibit the  
DHFR Activity of Rv2671 in Vitro 
Two FDA approved DHFR inhibitors, TMP and TMQ, were tested for inhibitory 
activity against Rv2671. TMP is a selective DHFR inhibitor which typically shows about 
2,500 times more potency against bacterial DHFR over human DHFR.194 TMQ is a 
DHFR inhibitor used in cancer treatment195 and does not show selectivity between 
bacterial and mammalian DHFRs.196 A 350-fold difference was observed in the IC50 
values of TMP (Figure 16A) and TMQ (Figure 16B) to Rv2671 (93.5 ± 5.2 µM and 0.28 
± 0.02 µM, respectively). Although TMP is usually selective for bacterial DHFRs, it 
shows a low inhibition of not only Rv2671 but also Mtb DHFR (IC50 for TMP is 16.5 
µM197).  
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The structures of Rv2671 in complex with NADP+ and either TMP or TMQ 
(Figure 16C) revealed the molecular basis for the differences in inhibitory activity. The 
overall structures of the protein with inhibitors are similar to the NADP+ bound 
structure. For both inhibitors, hydrogen bonding interactions with Rv2671 appear to be 
the dominant binding interaction for the 2,4-diaminopyrimidine and the quinazoline 
group. The 2,4-diaminopyrimidine group of TMP forms six hydrogen bonds with 
residues of Rv2671 including Asn44, Asp67, Thr214, and a water molecule (Figure 
16D). However, the quinazoline ring of TMQ forms seven H-bonds with residues of 
Rv2671 including Asn44, Phe45, Asp67, Glu193, Thr214, and Glu91 (Figure 16E). 
When the two structures are superimposed, the 2,4-diaminopyrimidine group of 
TMP overlaps and is nearly coplanar (about 5 degrees out of plane) with the 2,4-
diaminopyrimidine part of TMQ. The slight rotation results in one extra hydrogen bond 
between Rv2671 and TMQ, but the binding site of the two rings is identical. A more 
detailed analysis of the hydrogen bonding interactions between Rv2671 and the ligands 
is provided in Table A-1. 
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Figure 16. Crystal structure of Rv2671 in complex with TMP or TMQ. (A) The mean % 
inhibition values of Rv2671 are plotted against the log10 concentration of the DHFR 
inhibitor TMP. The calculated IC50 value is 93.5 ± 5.2 µM. (B) The mean % inhibition 
values of Rv2671 are plotted against the log10 concentration of the DHFR inhibitor 
TMQ. The calculated IC50 value is 0.28 ± 0.02 µM. (C) Ribbon representation of 
Rv2671 (tan) in complex with TMP (yellow) and TMQ (orange). (D) Binding of the 
TMP with Rv2671. The simulated annealing omit map contoured at 2.5σ around the 
inhibitor TMP is shown in blue. The key residues interacting with TMP are labeled and 
shown as sticks in green. The hydrogen bonds are shown as dashed lines. (E) Binding of 
TMQ with Rv2671. The simulated annealing omit map contoured at 2.5 σ around the 
inhibitor TMQ is shown in blue. The main residues interacting with TMP are labeled 
and shown as green sticks. Different binding modes of the trimethoxybenzyl rings of 
TMP and TMQ in Rv2671 can be observed in D and E. The trimethoxybenzyl ring of 
TMP in the complex structure is perpendicular to Phe71. The trimethoxybenzyl ring of 
TMQ in the complex structure is parallel to Phe71. 
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The trimethoxybenzyl groups of TMP and TMQ were found to be in different 
binding orientations with Rv2671 (Figure 16C) due to the extra secondary amide in the 
linker region of TMQ which allows the trimethoxybenzyl ring to flip and move away 
from α2. The ring plane of the trimethoxybenzyl group of TMP is perpendicular to that 
of Phe71 in Rv2671 (Figure 16D), but the trimethoxybenzyl ring of TMQ in Rv2671 is 
parallel to the ring plane of Phe71 (Figure 16E). Different trimethoxybenzyl ring binding 
conformations result in different binding cavities, and the trimethoxybenzyl groups hold 
only via the van der Waals interactions with Rv2671, especially the hydrophobic effects. 
Since the hydrophobic interactions are the major contacts between the trimethoxybenzyl 
ring and the protein, the hydrophobicity of the ligand and its binding cavity was 
analyzed using the PLATINUM server, which calculates the hydrophobic properties of 
molecules and evaluates their match or mismatch in the protein−ligand complexes.198 
The calculated hydrophobic match surface (SLL) between TMP and the surrounding 
residues is 0.06 Å2 compared with 34.24 Å2 between TMQ and its environment, and the 
fraction of lipophilic match (Match2) of TMP is 0.0007 compared with 0.2175 of TMQ. 
The higher match numbers of TMQ indicate better hydrophobic contacts between TMQ 
and Rv2671. The additional hydrogen bond and better hydrophobic interactions with the 
trimethoxybenzyl ring results in significantly better inhibition by TMQ compared with 
that of TMP.  
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Structural Comparison with Known RibDs/Rib7s from Other Organisms Reveals 
Differences in the Active Sites 
A structural similarity analysis using DALI199 identified a number of closely 
related homologues of Rv2671, and over 700 entries were identified with a Z-score 
above 2. Out of the 700 entries, 7 pyrimidine reducatases were found to be the closest 
structural homologues with Z-scores ranging from 16 to 27 and rmsd of Cα ranging 
from 2.1 to 2.6 Å, 4 of which were RibD/Gs, 1 was a Rib7, and 2 were putative 
pyrimidine reductases from different species. DHFRs also exhibited a significant match 
with 34 dihydrofolate reductases or bifunctional dihydrofolate reductase−thymidylates 
with Z-scores ranging from 11.4 to 18.7 and rmsd ranging from 1.8 to 2.9 Å. A 
pyrimidine reductase-like protein from C. diphtheria (2p4g) belonging to the 
monofunctional RibD_C family is the closest structural homologue of Rv2671 (Z-score 
of 27.1 and rmsd of 2.6 Å).  
The AROPP reductase domain of RibD/Gs and Rib7s (DAROPP reductases) are 
often classified as pyrimidine reductases with identical reaction mechanism, overall 
structure, and substrate binding residues.200 2,5-Diamino-6-ribosylamino-4(3H)-
pyrimidinone 5’-phosphate (DAROPP) is the Rib7’s substrate and 5-amino-6-
ribosylamino-2,4(1H,3H)-pyrimidinedione 5’-phosphate (AROPP) is the substrate of the 
reductase domain of RibD/Gs (Scheme 1).171, 172 DAROPP and AROPP differ at the C2 
position of the pyrimidine ring; DAROPP has an amino group in place of AROPP’s keto 
group. The distinct difference of RibD/Gs and Rib7s is a conserved lysine which 
interacts with the keto group of AROPP in the RibD/Gs. Pyrimidine reductases and 
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Rv2671 share a common core structure including the central β-sheet and the flanking α-
helices. The N-terminal region and α6 (in Rv2671) show the most structural diversity. 
For RibD/Gs, the N-terminus of the reductase domain connects to the deaminase 
domain.184, 185 For Rib7s and Rv2671, the N-terminal region participates in the 
dimerization of two subunits. Helix α6 in Rv2671 is a loop in RibD/Gs, and in Rib7s the 
α6 helices are located in different spatial positions depending on the length of the 
adjacent cofactor binding loop.  
Bs RibG in complex with ([(2R,3S,4R,5E)-5-[(5-amino-2,6-dioxo-3H-pyrimidin-
4-yl)imino]-2,3,4-trihydroxy-pentyl] dihydrogen phosphate (AIF) is the only structure 
available in the protein databank (PDB) of a RibG with a substrate (analogue in this 
case) of a pyrimidine reductase.193 AIF is a proposed intermediate of the AROPP 
reduction reaction. The structures of Rv2671 and the Bs RibG-AIF complex were 
superimposed using the Matchmaker function of Chimera.201 The two structures were 
very similar to an rmsd of 1.9 Å over 202 Cα pairs. AIF was located at the cleft created 
by L3-η1-L4, L6, α2, α3, and the central β-sheet; α2, α3 and the central β-sheets were in 
similar spatial positions between the two structures, but the L6 loop of Rv2671 was 2.8 
Å away from the phosphate group of AIF and the region between L3-η1-L4 was 4.7 Å 
closer to α2 compared to the analogous regions of Bs RibG.  
The enzymatic reaction of pyrimidine reductases is initiated by a conserved 
ionizable residue to abstract the proton from the amine group next to C1 of 
DAROPP/AROPP to form a Schiff base intermediate at C1, followed by a direct hydride 
transfer to C1 from the nicotinamide group of NADPH.183, 184, 193 The amino acids 
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proposed for the proton abstraction are Asp200 in E. coli RibD and Glu290 in Bs RibG. 
In the structure of Rv2671, Glu193 corresponds to Bs RibG Glu290, and Glu91 
corresponds to Asp200 of E. coli RibD. Although the length of the side chains of Glu 
and Asp differ by one carbon, the distance between the side chain oxygen of Glu91 and 
the amine nitrogen beside the C1 of the modeled AIF is 2.8 Å away, within proton 
transfer distance. However, based upon the superimposed structures, two differences in 
the active site could interfere with the binding of DAROPP/AROPP to Rv2671. First, 
there could be a clash between the pyrimidine ring and the backbone of Rv2671. As 
stated earlier, the location of L3-η1-L4 is different between Rv2671 and Bs RibG, and 
the backbone of L3-η1 in Rv2671 showed the potential for overlap with the pyrimidine 
ring of AIF in the superimposed structure. Although the possibility of main chain 
conformational changes cannot be ruled out, the distance between the main chain 
carbonyl group of Ser59 of Rv2671 and the O4 of the AIF from the Bs RibG structure is 
1.14 Å. Second, several conserved residues that are involved in substrate binding among 
functionally characterized pyrimidine reductases are not present in Rv2671 (Figure 17); 
for example, Thr171, Arg183, Asp199, Arg206, and Glu290 interact directly with AIF in 
Bs RibG and are not conserved in Rv2671. The backbone of Ala153 in Rv2671 overlaps 
with the side chain of Thr171 in Bs RibG. The pyrimidine ring of AIF forms hydrogen 
bonds with the hydroxyl group of the side chain (2.1 Å) and the main chain nitrogen (3.1 
Å) of Thr171 in Bs RibG. The main chain of Glu91 in Rv2671 is in the position of the 
main chain of Asp199 in Bs RibG; the side chain oxygen of Asp199 forms hydrogen 
bonds with two ribosyl hydroxyl groups of AIF (2.8 Å and 3.1 Å). The side chains of 
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Arg183 and Arg206 in Bs RibG interact with the phosphate of AIF by hydrogen bonds 
and electrostatic interactions. Arg75 in Rv2671 was on top of Arg183 in Bs RibG. 
Met98 of Rv2671 corresponds to Arg206 in Bs RibG, but the distance between the two 
main chain carbons was 3.3 Å since Met98 is located on L6. The differences between the 
substrate binding residues, especially missing Thr171 and Arg206, may cause Rv2671 
not to bind to DAROPP or AROPP.  
 
 
 
Figure 17. Residue differences between the substrate binding sites of Rv2671 and Bs 
RibG. Superposition of NADP+ bound Rv2671 (blue) with the AIF bound Bs RibG 
(yellow) is shown in a stereo view. AIF and the residues directly interacting with AIF in 
Bs RibG are shown as yellow sticks, and the corresponding residues in Rv2671 are 
shown as green sticks. 
 
 
Rv2671 Is Not a DAROPP or AROPP Reductase 
As discussed above, the annotation and structural similarity suggest two possible 
biological substrates for Rv2671: DAROPP or AROPP. Due to the instability of 
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DAROPP and AROPP, these substrates were prepared enzymatically by E. coli RibA 
and E. coli RibD for the characterization of the pyrimidine reductase activity of Rv2671. 
Rv2671 showed no detectable reductase activity for either DAROPP or AROPP with 
different enzyme concentrations as well as substrate concentrations (Figure A-3). As a 
positive control, pure recombinant E. coli RibD showed both deaminase and reductase 
activity under the reaction condition described in the Experimental Procedure section. 
Rv2671’s inability to catalyze the reduction of either DAROPP or AROPP under the 
tested conditions suggests that it is not a pyrimidine reductase and therefore not involved 
in the riboflavin biosynthetic pathway. 
The evolutionary relationship between Rv2671, pyrimidine reductases, and 
DHFRs are apparent in the phylogenetic tree (Figure 18) constructed with 9 pyrimidine 
reductases from Actinobacteria which showed >50% sequence similarity to Rv2671, 15 
DHFRs, 10 functionally identified RibDs or Rib7s, and 4 enoyl ACP reductases used as 
the out-group control. The full tree contained three well-supported monophyletic groups, 
enoyl ACP reductases, DHFRs, and RibDs/Rib7s. Although Rv2671 is part of the 
RibDs/Rib7s superfamily, the Rv2671-like pyrimidine reductases from Actinobacteria 
formed an independent clade within the RibD/Rib7 family. These enzymes have a 
conserved Asp (Asp67 in Rv2671) for pteridine recognition and a Glu (Glu91 in 
Rv2671) in place of the catalytically critical Asp of the pyrimidine reductases (Figure A-
4). This indicates that this group of enzymes, with high sequence similarity to Rv2671 
from Actinobacteria, is likely misannotated. The ability of Rv2671 to catalyze the 
reduction of dihydrofolate to tetrahydrofolate or dihydropteroic acid to tetrahydropteroic 
  82 
acid further suggests that this particular group of proteins appears to have a fairly 
nonspecific dihydropteridine reductase activity. Moreover, the inability of Mtb Rv2671 
to function as an AROPP reductase suggests that Mtb RibG (Rv1409) is likely to be the 
true AROPP reductase that generates ARIPP in the riboflavin biosynthetic pathway of 
Mtb. 
 
 
Figure 18. Phylogenetic tree of pyrimidine reductases and DHFRs. Sequences were 
aligned with MUSCLE; the tree was generated by the approximation of the standard 
Likelihood Ratio Test with PhyML.The numbers at the nodes indicate the level of 
confidence for the branches. 
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Materials and Methods  
 
Materials 
All chemical reagents used in buffers, protein purification, and enzymatic assays 
were purchased from Sigma-Aldrich (St. Louis, MO). Dihydropteroic acid was 
purchased from Schircks Laboratories (Switzerland). 
 
Cloning, Expression, and Purification of Rv2671 
The sequence of full length Rv2671 gene was amplified from the Mtb H37Rv 
genome by PCR. Primers were 5’-GGACCTCCATATGCCCGACTCTGGTCAGC-
TCG-3’ and 5’- CCCAAGCTTTCAGGTCTTGACGTAGCGGGTGTACAGG-3’. The 
amplified gene was inserted into a pET28b expression vector (Novagen) containing an 
N-terminal 6x-His tag with the TEV cleavage site using the NdeI and HindIII restriction 
sites. The plasmid was transformed into BL21(DE3) Escherichia coli (E. coli) cells 
(Novagen) for Rv2671 expression. The cells with the plasmid were grown at 37 °C to 
OD600 ~ 0.6−0.8 in LB medium with 50 µg/mL kanamycin followed by induction with 1 
mM IPTG and grown overnight at 18 °C. The cells were lysed via a Microfluidizer M-
100P (Microfluidics, Worcestershire, UK) in lysis buffer (50 mM Tris, pH 7.5, 500 mM 
NaCl, 5% glycerol, 1 mM PMSF, 10 µg/mL DNase, and 2 mM MgCl2) and centrifuged 
at 27,216g for 1 h. The supernatant was purified over a nickel column (GE Healthcare) 
with a 0 to 300 mM imidazole gradient and the 6x-His tag was cleaved using tobacco 
etch virus protease. The protein was >95% pure, as observed by SDS−PAGE, and was 
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concentrated to 7.5 mg/mL, flash frozen, and stored in dialysis buffer (50 mM Tris, pH 
7, 50 mM NaCl, 5% glycerol, 1 mM DTT) at −80 °C. The concentration of the protein 
was determined by measuring A280 using NanoDrop 2000 UV−vis spectrophotometer 
with anextinction coefficient of the enzyme of 17,545 M−1cm−1  
 
Crystallization  
In order to obtain cocrystal structures, Rv2671 was incubated with substrates or 
inhibitors and screened for crystallization conditions with a Mosquito liquid dispenser 
(TTP Labtech, Cambridge, MA, USA) using the sitting drop vapor diffusion technique 
in the CrystalMation Intelli-Plate 96-3 low-profile crystallization plate (Hampton 
Research). For each condition, 1 µL of protein (7.5 mg/mL) and 1 µL of crystallization 
formulation were mixed, and the mixture was equilibrated with 50 µL of crystallization 
solution in the reservoir well. Full length Rv2671 protein crystals were further optimized 
via hanging drop vapor diffusion by incubating 1.5 µL of purified protein solution with 
1.5 µL of crystallization solution (0.2 M NaCl, 0.1 M Bis-Tris, pH 6.5, and 25−27% 
PEG 3350) at 18C for 2 d. Crystals were cryo-protected with 30% glycerol and flash 
frozen prior to data collection. For the NADP+ complex crystals, 2 mM NADP+ was 
cocrystallized with Rv2671 using the above procedure. The crystals of the Rv2671 with 
NADP+ and trimetrexate (TMQ) bound were also obtained from cocrystallization with 2 
mM NADP+ and 2 mM TMQ. The Rv2671 crystal in complex with tetrahydrofolate 
(THF)-NADP+, trimethoprim (TMP)-NADP+, and dihydropteroic acid (DHP)-NADP+ 
were obtained by soaking 5 mM of compounds into the NADP+ binary crystals.  
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Data Collection and Structure Determination 
Data were collected at Argonne National Laboratory using the Advanced Photon 
Source (APS) beamline 19ID or 23ID-B. All data were processed and reduced using 
HKL3000.202 The structure of the copurified NADP(H) bound Rv2671 was solved by 
molecular replacement using MOLREP203 in CCP4204 with the protein atomic 
coordinates for the truncated pyrimidine reductase-like protein of Corynebacterium 
diphtheria from the Protein Data Bank (accession code 2P4G, deposited by Joint Center 
for Structural Genomics). The exact search model contains residues 36−86 and residues 
174−258 of 2P4G. The complex structures were solved by molecular replacement using 
MOLREP203 in CCP4204 with the solved copurified NADP(H) bound Rv2671 structure. 
These crystals belong to the C2221 space group and contained one molecule in the 
asymmetric unit. Refinement and manual model building were performed with Phenix205 
and COOT,206 respectively, and TLS was not used in the refinement. 
 
Enzyme Kinetics 
The DHFR activity of Rv2671 was measured in a 1 mL solution containing 100 
mM HEPES, 50 mM KCl, 200 µM NADPH, 50 mM 2-mercaptoethanol, and 11.1 µg 
Rv2671 at pH 7.5, which was adapted from a similar assay to what has been previously 
reported for E. coli DHFR.207 Assays were started by adding DHF in concentration 
ranging from 0 µM to 250 µM. Enzyme activity was monitored using a Cary 100 
spectrophotometer at 340 nm. Initial velocity data were fitted with the 
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Michaelis−Menten equation208 using the SigmaPlot program (Systat Software, San Jose, 
CA). 
The dihydropteroic acid reductase (DHPR) activity207 of Rv2671 was measured 
in 200 µL of enzyme solution containing 100 mM HEPES, 50 mM KCl, 200 µM 
NADPH, 50 mM 2-mercaptoethanol, and 1.7 µg of Rv2671 at pH 7.5. Assays were 
started by adding 10 µL of DHP from 0 µM to 530 µM. Enzyme activity was monitored 
using a Cary 100 spectrophotometer at 340 nm. Initial velocity data were fitted with the 
Michaelis−Menten equation208 using the SigmaPlot program (Systat Software, San Jose, 
CA). 
The DHFR activity inhibition assay was performed under the same conditions 
described above but with the addition of 5 µL of inhibitor in 100% DMSO. The inhibitor 
was preincubated with the protein for 10 min. After preincubation, 5 µL of DHF was 
added to a final concentration of 200 µM in order to start the reaction. The reaction 
activity with 5 µL of DMSO alone served as a negative control. Activity data were 
plotted and fitted into the four parameter logistic equation (Eq. 1) by the SigmaPlot 
program (Systat Software, San Jose, CA). 
 
  %inhibition = min+ !"#-!"#!! !"#!"[!"#!$!%&']!"!" -!"##$#%&' Eq. 1  
  
The pyrimidine reductase activity of Rv2671 was followed by monitoring 
NADPH oxidation at 340 nm in a solution containing 50 mM HEPES, 5 mM MgCl2, 200 
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µM NADPH, 30 mM DTT, and 1.3226.50 µg/mL Rv2671 at pH 8. The substrates, 
DAROPP and AROPP were synthesized enzymatically. DAROPP was generated by 
mixing 5 mM GTP, and 2 mg/mL E. coli GCH-II and AROPP was synthesized by 
incubating 1 mg/mL E. coli RibD with DAROPP in the absence of NADPH.209, 210 The 
enzymes were removed by filtering through a 10 kDa cutoff concentrator (Vivaspin 500 
centrifugal concentrator). DAROPP was analyzed as its diacetyl derivative and detected 
by fluorometric HPLC. AROPP was analyzed by LC-MS using an SHIMADZU LCMS-
2010 spectrometer.  
 
HPLC Analysis of Tetrahydrofolate Formation 
Rv2671 (400 nM) was incubated with 500 µM NADPH and 200 µM DHF in the 
aforementioned buffer (100 mM HEPES, pH 7.5, 50 mM KCl, and 50 mM 2-
mercaptoethanol). Aliquots were removed every 2 min over a 10 min period and were 
then added to a solution of 0.1 M TCA and 0.55 M ascorbic acid to stop the reaction.211 
To extend the stability of THF, the pH of the reaction mixture was immediately adjusted 
to pH 4 by adding NaOH.211 The denatured protein was removed by centrifuging at 
16,200g for 10 min at 4 °C. An Agilent technologies HPLC (1200 infinity) with a 
reversed-phase C18 Atlantis T3, 5 µm, 4.6 × 250 mm column (Waters) was used to 
separate the components in the reaction mixtures.211 The column was eluted by the 
following optimized gradient at a 1 mL/min flow rate: solvent A is water, solvent B is 
100 mM KPi pH 6.6, and solvent C is methanol; 0 min 100% B, 4 min 25% A 60% B 
15% C, 8 min 20% A 40% B 40% C, 14 min 10% A 10% B 80%C, 18 min 10% A 10% 
  88 
B 80% C, 20 min 25% A 50% B 25% C, 22 min 100% B, and 25 min 100% B. The 
absorbance at 290 nm was monitored. The fluorescent chromatograph was monitored 
with excitation at 290 nm and emission at 360 nm. 
 
Evolutionary Tree Construction 
The amino acid sequences of thirty-eight representative homologues/orthologues 
were selected to generate the phylogenetic tree including 9 pyrimidine reductases from 
Actinobacteria, 15 DHFRs, 10 RibDs or Rib7s, and 4 enoyl ACP reductases used as the 
reference genes. Nine pyrimidine reductases from Actinobacteria were selected from the 
NCBI reference protein sequence database,212-214 which showed >50% sequence 
similarity with Mtb Rv2671. The DHFRs and RibD/Gs were selected from functionally 
characterized proteins. The phylogenetic tree was generated by the Phylogeny.fr 
server215 which used MUSCLE in order to carry out the multiple alignments of protein 
sequences,216 PhyML to build the tree using the marginal likelihood method,217 and 
TreeDyn in order to generate tree rendering.218 The sequences used to generate the tree 
are listed in Supplementary information.  
 
  89 
CHAPTER IV 
KINETICS, STRUCTURE AND INHIBITORS OF MTB IDH2 
 
 
Introduction 
 
Enzymes in the central carbon metabolism (CCM) are newly identified anti-
tubercular drug targets. CCM is an integration of pathways for the transport and 
oxidation of the carbon sources in all organisms. The tricarboxylic acid (TCA) cycle and 
the glyoxylate shunt are the pivots of the CCM in terms of deploying the carbon flux 
during catabolism of different carbon sources. These two pathways bifurcate at isocitrate 
(ICT) and determine its metabolic fate. ICT is the substrate of isocitrate dehydrogenase 
(IDH) in the TCA cycle and isocitrate lyase (ICL) in the glyoxylate shunt. The 
importance of ICL has been reviewed in Chapter I. It helps Mtb to sustain in 
macrophages and dormancy.219 The ICL knock-out studies115 have further demonstrated 
the potential of ICL to be a drug target for persistent Mtb. Mtb ICLs have been 
intensively studied; however, such studies on Mtb IDHs are lacking, although their 
activity may be the determinant of the carbon flux in Mtb.  
IDH is a decarboxylating dehydrogenase (EC 1.1.1.42). It catalyzes a two-step 
reaction that converts ICT to α-ketoglutarate (also called 2-oxoglutarate, 2OG), the latter 
being the precursor of glutamate (Figure 19). The first step of the reaction is initiated by 
a deprotonation at the 2-hydroxyl group of ICT, triggering a stereospecific hydride 
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transfer from C2 toward the cofactor NAD(P)+ to generate NAD(P)H and an unstable 
oxalosuccinate intermediate. In the second step, this unstable intermediate undergoes a 
decarboxylation at the C3, and followed by a tautomerization of the enol intermediate to 
produce the keto product, 2OG.220-227 NAD(P)H and CO2 are therefore generated as by-
products during the reaction. Divalent cations, typically Mg2+ or Mn2+, are required to 
stabilize the oxalosuccinate and enolate intermediates during this catalytic reaction.228, 
229  
A lysine-tyrosine pair was proposed to be the acid-base pair involved in the 
catalytic mechanism. A lysine (Lys230’ from the biologically neighboring subunit in E. 
coli IDH (Ec IDH)) is first deprotonated by the side chain of its neighboring Asp 
(Asp307 in Ec IDH) or a hydrogen bonded water. The deprotonated Lys230’ then serves 
as a base to abstract the proton of the 2-hydroxyl group of ICT in the first step. In the 
decarboxylation step, the metal ion acts as a Lewis acid, and the protonated Lys230’ 
provides a proton to the enol oxygen. In the tautomerization reaction, the deprotonated 
Lys230’ again serves as a general base to accept the 2-hydroxyl group of the enol 
intermediate, and a tyrosine residue (Tyr160 in Ec IDH) functions as a general acid to 
protonate C3 to generate the ketone product (Figure 19).220, 230 
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Figure 19. Proposed catalytic mechanism of IDH220, 230 
 
 
 
IDHs can be classified into three main subgroups, type I, type II, and monomeric 
IDHs according to a sequence-based phylogenetic analysis.231 The type I and type II 
subfamilies usually form homodimers. Two IDHs, Mtb IDH1 and Mtb IDH2, are 
presented in Mtb. Mtb IDH1 belongs to the type I subfamily, and Mtb IDH2 belongs to 
the monomeric IDH family. The structure, kinetics, and catalytic mechanisms of 
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homodimeric NADP-dependent IDHs, including Mtb IDH1, have been extensively 
studied. However, there has been little detailed investigation of monomeric IDHs. 
Although several monomeric NADP-dependent IDHs from prokaryotes have been 
isolated and functionally characterized, including Acinetobacter lwofii,232 Azotobacter 
vinelandii (Av IDH),233 Vibrio sp. ABE-1,234 Vibrio parahaemolyticus Y-4,235 
Corynebacterium glutamicum (Cg IDH),236 Colwellia maris,237 Chlorobium limicola,238 
Streptomyces diastaticus No. 7 M1033,239 and Streptomyces lividans TK54,240 they have 
not been studied as extensively as the homodimeric IDHs. To date, there has been only 
one kinetic study and two structures reported.241-245 The kinetic study was established 
with Av IDH in 1972.244 The reaction undergoes a rapid randomly sequential substrate 
binding and an ordered product releasing following the order of CO2, 2OG, and 
NADPH. In 2002, Yasutake et al. solved the first monomeric IDH’s structure, the 
structure of Av IDH in complex with ICT and Mn2+.242 The structures illustrated a highly 
structural conservation at the active sites between the monomeric and dimeric IDHs. 
However, the diversity was observed in NADP+ binding cavity of monomeric IDHs, 
which explained the high NADP+ specificity of monomeric IDHs.  
Escherichia coli IDH (Ec IDH) studied as a prototype of the prokaryotic IDHs, is 
regulated by a unique bifunctional enzyme, isocitrate dehydrogenase kinase/phosphatase 
(AceK).246 The gene aceK is located at the acetate operon, which also contains the genes 
encoding the glyoxylate shunt enzymes, ICL and malate synthase. AceK determines the 
activity of Ec IDH via a reversible phosphorylation (inactivate) and dephosphorylation 
(activate) of Ec IDH Ser113.247 Ser113 mediates the binding of ICT during the reaction. 
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ICT binding was under the detection limit for the phosphorylated Ec IDH, and the 
activity dropped to 0.15% of that of the unphosphorylated Ec IDH.248 
As mentioned above, Mtb has two IDHs. It is not clear why Mtb requires two 
IDHs, but the monomeric IDH2 is believed to participate in the TCA cycle since some 
mycobacterial species have only monomeric IDH. Moreover, no transposon insertion 
was observed in the gene encoding Mtb IDH2 in the transposon mutagenesis data, 
suggesting Mtb IDH2 is essential. However, an Mtb IDH2 knock-out strain can be 
established, suggesting that Mtb IDH2 is non-essential in vivo. The genetic observation 
can be a false positive in the transposon mutagenesis. The regulation of Mtb IDHs is also 
controversial. Mtb IDH1 has been proposed to be regulated by the phosphorylation and 
dephosphorylation based regulatory mechanism as Ec IDH as a phosphorylated, inactive 
Mtb IDH1 was observed after treated with mycobacterial eukaryotic-like Ser/Thr protein 
kinase G (pknG) in vitro.249 However, some evidence did not support this hypothesis 
including that the IDH activity did not increase in the pknG knock-out strain, and no 
cognate dephosphorylating enzyme was identified. These results suggest a need to 
reinvestigate the regulation mechanism of Mtb IDH1.Dissimilar to the homodimeric 
IDHs, the regulatory mechanisms of monomeric IDHs are still unclear.  
It has been shown that knock-out Mtb IDH2 would increase the efficacy of the 
ICL inhibitor, 3-nitropropionate.118 Therefore, inhibitors of Mtb IDH2 may have 
synergistic effect with Mtb ICLs inhibitors. There are no reported small molecule 
inhibitors for monomeric IDHs. However, the research into the inhibitors of human 
IDH1 and IDH2 belonging to the type-II IDH subfamily has been intensively studied 
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recently.250 More specifically, human mutated NADP-dependent IDHs (HIDH1 and 
HIDH2) are attractive targets for the cancer therapy since somatic missense mutations in 
HIDH1 or HIDH2 have been identified in several human cancers, especially 
glioblastoma,251, 252 sarcoma,253, 254 and acute myeloid leukemia (AML). 255, 256 The 
functional homology between Mtb IDH2 and HIDH1/HIDH2 provides the potential to 
repurpose the inhibitors of HIDH1/HIDH2 to prohibit the activity of Mtb IDH2. 
In this chapter, studies on the kinetics, mechanism, and structure of Mtb IDH2 
are discussed. The knowledge of Mtb IDH2 is not only the necessary building block for 
understanding the carbon utilization of Mtb during infection, but also an important 
information for the drug development targeting enzymes in the analeptic glyoxylate 
shunt. In addition, the study of Mtb IDH2 enhances our understanding of monomeric 
IDHs. A structure comparison between Mtb IDH2 and human IDHs revealed the 
dissimilarity in the overall structure and the NADP+ binding site as expected, suggesting 
the potential to find a selective inhibitor. The similarities in the ICT binding site and the 
catalytic residues, however, suggest that the inhibitors for HIDH1/2 mutants have the 
potential to inhibit Mtb IDH2. Here a preliminary inhibitor study for Mtb IDH2 was 
implemented. Four HIDH1/2 mutants’ inhibitors were first tested for inhibition of Mtb 
IDH2. Next, a high-throughput screening (HTS) assay was established and optimized to 
explore structurally new Mtb IDH2 inhibitors from two anti-tubercular whole cell active 
compound collections.    
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Results and Discussion 
 
Enzyme Assay and Kinetic Mechanism of Mtb IDH2  
All IDHs, including Mtb IDH2, require metal cations, specifically Mg2+ or Mn2+, 
to stabilize the reaction intermediate during the enzymatic reaction. The maximal 
activity of Mtb IDH2 was achieved when Mn2+ was used as the metal cofactor. Only 
20% of the maximal enzyme activity was detected when Mn2+ was substituted by the 
same amount of Mg2+. Additionally, Mtb IDH2 is specific for NADP+, while does not 
exhibit activity with NAD+.  
A steady-state kinetics with varied concentrations of NADP+ and ICT were then 
conducted in the presence of Mn2+. Initial velocity data of Mtb IDH2 presented in a 
double reciprocal plot with NADP+ as the variable and ICT as the fixed substrate yielded 
a series of parallel lines (Figure 20A). Likewise a plot of 1/υ versus 1/[ICT] at different 
fixed levels of NADP+ also gave a parallel line pattern (Figure 20B). The data fit best to 
the equation for a Ping-Pong mechanism (Eq. 3). The kinetic parameters were obtained 
as kcat= 116.6 ± 2.05 s-1, Km for NADP+= 157.8 ± 9.10 µM, and Km for ICT= 36.7 ± 2.55 
µM. It is unexpected to observe a Ping-Pong mechanism for an oxidative 
decarboxylation reaction, considering that a hydride transfer from one substrate 
intermediate (deprotonated ICT) to the cofactor (NADP+) is involved in the reaction that 
clearly suggests the existence of the transition complex.  
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Figure 20. Double reciprocal plots of the initial velocity kinetics for Mtb IDH2. (A) 1/υ 
versus 1/[NADP+] at different fixed concentrations of ICT, (B) 1/υ versus 1/[ICT] at 
different fixed concentrations of NADP+. 
 
 
The substrate inhibition and product inhibition experiments were used to further 
investigate the likelihood of a Ping-Pong mechanism. In the forward reaction, no 
substrate inhibition phenomenon was observed when the concentrations of either DL-
ICT or NADP+ were up to 50-fold higher than the Km values. Table 9 summerizes the 
inhibition parameters and the patterns of double-reciprocal plots while using the 
products, 2OG or NADPH, as the inhibitors. Due to the relatively high Km for NADP+, 
the product inhibition study was only conducted when each substrate was held at the 
sub-saturating level. NADPH was a competitive inhibitor against NADP+ and a mix-type 
inhibitor against ICT. 2OG was a mix-type inhibitor against either NADP+ or ICT. These 
data do not support a Ping-Pong mechanism but agree with an ordered sequential 
mechanism in which NADP+ binds first. 
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Table 9. Product inhibition patterns and kinetic parameters for Mtb IDH2 
Inhibitor Fixed substrate Varied Substrate Pattern Fitted parameters (µM) 
NADPH ICT NADP+ C appKis= 22 ± 1 
NADPHH NADP+ ICT NC 
appKis= 117 ± 28 
appKii= 65 ± 2 
2OG NADP+ ICT NC 
appKis= 428 ± 84 
appKii= 4,555 ± 1,001 
2OG ICT NADP+ NC 
appKis= 846 ± 168  
appKii= 2,038 ± 149 
 
 
The observation of parallel line pattern in the initial velocity study could be 
explicated by one of the special condition suggested by Segel that a Kia, which is 
referred to a dissociation constant value of NADP+, is much smaller than its Michaelis-
Menten constant (KmA).257 Under this condition, the equation of the steady-state 
sequential mechanism Eq. 2 is reduced to Eq. 3 as the value of Kia*Kb is hard to 
investigate and consequently resulting in a parallel line pattern for a sequential 
mechanism. 
 
 ! = !!"# ! !!!!!" + !!" ! + !!" ! + ! !  Eq. 2 
 
The product releasing mechanism can also be determined via the product 
inhibition study. The competitive inhibition of NADPH with respect to NADP+ and the 
mixed type inhibition with the respect to ICT suggest that NADPH is the last released 
product. The overall reaction scheme is shown in Scheme 3. 
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Scheme 3. Proposed kinetic mechanism of Mtb IDH2 
 
 
 
 
Overall Structure of NADP+ Bound Mtb IDH2 
The crystal structure of NADP+ bound Mtb IDH2 was determined at a resolution 
of 2.67 Å by molecular replacement using the structure of Av IDH (1J1W241) as a search 
model and refined to a final Rwork/Rfree of 17/23%. The final model includes four protein 
chains, four NADP+, two malonate, one malate, and one succinate molecules in one 
asymmetric unit of the structure. The details of the refinement are shown in Table 10.  
Mtb IDH2 is an α/β protein composed of 27 α-helices, 6 η-helices, and 24 β-
strands (Figure 21). It can be divided into a large domain (residues 136−567) and a small 
domain (residues 5−137 and 568−743). The large domain consists of 13 α-helices 
(α7−α19), 3 η-helices (η4−η6), and 19 β-strands (β4−β22). The small domain is 
composed of 14 α-helices (α1−α6 and α20−α27), 3 η-helices (η1−η3), and 5 β-strands 
(β1−β3 and β23−β24). The β-strands from the small domain and five β-strands (β4, β15, 
and β20−β22) from the large domain form an interdomain β-sheet. This β-sheet consists 
of eight parallel β-strands and two anti-parallel β-strands. In addition, a pseudo two-fold 
axis was observed in the large domain (Figure 21). The catalytic site is located in the 
cleft between the two domains. 
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Table 10. Crystallographic data collection and refinement statistics of the NADP+ bound 
Mtb IDH2 structure 
 NADP+ bound Mtb IDH2 
Data collection  
Space group P1 
Cell dimensions    
    a, b, c (Å) 74.8, 110.9, 114.9 
    α, β, γ  (°)  86.0, 78.6, 76.8 
Resolution (Å) 50- 2.67 (2.72-2.67) * 
Rsym  0.115 (0.596) 
I/σI 16.72 (3.99) 
Completeness (%) 98.35 (94.02) 
Redundancy 3.9 (3.9) 
  
Refinement  
No. reflections 390141 
Rwork/ Rfree 0.17/0.23 
No. atoms  
    Protein 22932 
    Ligand/ion 263 
    Water 490 
B-factors  
    Protein 39.30 
    Ligand/ion 33.70 
    Water 30.90 
R.m.s deviations  
    Bond lengths (Å)  0.012 
    Bond angles (º) 1.29 
Ramachandran plot 
statistics (%) 
 
    Favored 96 
Allowed 3.63 
Outliers 0.37 
* Resolution values for collection and refinement are the same. 
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Figure 21. Overall structure of NADP+ bound Mtb IDH2 and the pseudo two-fold axis in 
the large domain. NADP+ bound Mtb IDH2 is shown in ribbon representation and 
colored by secondary structural elements; strands, grey ribbon; helices, green ribbon; 
loops, yellow tube. NADP+ is shown in pink and located in the cleft between the large 
domain and the small domain. 
 
 
 
Structural Comparison with Other Monomeric IDHs 
In addition to the structures of Av IDH and Cg IDH, the structure of Mtb IDH2 
was the third solved monomeric IDHs. A structural similarity search was performed by a 
pairwise comparison using the DALI structural similarity search server,ƒ199 which used 
Z-scores to estimate the results. A higher Z-score indicates a better similarity, and a 
structure with a Z-score greater than two suggests a significant similarity to the parental 
structure. A total of 116 structures were found with a Z-score greater than two, and as 
expected, Av IDH and Cg IDH were identified as the closest structural homologues of 
Mtb IDH2. Av IDH (1ITW242) exhibited a Z-score of 58.5 and a rmsd of 1.9 for 735 Cα 
atoms; Cg IDH (3MBC243) exhibited a Z-score of 56.4 and a rmsd of 5.6 for 728 Cα 
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atoms. Overall, the structures are similar. The structural comparisons were conducted 
between individual domains as interdomain movements were observed in Av IDH and 
Cg IDH. For the small domain, these three structures contained the same secondary fold 
and topology (Figure 22A). For the large domain, spatial differences were observed in 
the region of α11 to α14 and the loop (residues 255−266) at the active site. The region of 
α11 to α14 in Cg IDH showed a 22.7° rotation compared with that of Av IDH and Mtb 
IDH (Figure 22B). The flexibility of the active site loop reinforces the substrate induced 
interdomain movement. 
 
 
Figure 22. Structural comparisons of small and large domains. (A) Superimposed 
structures of the small domains of Mtb IDH2 (brown), Av IDH (blue), and Cg IDH 
(pink). (B) Superimposed structures of the large domains of Mtb IDH2 (brown), Av IDH 
(blue), and Cg IDH (pink). 
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Hinge-bending interdomain motions with two hinges were observed in Av IDH 
and Cg IDH (Figure 23). After compared with the structures of the reported Av IDH and 
Cg IDH, I concluded that this NADP+ bound Mtb IDH2 is in a closed conformation. The 
α6 (residues 137−143 in Mtb IDH2) and β23 (residues 568−571 in Mtb IDH2) were 
assigned as the corresponding hinges by the program DYNDOM258 using the open 
conformational Av IDH structure (1ITW242) as the comparison model.    
 
 
Figure 23. Interdomain motions of monomeric IDHs. The domain movement of Cg IDH 
is shown in left panel by superimposing the structures of Cg IDH with the open (in 
yellow) and closed (in blue) conformations. The middle panel presents the domain 
movement of Av IDH by superimposing the structures of Av IDH with the open (in 
green) and closed (in pink) conformations. In the right panel, the domain movement of 
Mtb IDH2 is predicted by overlaying the closed conformation Mtb IDH2 (in purple) with 
the open conformation Av IDH (in green). 
 
 
 
NADP+ Binding Site 
Four NADP+ molecules were modeled into unambiguous electron densities at the 
cleft between the two domains of all four molecules in the asymmetric unit (Figure 21). 
13.1°	rota*on	 12.7°	rota*on	
Cg	IDH	 Av	IDH	 Av	IDH	vs	Mtb	IDH2	
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Each NADP+ forms 27 hydrogen bonds with the residues of its corresponding Mtb 
IDH2. Figure 24 illustrates the detailed hydrogen bonding and hydrophobic interactions 
between Mtb IDH2 and the NADP+. The nicotinamide group of the NADP+ forms 
hydrogen bonds with the main chain amide nitrogen of Asn87 (3.1 Å) and a water 
molecule (3.3 Å). The adenine group of NADP+ has hydrophobic interaction with the 
side chains of Thr564, Ala566, Trp604, and Asp605. Furthermore, the N1 and N6 atoms 
of the adenine group form hydrogen bonds with the main chain oxygen and nitrogen of 
Asp605 (3.0 Å and 3.0 Å). Five hydrogen bonds are observed between the residues 
His592, Arg603, and Arg652 and the 2’-phosphate group of the adenosine. More 
specifically, the phosphate group forms two hydrogen bonds with the granidinium 
groups of Arg603 (2.5 Å and 3.0 Å) and Arg652 (2.9 Å and 3.3 Å) individually and a 
hydrogen bond with the side chain of His592 (2.8 Å). The hydrogen bonds between the 
2’-phosphate group on the ribofuranose and the protein may lead to the selectivity of 
NADP+ instead of NAD+ in the Mtb IDH2. 
 
Catalysis 
So far, the Mtb IDH2 structures in complex with ICT or 2OG have not been 
obtained. However, some ICT analogs including malonate, malate, and succinate, which 
existed as ingredients of the crystallization condition, were fortuitously crystallized in 
the active site of the NADP+ bound Mtb IDH2 structure. A malate molecule was 
modeled into the electron density map of chain A. It forms six hydrogen bonds with its 
surrounding residues. 
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Figure 24. Detailed interactions between NADP+ and Mtb IDH2. A Ligplot259 plot 
presents the interactions between NADP+ and Mtb IDH2. The bonds are shown in 
orange. The carbon atoms, oxygen atoms, nitrogen atoms, and phosphorus atoms are 
colored by black, red, blue, and purple. The hydrogen bonds are in green dashed lines. 
 
 
 
The side chain of the following residues each forms one hydrogen bond with the 
modeled malate including Ser89 (3.3 Å), Ser134 (2.8 Å), Asn137 (3.1 Å), Arg141 (3.0 
Å), Lys257 (2.7 Å), and Arg550 (2.2 Å). The hydrogen bond assignment was conducted 
by the LigPlot software259 with its default parameter. The positioning of the malate 
suggests that Lys257, Tyr422 and Asp511 facilitate the catalytic reaction in the Mtb 
IDH2, after comparing with the spatial location of the proposed lysine-tyrosine pair and 
the Asp307 in the Ec IDH structure (4AJ3260) (Figure 25). 
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Figure 25. Active site comparison between Mtb IDH2 and Ec IDH illustrate the potential 
catalytic residues of Mtb IDH2. Superimposition of Mtb IDH2 (shown in pink) and Ec 
IDH (subunit A in blue and subunit B in yellow, PDB: 4AJ3) suggests that Lys257, 
Tyr422, and Asp511 in Mtb IDH2 are involved in the catalytic reaction.  
 
 
 
Proposed Reaction Mechanism of Mtb IDH2  
The solved NADP+ bound Mtb IDH2 structure is in a closed form with no 
accessible entrance for ICT, suggesting that ICT binds first as binding of NADP+ would 
lead to a closed conformation. This structural observation is controversial to the kinetic 
mechanism in which NADP+ binds first and followed by the ICT binding. To understand 
this binding order disagreement, we carefully re-investigated the structure. Notably, only 
the small domain contributes to the hydrogen bonding interactions between NADP+ and 
Mtb IDH2. Combined with the knowledge that ICT binding induces the interdomain 
change, which result in the angle between the large domain and the small domain 
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decrease and the structure is converted from an open to a closed conformation, a model 
was proposed (Figure 26). In this model, NADP+ first binds to the small domain of open 
conformational Mtb IDH2 and the following binding of ICT then triggers the closure of 
Mtb IDH2. In the solved structure, the observed ICT analogs may serve as the trigger for 
the domain closure. This model will explain the observations from the structure and the 
kinetics. 
 
 
Figure 26. Models of the proposed intredomain closure mechanism. NADP+ binds first 
to the small domain of the free Mtb IDH2 producing the binary complex. ICT binds next 
and triggers an open-to-closed transition. 
 
 
 
Mtb Monomeric IDH2 Is Not a Monomer  
Size exclusion chromatography was applied to determine the oligomeric state of 
Mtb IDH2 in solution in a previous report.261 Mtb IDH2 is the first homo-dimeric/homo-
tetrameric member of the monomeric IDH family that has been reported to date. Mtb 
IDH2 existed as a tetramer in a buffer with 50 mM NaCl, a trimer in 500 mM NaCl 
buffer, and a tetramer in 1M NaCl buffer.261 Trimer is not a constitutive oligomeric state 
of the enzyme; instead, it is a result of the dynamic equilibrium between the dimeric and 
Hinge	
Sma
ll	Do
main
		
Large	Domain	
ICT	NADP+	
Sma
ll	Do
main
		
Large	Domain	
NADP
+	
Domain	1	
Domain	2	
NADP+	ICT	
Hinge	
Hinge	
  107 
tetrameric state. The dissociation of the tetramer into dimers in the high salt condition 
indicates that the electrostatic interaction is the driving force of the dimerization between 
the two constituent dimers.  
To examine the pH effect, the oligomeric state of Mtb IDH2 was investigated at 
pH 6.5, which is the lower bound of the intrabacterial pH of Mtb.262 To obtain the 
desired pH, a phosphate buffer replaced the reported HEPES buffer. Mtb IDH2 existed 
as a dimeric form in the phosphate buffer at pH 6.5 and as a mixture of dimer and 
tetramer in the ratio 3:1 at pH 7.5. The ionic strength of the examining buffer (50 mM 
phosphate buffer, 50 mM NaCl, pH 7.5) is 179 mM, which is 321 mM less than 500 mM 
NaCl in the reported buffer. This result suggests that other than the ionic strength, the 
formation of the tetramer can be influenced by pH or buffers. To investigate these two 
factors, the oligomeric states were determined in the different buffers, which contain 
same ionic strength and pH (Table 11). Different oligomeric states were observed 
suggesting that the formation of the tetramer is sensitive to the buffer systems. The 
results of the oligomeric states investigation indicate that the tetramer is unstable and 
affects by environmental factors such as the ionic strength and the buffers, but the 
homodimer is stable. 
 
Table 11. Oligomeric states of Mtb IDH2 in different buffer system 
Buffer NaCl (mM) Ionic Strength (mM) pH Oligomeric state 
50 mM phosphate  50 132 6.5 2 
50 mM MOPS 50 132 6.5 2.5 (D:T= 3:1) 
50 mM PIPES 50 132 6.5 3 (D:T=1:1) 
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By scrutinizing the crystal structure of Mtb IDH2, nine hydrogen bonds were 
observed between the assigned chains A and D (Figure 27). The side chains from 
Arg172, Arg179, Glu390, Thr397, and Arg529 of chain A and the side chain or main 
chain from Gln389, Glu390, Asn398 and Arg529 of chain D conducted the formation of 
hydrogen bonds in the dimer interface.  
 
 
Figure 27. Interface interaction between chain A and chain D in the NADP+ bound Mtb 
IDH2 structure. Hydrogen bonds between the residues of chain A (yellow) and chain D 
(pink) are shown in black dotted lines. 
 
 
A site-directed mutagenesis study was implemented to validate if this dimer 
observed in the crystal structure is a result of the crystal packing or is physiologically 
relevant. Three Mtb IDH2 mutants were constructed and purified including Mtb IDH2 
E390R, Mtb IDH2 R529E and Mtb IDH2 E390R/R529E double mutant. E390 and R529 
were chosen as site-directed mutagenesis targets due to the symmetrical formation of an 
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electrostatic interaction in the structurally dimer interface. The oligomeric states of the 
purified Mtb IDH2 mutants were analyzed by the size exclusion chromatography (Figure 
28). A phosphate buffer at pH 6.5 was used to conduct the experiment since the homo-
tetramer is fully dissociated under this condition. E390R mutant exists as a monomer in 
solution, and the dimerization is restored when the R529E mutation was introduced. The 
monomeric form of the E390R mutant indicates that the dimer between chain A and D is 
biologically relevant, and E390 and R529 are crucial for the dimerization. Alternatively, 
the R529E mutant remained as a dimer in solution. This result implies that the residual 
interactions are sufficient to drive the dimerization. Therefore, the dimerization process 
disturbed by E390R mutation not only via the interruption of the electrostatic interaction 
between E390 and R529, but also the steric hindrance of two arginines between two 
subunits and consequently disturbing other interactions. To test if the biological dimer is 
activity relevant, the activity assay of the mutant Mtb IDHs were performed. The E390R 
and R529E mutants showed slightly higher activity but did not achieve a significant 
difference compared to the activity of the wild-type (WT) enzyme. This result indicates 
that the dimeric form is not required for the enzymatic activity.  
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Figure 28. Size exclusion chromatography of wild-type and mutants of Mtb IDH2s. The 
purified proteins (0.1 mL, 10mg/mL) were loaded to a Superdex200 10/300 column 
equilibrated with binding buffer (50 mM sodium phosphate buffer pH 6.5 and 50 mM 
NaCl). WT (pink trace), R529E (blue), and double mutant (red) Mtb IDH2s were eluted 
from the column at molecular mass of ~ 164 kDa, which is corresponding to a dimer. 
Alternatively, E390R Mtb IDH2 (blue) were eluted from the column at molecular mass 
of ~ 82 kDa, suggesting that E390S Mtb IDH2 is a monomer under this buffer condition.  
 
 
Structural Comparisons between Mtb IDH2 and Human IDHs 
Besides essentiality, the ability to provide the selectivity is another determinant for a 
good drug target. The “selectivity” can be exhibited when the enzyme of interest is (i) 
lack of human homologs, (ii) possessing a non-essential human homologue, or (iii) 
showing sufficient differences from its human counterpart. Sequence and structural 
comparisons were conducted to evaluate whether Mtb IDH2 is a good target from the 
selectivity perspective. Human and higher eukaryotes cells have three isoenzymes of 
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IDHs. Human IDH1 and IDH2 (HIDH1 and HIDH2) are NADP+-dependent 
homodimeric IDHs belonging to the type II superfamily. Human IDH3 (HIDH3) is an 
NAD+-dependent octamer and composed of three subunits in a ratio of α2βγ.263 HIDH1 
locates in the cytoplasm.264 HIDH2 and HIDH3 are found in the mitochondrial.265 
HIDH3 participates in the TCA cycle for energy generation. The subunit α is the 
catalytic subunit.266 The subunits β and γ function as the regulatory units. The roles of 
HIDH1 and HIDH2 remain unclear, but it is believed that they serve to maintain the 
redox balance and protect the cell from the oxidative induced damage.131, 267 Mtb IDH2 
showed low sequence identity (5−12%) with human IDHs implying the difference for 
selection. Notably, it is usual that proteins show high structural similarity with low 
sequence similarity. Therefore, structural comparisons of the regions and the residues 
that are critical for the function of proteins are required to evaluate the similarity 
between two enzymes. The structural comparisons were performed between Mtb IDH2 
and two structurally known human IDHs, HIDH1 and HIDH2. First, it is worth to 
mention that the active sites of HIDH1 and HIDH2 showed high similarity including the 
catalytic residues and the NADP+ binding residues. As expected, the catalytic residues 
were conserved but were different in the NADP+ binding pocket for Mtb IDH2 and 
HIDH1/HIDH2. Figure 29 shows the NADP+ binding residues. The similarity of the 
catalytic residues implies the potential that mutant HIDHs’ inhibitors can be inhibitors 
for Mtb IDH. The diversity of the NADP+ binding site indicates the possibility to find a 
unique inhibitor for monomeric IDHs.  
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Figure 29. Schematic representations of the NADP+ binding residues of Mtb IDH and 
HIDH1/HID2 
 
 
Inhibitory Tests for HIDHs’ Inhibitors 
Although the sequence (5−12% sequence identity) and the overall structure of 
Mtb IDH2 are dissimilar to that of HIDHs, inhibitory test of the known HIDHs mutant 
inhibitors against Mtb IDH2 is still a good starting point since the active site residues of 
Mtb IDH2 and HIDHs are conserved. Four known HIDH1 inhibitors (Table 12) were 
assayed against the recombinant Mtb IDH2 at a single concentration point of 20 µM in 
duplicates. AGI-5198,268 AGI-6780,269 and 1BZ270 showed poor inhibitory activity 
against Mtb IDH2 (AGI-5198: 0%, 1BZ: 5.7% inhibition, and AGI 6780: 20% 
inhibition). Alternatively, SYC-3 demonstrated 100% inhibition against Mtb IDH2 at 20 
µM; hence, an IC50 evaluation was conducted. SYC-3 exhibited an IC50 of 5.2 ± 3.1 µM 
against Mtb IDH2 (Figure 30). A structure activity relationship (SAR) and protein-
inhibitor complex structure study of SYC-3 are in progress. 
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Indeed, the Mtb IDH2 inhibition profiles of SYC-3 and AGI-6780 are expected 
based on their binding modes in HIDH1. SYC-3 binds at the relatively conserved active 
site,271 so it is likely to be a shared inhibitor. To the contrary, AGI-6780 binds at the 
dimer interface,269 which does not exist in Mtb IDH2. The structural difference 
consequently leads to an inhibition discrepancy. However, it is unclear why 1BZ is 
inactive against Mtb IDH2 since its binding site is similar to that of the SYC-3.270 In 
fact, except for 1BZ, the overall inhibition pattern of Mtb IDH2 agrees the reported 
inhibition pattern against the WT HIDHs; compiled data are shown in Table 12.  
 
 
Table 12. Inhibitory activity of HIDHs’ inhibitors against Mtb IDH2 
Compd % Inhibition  
at 20 µM 
IC50 (µM) Ki (µM) 
HIDH1 (WT) HIDH2 (WT) HIDH1 (WT) 
AGI-6780 21.2 >100269 0.190 ± 0.0081269 - 
AGI-5198 -0.5 >100268 >100268 - 
1BZ 5.7 - - 16.8270 
SYC-3 100.0 - - 8.8 ± 0.4271 
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Figure 30. Inhibitory dose-response curve to determine the IC50 of SYC-3 for Mtb IDH2. 
Data represent mean values of duplicate experiments. 
  
 
High-Throughput Screening 
To identify novel chemical inhibitors that are unique for Mtb IDH2 as well as 
monomeric IDHs, we further adapted the Mtb IDH2 enzyme assay to a high throughput 
format. The robustness and reproducibility of the assay for the HTS assay was evaluated 
by statistical analysis and yielded a Z’ factor of 0.6. The reaction without enzyme was 
used as the positive control for the calculation since there was not a good Mtb IDH2 
inhibitor when the experiment initially was performed. Using this assay, we screened 
1,993 compounds including two collections of Mtb whole cell active compounds. The 
first collection is called the SRI library from Southern Research Institute. This library is 
composed of 1,113 Mtb H37Rv whole cell active compounds among 100,997 
structurally different drug-like compounds from ChemBridge Corporation.272 These 
IC50 =  5.2 ± 3.1(µM ) 
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%
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compounds established >90% inhibition against the H37Rv whole cell growth assay in 
7H12 media at 10 µg/mL and did not show toxicity in the Vero cell-based cytotoxicity 
assay. The second collection is called the Sac_1 Hit plates. The anti-tubercular whole 
cell activity screening of the Sac_1 library was performed in house (Hughes, R. and 
Sacchettini, J., personal communication). A library containing 50,099 drug-like 
molecules was screened against Mtb mc27000 strain in M9 media with sodium acetate as 
the carbon source. Compounds showing greater than 50% inhibition of the whole cell 
growth were selected as hits. A total of 880 compounds were found in the primary 
screen and 70% of them showed inhibition in the retest. The results of the HTS against 
Mtb IDH2 are summarized in Table 13. We obtained 14 candidates when a cutoff of 
>75% inhibition was applied. The 14 candidates were first retested at 50 µM for 
inhibition against Mtb IDH2 with material being drawn from the original stock solution 
plates. Two among 14 original hits were confirmed as true enzyme hits; shown in Figure 
31A. Compound 7365674 was dropped due to low inhibitory activity (40% inhibition at 
20 µM) and the higher potency against H37Rv than Mtb IDH2 implying that Mtb IDH2 
is not the molecular target of this compound. This yielded one confirmed hit (6144788) 
was selected for resupply from ChemBridge.  
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Table 13. Summary of the HTS results 
Total # of Compounds Screened 1,993 
Hits from Primary Screen 14 (0.7%) 
Secondary Validation 2- Confirmed hits (0.1%) 
Individual Library Successful rate 
SRI Library Collection 
Total # of Compounds Screened 1,113 
Hits from Primary Screen 13 (1.2%) 
Secondary Validation 2- Confirmed hits (0.18%) 
Sac_1 Hit Collection 
Total # of Compounds Screened 880 
Hits from Primary Screen 1 (0.1%) 
Secondary Validation 0- Confirmed hits (0%) 
 
 
Structure-Activity Relationship Study 
The sulfonamide containing molecule (6144788) is an inhibitor of Mtb IDH2 
with an IC50 value of 2.2 µM (Figure 31B). Compound 6144788 was then either soaked 
into the existence crystal or co-crystallized with Mtb IDH2. No intact drug density was 
observed in the calculated electron density map in all experimental trials. The low 
solubility of the compound 6144788 in the crystallization buffer may cause the failure to 
obtain the protein-inhibitor complex structure. The cLogP of 6144788 (Figure 31C) is 
higher than a lead like molecule, which is often between 1−3. Therefore, a preliminary 
structure-activity relationship (SAR) study was carried out with a series of commercially 
available sulfonamide structural derivatives (Table 14-17) to improve the potency of Mtb 
IDH2 inhibition and to address the solubility issue. 
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Figure 31. Detailed information of the hits from the HTS assay. (A) Chemical structures, 
enzyme inhibitory and the whole cell activity of the two obtained hits. (B) IC50 curve of 
6144788 against Mtb IDH2 in the enzyme assay. (C) Molecular information of 6144788. 
 
 
A total of 19 commercially available derivatives of the parental hit were 
collected and assayed against Mtb IDH2, but none of them showed significant 
improvement in inhibition in this preliminary SAR study, The tested compounds can be 
classified into five main structural sub-groups.  
Molecules in sub-group 1 retained the N-(naphthalen-1-yl)benzenesulfonamide 
scaffold of the parental compound but incorporated multiple substitutions on the 
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aromatic rings. When 4-fluorophenyl is changed to 4-ethylphenyl and naphthyl in 
compounds 1-1 and 1-2, the inhibitory activity decreased slightly. In addition to the 
substitution of 4-fluorophenyl to 4-chlorophenyl and naphthyl, the bromo group was 
removed from compound 1-3 and 1-4. These modifications also reduced the inhibitory 
effects. Lower inhibitory activity of 1-3 comparing with 1-2 demonstrated the 
importance of the bromine substitution at the naphthalene group. Different functional 
groups were incorporated to investigate the role of the para-position of the phenyl ring 
including an alkyl, a different halogen or replacement with a fusing ring. Although the 
halogen atoms are commonly used to increase the hydrophobicity during the hit 
optimization, their abilities to form weak hydrogen bond (ex: CF…HN) or halogen bond 
interaction, orthogonal multipolar interactions and the cation-pi interaction are 
considered to play an important role to improve inhibitor’s potency.273-275 The inhibitory 
activity increases with the hydrophobicity increase in the comparison of 1-1 and 1-2 
indicating the participation of the hydrophobic interaction. However, the fluoro- 
substituent parental hit and the chloro- substituted 1-4 showed better inhibition than the 
naphthyl modified 1-2 and 1-3 further suggesting that the electron withdrawing and 
weak hydrogen/halogen bond forming characteristic carried by the halogen atoms may 
be also involved in the binding mechanism.  
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Table 14. Structures and inhibitory activity of sub-group1 
 
Compd R1 R2 % Inhibition 
at 20 µM 
IC50 (µM) clogP 
1-1 
 
1-Br, 2-OH 72.1  5.05 
1-2 
 
1-Br, 2-OH 124.5 3.9 5.20 
1-3 
 
2-OH 46.9  4.05 
1-4 
 
2-OH 76.9 15.8 4.10 
1-5 
 
1-H, 2-H 0.3  5.17 
1-6 
 
1-H, 2-H −4.6  2.80 
 
 
To investigate the importance of the naphthalene core connecting to the amino 
group of the sulfonamide, a series of benzensulfonamide derivatives were collected and 
formed sub-group 2. None of these derivatives exhibited inhibition against Mtb IDH2. 
Notably, the replacement of the phenyl group is the only difference between the parental 
hit and compound 2-2. These results clearly highlight the importance of the naphthalene 
ring. 
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Table 15. Structures and inhibitory activity of sub-group2 
 
Compd R1 R2 % Inhibition 
at 20 µM 
2-1  1-Br, 2-OH 24.7 
2-2 1-F 1-Br, 2-OH 3.9 
2-3 1-OMe, 2-NH2 2-OEt −18.9 
2-4 1-COOH  −2.1 
2-5   −12.1 
 
 
 
One critical liability with this series of compounds is its poor solubility, which 
hinders the process of both testing in the binding assay and the structural study of the 
complex. Based on the results of sub-group 1 and 2, the naphthalene ring is essential for 
the activity but results in limited solubility of the compounds. Therefore, we attempted 
to overcome this issue by replacing the naphthalene with heterocyclic ring groups. As 
shown in Table 16 and Table 17, sub-groups 3 and 4 are the collections in which the 
naphthalene is replaced by a quinoline ring. Although all molecules in these two sub-
groups exhibited lower potency compared to the parental hit, in general, better 
inhibitions were achieved by the sub-group 4 than the sub-group 3. This result again 
demonstrates the importance of substituent at the quinolone, which is in agreement with 
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the observation in sub-group1. These results demonstrated the possibility to obtain a 
potent compound with better solubility once a proper substituent is incorporated.   
 
Table 16. Structures and inhibitory activity of sub-group3 
 
Compd R group % Inhibition 
at 20 µM 
cLog P 
3-1 
 
25.7 3.39 
3-2 
 
23.4 4.43 
3-3 
 
10.4 3.13 
3-4 
 
29.4 3.28 
3-5 
 
24.7 2.50 
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Table 17. Structures and inhibitory activity of sub-group4 
  
Compd R1 group R2 group % Inhibition 
at 20 µM 
cLog P 
4-1 
 
1-Cl,  
3-Cl 
63.2 5.42 
4-2 
 
3-Br 63.3 3.83 
4-3 CH3 2-OMe 12.2 1.62 
 
 
 
Conclusion 
 
The biochemical and biophysical properties of Mtb IDH2 were thoroughly 
studied and characterized in this chapter. The kinetic data suggested that Mtb IDH2 
underwent a sequential mechanism in which NADP+ bound first and NADPH released 
last. The X-ray structure of Mtb IDH2 was solved for the first time, which is also the 
third reported structure of monomeric IDHs. The NADP+ bound Mtb IDH2 was 
observed in a closed conformation. Intriguingly, instead of a monomer, Mtb IDH2 
formed a dimer in solution. Through the structural investigation, E390 and R529 were 
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proposed to be the critical residues participating in the dimerization by providing the 
electrostatic interactions, which was further demonstrated by the site-directed 
mutagenesis study. The E390R Mtb IDH2 is a monomer in solution due to the 
interruption of the interactions and a steric hindrance. The mutation did not alter the 
activity of Mtb IDH2 indicating the dimer form was irrelevant in this activity.  
The sequence and structural conservations of the catalytic residues between Mtb 
IDH2 and HIDHs suggest that the inhibitors of HIDHs can be inhibitors for Mtb IDH2 if 
they bind at the catalytic site. Alternatively, the diversity at the NADP+ binding cavity 
indicates the potential to find inhibitors that are unique for monomeric IDHs. To identify 
inhibitors for Mtb IDH2, reported inhibitors of homologues (HIDHs) and two 
structurally diverse Mtb whole cell active libraries were assayed against Mtb IDH2. Two 
compounds, one from the HIDHs inhibitor collection and one from the whole cell active 
collections, showed low µM IC50 values against Mtb IDH2. A preliminary SAR study 
was conducted to improve the potency and the solubility of the compound 6144788. 
However, the potency of the inhibitor did not improve through the optimization. 
Although none of the derivatives exhibited better potency in the preliminary SAR 
studies, these studies revealed the critical components of these inhibitors. Briefly, it is 
required for the naphthalene group to connect to the amino group of the sulfonamide 
linker, and the substituents at the naphthalene ring are also critical for the activity. 
Moreover, a para-halogen substituted phenyl ring attaching to the sulfur group of 
sulfonamide group is preferred. This information could serve as a platform for future 
inhibitor design. The failure of the structural and binding assay studies suggest that the 
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solubility issue needs to be addressed before the inhibition mechanism and binding mode 
of compound can be successfully illustrated.   
 
Materials and Methods  
 
Protein Expression and Purification 
Full length Mtb Rv0066c gene was amplified from Mtb H37Rv genomic DNA by 
PCR with primer pairs, 5’-GGGAATTCCATATGATGAGCGCCGAACAGCCGACC-
3’ and 5’-CCCAAGCTTTCA GCCTTGGACAGCCTCCAGC-3’. The amplified gene 
was inserted into a pET28b (Novegen) expression vector fused with a TEV cleavage site 
and an N-terminal 6x-His tag using the NdeI and HindIII restriction sites. This 
engineered vector was transformed and expressed in the E. coli Rosseta (DE3) strain 
(EMD Millipore). E. coli cells with the vector grew at 37 °C in LB media with 50 µg/mL 
kanamycin (Gold Biotechnology, USA) and 34 µg/mL chloramphenicol (Gold 
Biotechnology, USA) to OD600 of 0.6 and were then induced by 0.5 mM IPTG (Gold 
Biotechnology, USA) at 18 °C overnight. The induced cells were collected and 
centrifuged down at 4000 rpm for 20 min. The cell pellets were suspended in the lysis 
buffer (50 mM Tris, pH 8.0, 500 mM NaCl, 1 mM PMSF, 10 µg/mL DNase and 2 mM 
MgCl2), and lysed by a Microfluidizer M-100P machine (Microfluidics, Worcestershire, 
UK). The cell lysates were centrifuged at 15,000 rpm for 1 h. The supernatant was 
purified by affinity chromatography using a nickel column (GE Healthcare). The 
supernatant of the lysed cells was loaded on the column and washed by a wash buffer 
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(50 mM Tris, pH 8, 500 mM NaCl, and 30 mM imidazole). The target proteins were 
eluted by an elution buffer (50 mM Tris, pH 8, 500 mM NaCl, and 500 mM imidazole) 
with a gradient.  
The TEV cleavage site and His-tag congregated Mtb IDH2 were incubated with 
the tobacco etch virus protease for 12 h at 4 °C and reloaded on the nickel column. The 
flowing through containing pure proteins was collected. The pure Mtb IDH2 was 
concentrated to 30−40 mg/mL, flash frozen, and stored in a storage buffer (50 mM Tris, 
pH 7.4, 50 mM NaCl) at −80 °C. The protein concentration was estimated using the A280 
measured Nano Drop 2,000 with calculated extinction coefficient and molecular weight 
(67270 M−1cm−1 and 82.69 kDa). 
 
Enzyme Assays and Kinetic Studies 
The activity of Mtb IDH2 was determined by monitoring the reduction of 
NADP+ to NADPH. The absorbance changing of NADPH at 340 nm was measuring by 
a Cary 100 UV-Vis spectrophotometer (VARIAN, CA, USA) using a molar extinction 
coefficient of 6,220 M−1cm−1. Enzyme assays were conducted in 1 mL volume of 100 
mM HEPES, pH 7.5, 20 mM MnCl2, and 0.5−1 nM of Mtb IDH2. The final 
concentration of NADP+ varied from 125 µM to 5 mM, and the final concentration of 
DL-ICT varied from 25 µM to 600 µM. The reaction was initiated by adding the ICT 
and was monitored at room temperature. 
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Product Inhibition Studies   
The inhibition effects of NADPH and 2OG were investigated in this work. Initial 
velocity patterns were obtained by measuring the initial rate at different concentrations 
of one reactant, with the concentration of other reactants fixed at a subsaturating 
concentration, and at different fixed concentrations of the inhibitor including zero.  
 
Data Fitting 
The initial velocity data were fit to the equation of Ping-Pong mechanism (Eq. 3) 
 
 ! = !!"# ! !!!" ! + !!" ! + ! !  Eq. 3 
 
In Eq. 3, ν is the reaction rate (µmole/s/mg); Vmax is the maximum velocity of the 
reaction (µmole/s/mg); [A] and [B] are the concentration of substrate A and B (µM), 
respectively; KmA and KmB are Michaelis-Menten constants for substrate A and B (µM).  
Product inhibition data were globally fit to the competitive inhibition equation 
(Eq. 4) or the mixed-type inhibition equation (Eq. 5). 
 
 ! = !!"#1+ !!! 1+ !!!"  Eq. 4 
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 ! = !!"#[!]!! 1+ [!]!!" + [!] 1+ [!]!!!  Eq. 5 
 
In each equation, ν is the reaction rate; Vmax is the maximum velocity of the 
reaction, [S] is varied substrate concentration; [I] is varied inhibitor concentration. Kis is 
the inhibition constant for the slope. Kii is the inhibition constant for the intercept and Km 
is the Michaelis-Menten constant of substrate S. 
 
Protein Crystallization  
Full length purified Mtb IDH2 pre-incubated with 2 mM NADP+ were screened 
for the crystallization conditions with the Mosquito liquid dispenser (TTP Labtech, 
Cambridge, MA, USA) using the sitting drop vapor diffusion technique in the Crystal 
mation Intelli-Plate 96-3 low-profile crystallization plate (Hampton Research). For each 
condition, 1 µL of protein (10 mg/mL) and 1 µL of crystallization formulation were 
mixed; the mixture was equilibrated with 50 µL of the reservoir in the well. The NADP+ 
bound Mtb IDH2 crystals were further reproduced and optimized via a hanging drop 
vapor diffusion method by incubating equal volume of 20 mg/mL Mtb IDH2 with 2 mM 
NADP+ and the crystallization solution (8−10% Tacsimate pH 5.0, 18−20% PEG 3,350) 
at 18 °C for 1 to 2 weeks. 
  128 
Data Collection, Structure Determination, and Refinement 
Crystals were cryo-protected with 30% glycerol and flash frozen prior to data 
collection. Diffraction data were collected at the Advanced Photon Source (APS) 
beamline 19ID, Argonne National Laboratory. Data Sets were indexed, integrated, and 
scaled by the HKL-3000276 or HKL-2000 program package.202 The space group of the 
NADP+ complex crystal is P1 and the unit cell parameters are a= 74.8 Å, b= 110.9 Å, c= 
114.9 Å, α= 86.0°, β= 78.6°, and γ= 76.8°. There are four molecules in an asymmetric 
unit. Phase was obtained by molecular replacement using the known structure 1J1W241 
as the search model with the Molrep203 in CCP4 packages.204 The refinement was done 
by the Phenix205 refinement packages, and the NCS function was applied during the 
refinement. The manual model building was done by the program Coot.206  
 
Analytical Size Exclusion Chromatography 
The oligomeric state of the purified WT or mutated Mtb IDHs was estimated by 
the size exclusion chromatography. The samples (0.1 mL, 10mg/mL) were loaded to a 
Superdex200 10/300 column (GE Healthcare Bio-sciences) equilibrated with binding 
buffer (50 mM sodium phosphate buffer pH 6.5 and 50 mM NaCl). Protein standards 
(Bio-Rad) for calibrating gels were Thyroglobulin (bovine) (670 kDa), γ-globulin 
(bovine) (158 kDa), Ovalbumin (chicken) (44 kDa), Myoglobin (horse) (17 kDa), and 
Vitamin B12 (1.35kDa).  
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Site-Directed Mutagenesis of Mtb IDH2 
Mtb IDH2 in pET28b harboring a TEV cleavage site and a 6× His tag at the N-
terminus was used as template. Selected residues were altered to the desired residues 
using the QuikChange® site-directed mutagenesis kit (Stratagene). Primer sequences for 
the E390R are 5’-CGCGCATCTATCAGCGGATCATCAACTTCTG-3’ and 5’-
CAGAAGTTGATGATCCGCTGATAGATGCGCG-3’; for R529E are 5’-
CAAGTGCGATCCATGGAATACACGTGCGAGCGC-3’ and 5’-
GCGCTCGCACGTGTATTCCATGGATCGCACTTG-3’. Correct insertion of all 
mutations was confirmed by DNA sequencing. The modified plasmids were transformed 
into the E. coli Rosseta (DE3) strain (EMD Millipore). The expression and purification 
of mutated enzymes were followed the aforementioned procedures as the WT enzyme. 
 
 Enzyme Assay in 96-Well Microplates 
Mtb IDH2 activity was evaluated by measuring the production of NADPH in a 
continuous spectrophotometric assay. The reaction was conducted in 96-well half area 
UV-Star plates (Greiner) in a final volume of 100 µL at 25 °C. The selected compounds 
were dissolved and diluted to a desired concentration with 100% DMSO. Briefly, 90 µL 
reaction buffer (100 mM HEPES, pH7.5, and 20 mM MnCl2), 2 µL inhibitor solution 
and 2 µL Mtb IDH2 with a final concentration 0.5 nM were added into each well of the 
assay plate and incubated at room temperature for 10 min. The reaction was initiated by 
adding 2 µL NADP+ (500 µM) and 4 µL DL-ICT (200 µM) into each well. The reaction 
was monitored by measuring absorbance at 340 nm using a Multiskan GO microplate 
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reader (Thermo Fisher Scientific Inc.) under a kinetic mode over 10 min in 10 sec 
intervals. The linear region of the curve was used to determine the initial velocity 
parameters. The initial velocity of the no enzyme and 0.5 nM enzyme reactions were 
used as the 100% and 0% inhibition during calculation. The Mtb IDH2 inhibitory ability 
was determined by the following equation (Eq. 6): 
 
 %inhibtion = S− PCNC− PC ×100 Eq. 6 
   
in which S represents the initial velocity of the reaction with the test compound, PC is 
the initial velocity of the positive control (reaction without enzyme), and NC denotes the 
initial velocity of the negative control (reaction with DMSO only). 
 
High-Throughput Screening 
HTS assays were carried out in a 96-well format (Corning 3635) using a Cybio 
automation system. The 1st and 12th column were used for positive (DMSO, no protein, 
substrate) and negative controls (DMSO, protein, substrate) of the reaction. Screening 
compounds were filled in the inner 10 columns. Screening compounds (50 µM) were 
preincubated with 50 nM purified Mtb IDH2 in the reaction mixture containing 200 µM 
NADP+, 5 mM MgCl2, 25 mM Tris, pH 7.5, 25 mM NaCl at room temperature for 10 
min. The reaction was initiated by the addition of 5 µL of DL-ICT to a final 
concentration of 200 µM. The final reaction condition contains 2% DMSO. The 
absorbance at 340 nm for NADPH was measured by a POLARstar OPTIMA plate reader 
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(BMG LABTECH) at two time points immediately and 20 min after the addition of the 
substrate. The difference between the two time points is the signal used in the 
calculation. Z’ factor277 was then calculated to determine the quality of the high-
throughput screen using Eq. 7, in which σ represents the standard deviation, µ is the 
average, + and − stand for the high and low controls. 
 
 !! = 1−  3!! + 3!!!! − !!  Eq. 7 
 
A 75% inhibition was chosen as the initial hit cut-off threshold for this HTS 
assay. The hits were then picked from stock solutions and retested in duplicates. 
Validated hits were subsequently examined by a dose-response assay. 
 
Evaluation of IC50 Values with Dose-Response Curves  
The setting of the dose-response assay is the same as the inhibition assay. To 
obtain a dose-response curve, compounds were tested at concentrations ranging from 30 
nM to 50 µM. Each reaction was performed in duplicates. The IC50 values were 
determined by the four parameter logistic equation (Eq. 1) using the SigmaPlot program 
(Systat Software, San Jose, CA).   
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 
(Mtb). The emergence and prevalence of drug-resistant TB underscore an urgent need 
for novel anti-tubercular agents. Shortening the treatment duration is another important 
mission to control TB since the long therapeutic course is the major cause of the 
emergence of drug resistant strains. Antibiotic persisters, especially the environmental 
stress induced persisters, are thought to be responsible for the prolong treatment. 
Therefore, the short term goal is to develop a drug for the drug resistant TB, and the 
ultimate goal is to find a way to effectively kill the persistent bacteria, which show high 
antibiotic tolerance.  
Drug discovery is a long term project. The entire procedure takes on average 
about 7−10 years from early research to pre-clinical testing and then the clinical trials. 
The early research includes the target identification and the lead development. Two 
approaches are used for the early research: target-based and phenotypic approaches. The 
target-based approach starts from choosing a target and followed by a hit identification 
through an enzymatic based screening. The hit compound would be optimized in a 
structural-activity relationship (SAR) study and ultimately becomes a lead for the 
preclinical trials. Alternatively, the phenotypic approach initiates by screening for 
compounds with therapeutic effects in cells, tissues or whole organisms. Target 
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identification, mechanism of action determination, and lead optimization experiments 
will be performed on the compound of interest. The obtained lead then tests in the 
preclinical trials. In this dissertation, some basic science research involved in the target 
identification and evaluation were carried out to enhance the knowledge for developing a 
novel anti-tubercular drug.  
After decades of study, the productivity of the target-based drug discovery is 
lower than expected. One common cause of failure is the overestimation of the genetic 
results. Frequently, the genetic essentiality does not correlate with the in vivo 
requirement of its gene product. Therefore, the targets of the currently used 
pharmaceutical drug are the best choice since they passed the clinic validation. The 
molecular targets of most clinically used anti-tubercular agents are well studied. 
However, the study about the mechanism of action of PAS was rare since it has been 
removed from the first line prescription. Understanding the mechanism of action of PAS 
provides the platform for developing the next generation drug by improving the potency 
and/or lowering the toxicity. Isolation and screening for the genomic changes associated 
with PAS resistance were applied to examine the mechanism of action of PAS. Three 
folate pathway related enzymes (ThyA, DHFR, and FolC) were considered to be 
potential candidates, and followed by the overexpression experiments. The results 
suggested that DHFR is most likely to be the intracellular target of PAS. Based on this 
assumption, it is surprised to find that a strain with a mutation in the non-coding region 
upstream of the gene Rv2671, which was annotated as a riboflavin reductase, would 
cause PAS resistance. A complete biochemical and structure study was performed to 
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elucidate the molecular based of this mutant. The purified Rv2671 turns out to possess a 
low DHFR activity. The DHFR activity of Rv2671 indeed reinforces the idea that Mtb 
DHFR is the target of PAS. The mechanism of the PAS resistant mutant, which mediates 
by the high levels of Rv2671, is through a metabolic bypass. This study suggested that 
Mtb DHFR is a good target for the target-based drug screening, and the Rv2671 inhibitor 
would resolve the PAS resistant strain caused by a high level of Rv2671.   
As mentioned earlier, sometimes the gene products of the essential genes are not 
required for bacterial growth in vivo. Failure to adapt the essentiality results from the 
genetic study can be a consequence of various mechanisms. A metabolic bypass is one 
of them. Mtb ICLs are attractive targets for persistent Mtb. Mtb is unable to sustain in 
hosts and is avirulent when Mtb ICLs are knocked-out. Mtb ICLs are involved in the 
glyoxylate shunt and are located at the branch point of the glyoxylate shunt and the TCA 
cycle. Thus, the TCA cycle can serve as an alternative pathway to generate energy and 
biomass for cell survival when Mtb ICLs are inhibited. Hence, to effectively kill Mtb, it 
is necessarily to block both routes such as inhibiting both branch point enzymes, Mtb 
ICLs and Mtb IDHs. The biochemical and biophysical properties of Mtb IDH2 were 
detailed characterized to examine its druggability. The crystal structure of Mtb IDH2 in 
complex with NADP+ was determined at 2.5 Å resolution. The differences of the 
NADP+ binding site between Mtb IDH2 and human IDHs indicate the potential to find 
inhibitors that are specific for monomeric IDHs. Inhibitor studies were performed for 
Mtb IDH2 with a repurpose screen and an enzymatically high-throughput screening with 
two libraries composed of anti-tubercular agents. Two compounds, one from the HIDHs 
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inhibitor collection and one from the whole cell active collections (6144788), showed 
low µM IC50 values against Mtb IDH2. The structural and inhibitor studies of Mtb IDH2 
can be valuable starting points for other researchers. 
In this dissertation, DHFR was identified to be a good target for the follow-up 
target-based screening. In addition, for Mtb IDH2, a high-throughput enzymatic assay 
was developed, and preliminary inhibitor studies were conducted. Despite the valuable 
findings, there are several unanswered questions. First, even though all the evidence 
suggests that DHFR is the molecular target of PAS, the intracellular active form of PAS 
is not yet identified. The interaction between Mtb DHFR and the intracellular active 
molecule also needs to be established. For Mtb IDH2, the yield compounds still awaits 
optimization. A synergistic effect test between the inhibitors for Mtb ICLs and Mtb IDHs 
would be the next step; once potent compounds are obtained. 
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APPENDIX A 
SUPPORTING INFORMATION FOR CHAPTER III† 
 
 
Materials and Methods 
 
Sequences Used in the PhylogeneticTtree1-3 
NP_217187.1 Mycobacterium tuberculosis RibD (strain H37Rv), 
WP_015306567.1 Mycobacterium smegmatis pyrimidine reductase, WP_015288343.1 
Mycobacterium canettii RibD, WP_043789270.1 Rhodococcus wratislaviensis 5-amino-
6-(5-phosphoribosylamino)uracil reductase, WP_014986655.1 Nocardia brasiliensis 5-
amino-6-(5-phosphoribosylamino)uracil reductase, WP_030760612.1 Streptomyces 
diaminohydroxyphosphoribosylaminopyrimidine reductase, WP_044573862.1 
Saccharopolyspora spinosa 5-amino-6-(5-phosphoribosylamino)uracil reductase, 
WP_021764912.1 Leifsonia aquatica RibD, WP_044850442.1 Amycolatopsis orientalis 
5-amino-6-(5-phosphoribosylamino)uracil reductase, WP_017129922.1 Pseudomonas 
agarici diaminohydroxyphosphoribosylaminopyrimidine deaminase, WP_042697497.1 
Methanocorpusculum bavaricum 5-amino-6-(5-phosphoribosylamino)uracil reductase, 
WP_004014420.1 Escherichia coli RibD, WP_001150448.1 Shigella flexneri 
                                                
† This work has been published in and is reprinted with permission from: Cheng, Y. S., and Sacchettini, J. 
C. (2016) Structural insights into Mycobacterium tuberculosis Rv2671 protein as a dihydrofolate reductase 
functional analogue contributing to para-aminosalicylic acid resistance, Biochemistry 55, 1107-1119. 
Copyright 2016 by American Chemical Society. 
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diaminohydroxyphosphoribosylaminopyrimidine deaminase, NP_984897.1 Ashbya 
gossypii (strain ATCC 10895) AER037Cp, WP_010870176.1 Methanocaldococcus 
jannaschii 5-amino-6-(5-phosphoribosylamino)uracil reductase, NP_009711.3 
Saccharomyces cerevisiae (stain S288c) Rib7p, WP_032722052.1 Bacillus subtilis 
RibD, WP_003898867.1 Mycobacterium tuberculosis RibG, WP_000162469.1 
Streptococcus pneumoniae DHFR, WP_010865375.1 Thermotoga maritime DHFR, 
WP_011499411.1 Methanococcoides burtonii deaminase, XP_665866.1 
Cryptosporidium hominis (strain TU502) Dhfr, WP_000637197.1 Bacillus cereus 
DHFR, WP_033720836.1 Mycobacterium avium DHFR, WP_005769725.1 Coxiella 
burnetii DHFR, WP_033010007.1 Geobacillus stearothermophilus DHFR, 
WP_020321480.1 Klebsiella pneumoniae DHFR, WP_000175746.1 Staphylococcus 
aureus DHFR, WP_005689288.1 Lactobacillus rhamnosus DHFR, WP_024211602.1 
Escherichia coli DHFR, XP_002367252.1 Toxoplasma gondii ME49 bifunctional 
dihydrofolate reductase thymidylate synthase, XP_011775023.1 Trypanosoma brucei 
gambiense (stain DAL972) dihydrofolate reductase thymidylate synthase, 
XP_001351479.1 Plasmodium falciparum (strain 3D7) bifunctional dihydrofolate 
reductase thymidylate synthase, WP_031722695.1 Mycobacterium tuberculosis DHFR, 
gi|1155270|gb|AAB60183.1| Mycobacterium bovis enoyl ACP reductase, 
gi|690312203|gb|AIR14234.1| Mycobacterium tuberculosis (strain H37Rv) enoyl-ACP 
reductase, gi|387616665|ref|YP_006119687.1| (Escherichia coli strain O83:H1 str. NRG 
857C) enoyl-ACP reductase, gi|728888373|gb|AIY96767.1| Bacillus subtilis enoyl-ACP 
reductase. 
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Tables and Figures 
 
Table A-1. Hydrogen bond interactions between Rv2671 and TMP/TMQ 
Rv2671 TMP Distance (Å) 
Asp67 OD2 N2 2.53 
Asp67 OD1 N4 2.55 
Asn44 OD1 N4 3.24 
Thr214 OG1 N4 3.32 
Asn44 O N7 2.70 
Water 16 N7 3.15 
Rv2671 TMP Distance (Å) 
Asp67 OD2 N1 2.54 
Phe45 O N24 3.08 
Asn44 OD1 N24 2.98 
Thr214 OG1 N24 3.30 
Asp67 OD1 N24 2.75 
Asn44 O N25 2.67 
Glu193 O N25 3.14 
Water 52 O20 3.11 
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Figure A-1 Ribbon representation of Rv2671 and the gel filtration chromatography of 
Rv2671. (A) Ribbon representation of Rv2671 in complex with NADP+. The secondary 
structural elements are labeled sequentially. (B) Purified Rv2671 were used to 
investigate its oligomerization state in solution. The samples (0.1 mL, 14.5 mg/mL) 
were loading to Superdex200 10/300 GL column (GE Healthcare Bio-sciences) with 50 
mM Tris pH7.5, 50 mM NaCl at a flow rate of 0.3 mL/min. For calibration of the 
column the following size markers (Bio-Rad) were used: Thyroglobulin (bovine) (670 
kDa), γ-globulin (bovine) (158 kDa), Ovalbumin (chicken) (44 kDa) and Myoglobin 
(horse) (17 kDa). The figure depicts the elution profiles at 280 nm for Rv2671 (line) and 
standards (dot). Rv2671 were eluted from the column at molecular mass of ~ 56 kDa, 
suggesting that Rv2671 exists as a dimer in solution.  
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Figure A-2 Superimposition of the THF bound Rv2671 structure (blue) with the E. coli 
RibD structure (blue, 2OBC4). Pteridine ring of THF is colored in green. The conserved 
lysine of RibD (lys152 in E. coli RibD) clashed with the THF in the superimposition 
structures. Asn44 however is in the Rv2671 at the same position and forms a hydrogen 
bond with THF. Distance between the side chain carbonyl group of Asn44 from Rv2671 
and the NA2 atom of the pteridine is 3.1 Å. 
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Lys 152. Ec RibD 
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Figure A-3 Pyrimidine reductase activity assays. The reaction was followed by the 
consumption of NADPH by pyrimidine reductase activity. The absorbance at 340 nm 
was monitored for 20 min using a Cary100. (A) Rv2671 at 300 nM was tested for 
DAROPP reductase activity using DAROPP as substrate (circles). The in situ reaction of 
E. coli RibD was used as a positive control (triangles); DAROPP was added into the 
reaction mixture in the presence of full length E. coli and NADPH. The reaction without 
enzymes was conducted as a negative control (squares). (B) Rv2671 at 600 nM was 
tested for AROPP reductase activity using AROPP as substrate (triangles). The reaction 
with E. coli RibD was used as a positive control (squares) and the reaction without 
enzymes was conducted as a negative control (circles). 
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Figure A-4 Multiple sequence alignment of Rv2671 with its close orthologs and 
functionally characterized pyrimidine reductases. The alignment was generated by 
Muscule5 and visualized by ESpript 3.x.6 The sequences were number by the residue 
number of Rv2671 and Asp67 and Glu91 are marked with star, respectively. The 
sequences used in the alignment are: Mycobacterium tuberculosis RibD (strain H37Rv), 
Mycobacterium smegmatis pyrimidine reductase, Mycobacterium canettii RibD, 
Rhodococcus wratislaviensis 5-amino-6-(5-phosphoribosylamino)uracil reductase, 
Nocardia brasiliensis 5-amino-6-(5-phosphoribosylamino)uracil reductase, 
Streptomyces diaminohydroxyphosphoribosylaminopyrimidine reductase, 
Saccharopolyspora spinosa 5-amino-6-(5-phosphoribosylamino)uracil reductase, 
Leifsonia aquatica RibD, Amycolatopsis orientalis 5-amino-6-(5-
phosphoribosylamino)uracil reductase, Pseudomonas agarici 
diaminohydroxyphosphoribosylaminopyrimidine deaminase, Methanocorpusculum 
bavaricum 5-amino-6-(5-phosphoribosylamino)uracil reductase, Escherichia coli RibD, 
Shigella flexneri diaminohydroxyphosphoribosylaminopyrimidine deaminase, Ashbya 
gossypii (strain ATCC 10895) AER037Cp, Methanocaldococcus jannaschii 5-amino-6-
(5-phosphoribosylamino)uracil reductase, Saccharomyces cerevisiae (stain S288c) 
Rib7p, Bacillus subtilis RibD. The detail sequence accession numbers were listed in the 
supplementary materials and methods section. 
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